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Abstract 
Nasal allergen challenge (NAC) is a non-invasive model to study the 
mechanism of allergic rhinitis and effects of novel anti-inflammatory therapies. 
The repeatability and dose response of a single NAC was studied, followed by 
development of a daily repeat NAC model involving 4 challenges on 
consecutive days. However, the results of earlier published work could not be 
reproduced, since in nasal filter paper (FILT P) eluate in both studies there were 
no significant changes in levels of interleukin (IL)-4, IL-5 and IL-13. However the 
daily repeat NAC model did cause priming in terms of symptoms, eosinophils, 
and nasal lavage IL-5 and IL-13. Proposals were made for implementation of a 
synthetic absorptive matrix (SAM) as an alternative to Whatman's FILT P and 
also to deliver higher doses of allergen to the nose. Using SAM resulted in high 
serial levels of IL-4, IL-5 and IL-13 being detected in SAM eluates during the 
late phase after NAC (appendix). 
In cigarette smokers I requested subjects to exhale cigarette smoke through 
their noses, to provide a nasal cigarette smoke challenge method. FILT P is 
likely to distort detected levels of mediators in nasal secretions, but in FILT P 
eluates there were statistically significant elevations of IL-8 (p=0.01) and IL- 
12p70 (p=0.02) at baseline in Chronic Obstructive Pulmonary Diseae (COPD) 
patients. However there were increases in nasal lavage MCP-1 at 8h in COPD 
patients and healthy controls following cigarette smoke (p=0.02). 
A cigarette smoke conditioned medium (CSCM) was employed to stimulate 
whole blood upregulation of CD11 b measured by flow cytometry on leukocytes. 
CSCM caused upregulation of neutrophil CD11 b, but this could not be inhibited 
by anti-oxidants. In contrast, menadione (MQ) stimulates intracellular 
generation of oxidants, and this caused neutrophil CD11 b upregulation that was 
inhibited by glutathione. Xanthine with xanthine oxidase (X+XO) generates an 
extracellular source of oxidants, and this caused an increase in neutrophil 
CD11 b on washed blood cells, that could also be inhibited by glutathione. 
NAC or cigarette smoke nasal challenge, as well as stimulation of human whole 
blood with oxidants, have potential as challenge models - but SAM should be 
used instead of FILT P. 
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Abbreviations 
Abbreviation Definition 
AHR Airways hyperreactivity 
ARIA Allergic Rhinitis and its Impact on Asthma 
AU Arbitrary units 
BAL Bronchoalveolar lavage 
BSA Bovine serum albumin 
C3a Complement component C3a 
CD Cluster of differentiation 
CO Carbon monoxide 
COPD Chronic obstructive pulmonary disease 
CSCM Cigarette smoke conditioned medium 
DTT Dithiothreitol 
ECP Eosinophilic cationic protein 
EDN Eosinophil derived neurotoxin 
ELF Epithelial lining fluid 
EPO Eosinophil peroxidase 
FEV, Forced expiratory volume in 1 second 
FILT P Whatman's no 42 filter paper 
FVC Forced vital capacity 
GAFS Gated Autofluorescence and Forward Scatter 
GINA Global Initiative on Asthma 
GM-CSF Granulocyte macrophage colony stimulating factor 
GOLD Global Initiative on chronic Obstructive Lung Disease 
GRO-a Growth-regulated oncogene a 
GSH Reduced glutathione 
H202 Hydrogen peroxide 
HLA Human leukocyte antigen 
HOCL Hypochlorous acid 
ICS Inhaled corticosteroid 
Ig Immunoglobulin 
IL Interleukin 
IFN Interferon 
IP-10 Interferon-y inducible protein 10 
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Abbreviation Definition 
IQR Inter-quartile range 
LABA Long-acting 02-adrenoceptor agonist 
LPS Lipopolysaccharide 
LTB4 Leukotriene B4 
MAP-K Mitogen activated protein kinases 
MBP Major basic protein 
MCP-1 Monocyte chemotactic protein 1 
MFI Mean fluorescence activity 
MIP-1a Murine macrophage inflammatory protein 1 alpha 
MMP Matrix meta Iloproteinase 
Mo-AB Monoclonal antibody 
MPO Myeloperoxidase 
MQ Menadione 
NAC Nasal allergen challenge 
NADPH Nicotinamide adenine dinucleotide phosphate 
NF-KB Nuclear factor-kappa B 
NGF Nerve growth factor 
NO Nitric oxide 
N02 Nitrite 
N03 Nitrate 
02 Superoxide anion 
PAMPs Pathogen associated molecular patterns 
PBS Phosphate buffered saline 
PDE Phosphodiesterase 
PGD2 Prostaglandin D2 
RANTES Regulated upon Activation, 
Normal T-cell Expressed, 
and Secreted 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
RPMI media Roswell Park Memorial Institute media 
SAM Synthetic absorptive matrix = Accuwik Ultra 
SCCA Squamous cell carcinoma antigens 
SLIT Sublingual immunotherapy 
SNPs Single nucleotide polymorphisms 
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Abbreviation Definition 
SOD Superoxide dismutase 
TAME Na-p-tosyl-L-arginine methyl esterase 
TGF Transforming growth factor 
TLRs Toll like receptors 
TNF Tumour necrosis factor 
TSLP Thymic stromal lymphopoietin 
X Xanthine 
XO Xanthine oxidase 
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I Introduction 
1.1 Clinical aspects of allergic rhinitis, asthma and COPD 
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases that 
cause a large global burden of disease, with significant amounts of morbidity 
and mortality. Both asthma and COPD commonly present to General 
Practitioners and Respiratory Physicians. Allergic rhinitis is a common but 
generally mild condition, that nevertheless may cause considerable discomfort. 
1.1.1 Allergic rhinitis 
Allergic rhinitis is defined by the Allergic Rhinitis and its Impact on Asthma 
(ARIA) work group as "a symptomatic disorder of the nose induced after 
allergen exposure due to an IgE-mediated inflammation of the membranes 
lining the nose (1). " Allergic rhinitis is characterised by sneezing, nasal itching, 
nasal obstruction and mucous discharge. In addition patients can feel 
systemically unwell and suffer additional symptoms such as headaches, watery 
itchy eyes and skin rashes. If the rhinitis is severe it can cause disease of the 
paranasal sinuses causing pain or dysfunction of the Eustachian tube with 
resultant ear symptoms (2) Over 500 million patients worldwide suffer with 
allergic rhinitis (3) Allergic rhinitis is common in young working adults and can 
cause poor sleep, interruption of daily activities and can increase the severity of 
associated asthma. Allergic rhinitis has been shown to reduce attendance at 
school and work (4; 5) and in addition to the demand for access to medical 
treatment this is associated with a significant economic burden (6). 
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1.1.2 Asthma 
Asthma is a disease of variable airflow obstruction and is characterised clinically 
by variable cough, chest tightness and wheeze (7). Most patients are well 
between episodes although there is a significant minority who continue to have 
symptoms despite maximal therapy (8) Asthma is one of the most common 
diseases, with The World Health Organisation (WHO) estimating that globally 
there are 155 million asthma sufferers, affecting all ages in both high and low 
income countries (9). A review of the General Practice Research Database has 
shown that during the 1990's the prevalence of asthma in UK primary care was 
increasing (10). Studies have shown that asthma is associated with a significant 
reduction in health related quality of life (11-14). Among patients with asthma 
work limitation is common (15-17). Asthma has important social relevance as it 
affects school age children and hence can affect their educational progress, and 
also it occurs in young adults who form an important part of the workforce and 
can lead to significant economic costs (18; 19). 
1.1.3 COPD 
COPD is a common disease caused almost exclusively by smoking in 
industrialised societies, however only 10-20% of smokers develop COPD. The 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) has formulated a 
"Global Strategy for the Diagnosis, Management and Prevention of COPD", 
(www. goldcoad. com) that is regularly updated (20). 
A working definition of COPD is given within the GOLD Global Strategy (2007) 
as: "A preventable and treatable disease with some significant extrapulmonary 
effects that may contribute to the severity in individual patients. Its pulmonary 
component is characterised by airflow limitation that is not fully reversible. The 
Page 31 of 293 
airflow limitation is usually progressive and associated with an abnormal 
inflammatory response of the lung to noxious particles or gases. " Clinical 
features of COPD include cough, sputum production, wheeze and 
breathlessness. Pathology distant from the lung also occurs and includes right 
heart failure, systemic disease with cachexia and respiratory and peripheral 
muscle weakness (21). COPD is an important disease globally and the 
morbidity and mortality continue to rise with COPD predicted to become the 
third commonest cause of death by 2020(22) COPD is associated with a 
significant reduction in health-related quality of life (23-26). Whilst COPD 
generally affects the older population COPD it does still affect people of working 
age (27), and leads to work disability (28). 
The obstructive lung defect typical of COPD is a decreased FEVi compared to 
that predicted for an individual (29). The FEV1 should be measured following the 
inhalation of a bronchodilator and expressed as a percentage of that predicted 
for an individual (30). 
The exact burden of COPD is difficult to quantify as misdiagnosis and under 
diagnosis is common. A review of the General Practice Research Data 
Database estimates that nearly 900,000 patients in the United Kingdom have 
COPD (31), and COPD was recorded as the principal cause of death in 23,204 
people in 2004 (32). This makes COPD the fifth most common cause of death 
after ischaemic heart disease, stroke, lung cancer and pneumonia. COPD is 
also a leading cause of morbidity and mortality worldwide (33), and in addition 
the prevalence of COPD is increasing worldwide. 
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Table 1-1 Comparison of Allergic Rhinitis. Asthma and COPD 
Seasonal allergic rhinitis Asthma COPD 
Prevalence 500 million worldwide 155 million 900,000 
in UK 
worldwide 
Any Peaks in Over 40 years 
Age group childhood and 
middle age 
Aetiological Genetics Genetics Cigarette smoke 
factors Atopy Atopy Biomass fuels 
Mast cells Mild Mild 
Eosinophils Th2 cells Tc cells 
Pathogenesi Th2 cells mast cells Neutrophils and 
s of Eosinophils macrophages 
inflammatio Severe Severe 
n Neutrophils and Lymphoid 
macrophages follicles 
Sneezing Wheeze Cough 
Rhinorrhoea Cough Sputum 
Nasal itch Diurnal variation production 
Clinical Nasal obstruction Wheeze 
features Conjunctivitis 
Seasonal variation 
Bronchial hyper- 
reactivity 
Normal FEV1 / FVC < 70 FEV, / FVC < 70 
Reduced FEV, Reduced FEV, 
Lung Bronchodilator Limited 
function response bronchodilator 
response 
Latest ARIA GINA GOLD 
global 
guidelines 
Allergen avoidance Bronchodilators Smoking 
Anti-histamines Steroids cessation 
Current Steroids Anti-IgE Bronchodilators 
treatment Immunotherapy Allergen Steroids in more 
avoidance severe disease 
Immunotherapy 
Response Limited response to Good response Limited 
to treatment anti-histamines to steroids 
More directed therapies More directed More effective 
therapies to anti- 
allow reduction inflammatory 
Medical of steroid dose therapies 
needs Prevention of 
airway 
remodelling in 
severe disease 
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1.2 Molecular and cellular pathophysiology of allergic rhinitis, asthma and 
COPD 
1.2.1 Allergic rhinitis and asthma 
The immunopathology of allergic disease is complex and the clinical disease 
entity is a result of interaction between a variety of stromal and immune cells 
involving an array of inflammatory mediators. The pathogenesis of allergy and 
asthma as been the subject of several reviews in the literature from 2007 and 
2008 (34-38), and they all emphasise that a single mechanism cannot explain 
the clinical diversity of the disease. The hypothesis of allergen-triggered Th2 
stimulation and resultant inflammation is too simplistic, as illustrated by the way 
that cyclosporine has been disappointing as a therapy for severe asthma, 
indicating that the T cell may not be essential for the development of asthma. 
The role of the eosinophil has traditionally been thought to be pivotal to the 
development of asthma, however clinical trials of anti-IL-5 have shown profound 
reductions in peripheral blood eosinophil levels but have again produced 
disappointing clinical effects. It has been noted that subjects with more severe 
asthma that is resistant to steroids may have predominantly neutrophilic 
inflammation (39). 
The following description of the pathogenesis of allergic inflammation 
demonstrates that there are many potential mechanisms that can result in the 
clinical features of asthma. In addition, the genetic basis of asthma is not 
straightforward, with over 100 genes potentially involved, illustrating the 
complexity of gene-environment interactions in causing asthma phenotypes. 
Asthma is clearly a heterogeneous disease as evidenced by differing clinical 
presentations (e. g. allergic, aspirin-sensitive, exercise-induced, severe asthma 
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etc. ) and differing responses to treatments. Gary Anderson has published a 
thought-provoking recent review that has suggested that individual patients 
could be characterised and treatments tailored to the specific inflammation 
causing the majority of their symptoms, so called "endotyping of asthma"(38). 
1.2.1.1 Mast cells, eosinophils and changes in the early phase 
There has been interest in the pathological basis of allergic disease for over a 
hundred years (40). In 1879 Ehrlich first described mast cells and eosinophils, 
by performing microscopy on stained leukocytes (41). The description of IgE 
binding to mast cells and causing degranulation and hence mediator release 
was described by Johansson in 1967 (42). Mast cell degranulation is triggered 
by the binding of IgE to Fccl (43). The products of mast cell activation include 
the release of granule contents including histamine, heparin and ß-tryptase and 
the synthesis of inflammatory mediators such as prostaglandin D2 (PGD2) and 
leukotrienes. 
Allergen challenge of allergic individuals has been shown to increase levels of 
histamine and tryptase in nasal lavage fluid, and these changes are not seen in 
non-allergic subjects (44). Nasal allergen challenge (NAC) has also been noted 
to increase levels of histamine in nasal lavage fluid in a time and dose 
dependent manner (45). PGD2 is produced by mast cells and been detected in 
high concentrations at the site of allergic inflammation (46; 47). ß-Tryptase is a 
serine protease that is released from degranulating mast cells and has 
inflammatory actions through PAR-2 activation (48). In addition tryptase may 
also contribute to airway oedema through microvascular leakage (49). In a NAC 
study a reversible ß-tryptase and trypsin inhibitor has been shown to reduce 
symptoms, eosinophils, and levels of IL-5 following NAC (50). Nasal challenge 
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with ragweed antigen causes a rise in complement activation products in 
allergic but not normal subjects that correlated closely with symptoms, 
suggesting a role for complement activation in the early phase of the allergic 
response (51). 
Eosinophils are leukocytes of bone marrow origin that migrate via the 
bloodstream to mucosal sites. Eosinophils contain highly basic granules that 
give these cells their characteristic staining properties, and the granules can be 
released to combat parasitic infections (52). The eosinophil granule proteins 
include major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil 
peroxidase (EPO) and eosinophil derived neurotoxin (EDN). 
Of particular relevance to asthma is that MBP is prominent in the sputum and 
mucosal tissue of asthmatics, and can cause airways hyperreactivity (AHR) 
(53). GM-CSF, IL-3 and IL-5 are cytokines that enable eosinophil survival, 
acting via a common shared beta-chain (CD131) (52). Eosinophils are thus 
potentially long-lived tissue cells, which can produce cytokines (notably TGF-ß), 
present antigens, and interact with fibroblasts and participate in airways tissue 
remodelling (54). 
Eosinophils are also involved in the fibrotic reaction that occurs in allergic 
inflammation. The tenascins are a group of glycoproteins found in the 
extracellular matrix that are important in normal development and can be 
associated with pathology (55). In a skin challenge model eosinophil-derived 
factors that promote fibrosis (TGF-ß and IL-13) were associated with tenascin 
and procollagen-I immunoreactivity (56). Interleukin (IL)-5 is of crucial 
importance for eosinophilic inflammation, since it is the critical cytokine involved 
in eosinopoiesis in the bone marrow. A blocking antibody to IL-5 depletes 
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eosinophils from the circulation and sputum of asthmatic patients but, 
disappointingly, had no effect on the response to inhaled allergen, airway hyper- 
responsiveness symptoms, lung function or exacerbation frequency in 
asthmatic patients (57). Furthermore, 2 larger studies in patients with 
symptomatic asthma have demonstrated only minor effects of anti-IL-5 on lung 
function and symptoms in asthma (58). However, IL-5 may play a role in airway 
remodelling as anti-IL-5 reduces eosinophil infiltration and tenascin deposition 
in a skin model of allergen challenge (59). 
Neural mechanisms in allergic disease have been investigated. Nerve growth 
factor (NGF) enhances the production of substance P by neurons (60). 
Substance P is known to trigger smooth muscle constriction and acute 
inflammation (61; 62). Neurotropins such as NGF seem to be the link between 
immune and neural mechanisms of inflammation (63). Using capsaicin to 
stimulate nerves has shown that nonallergic rhninits is not characterised by 
increased responsiveness of capsacin-sensitve nerve fibres in contrast to 
allergic rhinitis where there is marked hyperresponsiveness (64). Hypertonic 
saline has been shown to cause nasal inflammation via a neural pathway and 
subjects with allergic rhinitis have an enhanced response involing capsicicin- 
sensitive fibres, consistent with nasal hyperresposiveness (65). A murine model 
has demonstrated that NGF augments the early phase allergic response 
through increased release of mast cell mediators (66). 
1.2.1.2 Epithelium and dendritic cells- T-cell recruitment and late 
symptoms 
The nasal epithelium is rich in dendritic cells, which are antigen-presenting cells 
with the ability to induce primary immune responses. Dendritic cells can prime T 
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helper cells directly although the exact mechanisms involved are not clear (67). 
Increased levels of mucosal dendritic cells are seen in both allergic rhinitis and 
asthma, and studies of blood derived dendritic cells have shown differences in 
the function of dendritic cells between atopic and normal subjects (68). 
T helper cells (CD4+) can be divided into 2 groups, Thl and Th2, based on their 
profile of cytokine production. Th2 cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and 
IL-13. Th1 cells produce IL-2, IFN-y, and TNF-p (69). The factors that determine 
which group of T helper cells are pre-dominant have been extensively studied, 
but not yet fully elucidated, although it is clear that it is a combination of genetic 
and environmental factors (70). The regulation of IgE production by B cells by 
cytokines produced by T-cell derived cytokines was initially described in mice 
(71) and was subsequently described in humans (72). It has long been known 
that there is an association between BAL T-cell activation, eosinophilia and 
asthma severity (73), and deactivation occurs following steroid treatment (74). A 
study of nasal biopsies following nasal allergen challenge has shown 
significantly increased numbers of activated T helper cells (75). 
The evidence suggests that allergen exposure causes Th2 recruitment and/or 
differentiation of these specific T cells. These Th2 cells then produce IL-4 and II- 
13 which induces IgE production from B cells (72). Degranulation of IgE-coated 
mast cells causes the acute changes seen in the early phase. IL-5 production 
by the Th2 cells would activate eosinophils and contribute to the late phase 
reaction (76). It has been shown that PGD2 stimulates the production of IL-4, IL- 
5 and IL-13 by human Th2 cells at levels found at the site of allergic 
inflammation, and gene transcription peaks at 2 hours (77). 
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Several studies have shown that interferon (IFN)-y is increased in asthmatics 
and that Thl activation occurs (78-80). It has also been shown that IFN-y- 
producing cells and IFN-y levels are increased during exacerbations of asthma 
(81; 82). Th1 activation can increase bronchial hyperreactivity once allergic 
disease is established (76). Thl activation occurs in the more severe forms of 
allergic disease including asthma, rhinitis and atopic dermatitis (82-85). 
Another set of CD4+ cells, known as Th17 cells, have recently been described 
that have an important role in inflammatory disease (86; 87). Th17 cells produce 
IL-17 and increased concentrations of this cytokine have detected in the sputum 
of patients with asthma (88). IL-17 has been shown to promote neutrophilic 
inflammation by inducing the release of pro-inflammatory cytokines from airway 
epithelial cells (89). It is hypothesised that Th17 cells are important in the 
development of the neutrophilic infiltration that occurs in more severe 
corticosteroid dependent asthma (90). It is now recognised that that specific 
cytokines can promote transcriptional factors such as T-bet, GATA3, RORyt, 
and Foxp3 that influence Th1, Th2, Th17, and Treg (T regulator) cells, 
respectively (91). CD4+ T cells can also differentiate into a group of cells 
labelled as Tregs that act to suppress T-cell responses (92), FOXp3 is a 
transcription factor that is responsible for the suppressive functions of Tregs. 
TGF-ß can also induce the transformation of naive CD4+ cells to become Tregs 
and are classified as inducible Tregs (93). 
The production of TH2-type cytokines such as IL-4, IL-5 and IL-13 are 
characteristic of allergic diseases. A study of nasal biopsies at 6 hours following 
nasal allergen challenge has shown that the levels of eosinophils but not T-cells 
increase in nasal mucosa. Co-localisation studies showed that the majority of 
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the IL-4 and IL-5 mRNA was associated with eosinophils (94). This is important 
because it suggests that eosinophils are the source of early phase cytokines 
that lead to the development of a late phase response. IL-5 levels have also 
been shown to increase in nasal filter paper samples during the early and late 
phase following nasal allergen challenge; however IL-4 was not detected in this 
study (95). Another biopsy study has shown that NAC induces a significant 
tissue eosinophilia with an associated increase in IL-8, IL-13 and RANTES 
mRNA-positive cells and that increased levels of IL-13 mRNA-positive cells are 
still present 1 week following single NAC (96). A co-localisation study has 
determined that the majority of RANTES mRNA-positive cells following NAC are 
macrophages, followed by eosinophils (97). It has been shown that following 
NAC there are parallel increases in eosinophil counts, eosinophil protein X, and 
eotaxin concentrations in nasal lavage fluid (98). 
NAC has been shown to increase levels of the cytokines IL-4, IL-5 and IL-13 in 
filter paper samples collected during the late phase. The chemokines eotaxin, 
RANTES, MCP-1, MIP-1a, IL-8 and IP-10 were also produced during the late 
phase. It has been shown in a guinea pig model of allergic rhinitis using an anti- 
IL-5 antibody that IL-5 is essential for eosinophil migration from the bone 
marrow to the nasal airway; neither IL-5 nor eosinophils are required for the 
development of nasal symptoms and nasal hyperresponsiveness (99). 
Interestingly levels of TH1 cytokines (IL-2, IL-3, IL-7, IL-12, IL-15, TNF-a, IFN-y, 
GM-CSF) were not affected (100). It has also been shown that a single dose of 
nasal steroid has the ability to abolish the IL-5 and IL-13 responses following 
nasal allergen challenge (101). 
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Inhalation of IL-4 increases levels of airways eosinophils (102), while intranasal 
administration of IL-4 to non-allergic individuals increased levels of IL-6, 
eosinophils, and neutrophils in nasal lavage fluid 24 hours following challenge 
(103). 
Changes to the epithelium in allergic rhinitis remains a controversial area. One 
study has shown that there is no evidence of epithelial damage (104). An 
electron microscopy study in perennial rhninits has shown increased numbers 
of epithelial cells with cytoplasmic vacuoles and markedly widened intercellular 
spaces, changes which are not visible on light microscopy (105). This break in 
integrity of the epithelial barrier may allow allergen to reach the subepithelial 
layers. In addition to the epithelial changes there has been shown to be 
thickening of the basement membrane (106). The protein filaggrin is involved in 
maintaining the tight junction between epithelial cells, and a genetic variants 
with abnormalities of this protein suffer from atopic dermatitis and asthma (107) 
Airway remodelling is seen in asthma and comprises epithelial cell mucus 
metaplasia, smooth muscle hypertrophy/hyperplasia, subepithelial fibrosis, and 
increased angiogenesis (108). Several cytokines have been implicated in this 
process including TGF-ß, VEGF, Th2 cytokines (IL-5, IL-9, IL-13) and NF-KB 
regulated cytokines (109). As described below there are differences in the 
histology of the nasal mucosa compared to the respiratory mucosa and the 
relevance of airway remodelling in allergic rhinitis has not been extensively 
studied, and it has been suggested that the differences in remodelling between 
allergic rhinitis and asthma may be due to the lack of smooth muscle in the 
nasal mucosa or their differing embryological origins (110). 
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Figure 1.1 shows how the inflammatory mechanisms above combine to produce 
the features of the early and late phase allergic response. 
Allergen 
Respiratory epithelium 
onlaining dendritic cell 
ttt 
Granule release 
/9F'ß h 
IL 4,5,13 
Med, alo, synthesis 
Nerv e reflex Vascular receptors 
B cell 
Sneezing Rhinorrhoea 
Itchiness Congestion 
I 
Early phase 
Nasal obstruction 
Mucosal hyperreactivity 
Late phase 
Figure i-1 Inflammatory mechanisms in the allergic response 
1.2.2 Comparison of allergic rhinitis and asthma 
The respiratory mucosa of the nose has many similarities to that of the bronchi. 
It consists of a pseudostratified columnar ciliated epithelium resting on a 
basement membrane under which there are vessels, mucous glands, 
fibroblasts, inflammatory cells and nerves. However there are differences, since 
in the nasal mucosa the blood vessels are much more prominent and there is 
an absence of airway smooth muscle (111). It has been noted that nasal 
symptoms frequently co-exist in patients with asthma (112), and review of 
epidemiological data shows that asthma and rhinitis often co-exist in the same 
patient (113). 
Patients with allergic rhinitis have increased bronchial sensitivity to 
methacholine or histamine especially during and slightly after the pollen season 
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(114; 115), and there is a two-way relationship between nasal and bronchial 
inflammation. It has been shown that bronchial allergen challenge leads to 
increases in nasal eosinophils and enhanced expression of IL-5 in nasal 
epithelium (116). Patients with allergic rhinitis with no history of asthma develop 
bronchoconstriction after endobronchial allergen challenge with associated 
inflammation (117; 118). There is considerable similarity between the 
inflammation that occurs in allergic rhinitis with that occurring in asthma. 
Examination of the bronchial mucosa in patients with allergic rhinitis shows 
eosinophilic inflammation (119). Increased numbers of mast cells have been 
seen in the both the nasal and bronchial mucosa in allergic disease (120121). 
Increased levels of Th2 lymphocytes have also been shown in both disease 
states (122; 123). The response following allergen challenge has an early and a 
late phase response in both the nose and the lungs (85; (124-126). One of the 
main differences in allergic rhinitis is that the lack of smooth muscle may affect 
airway remodelling. It has been shown that airway remodelling does - occur in 
rhinitis although this is much more pronounced in asthma (127). 
It can be seen that there is epidemiological and pathogical evidence that allergic 
rhinitis and asthma are closely related; and hence it is plausible to suggest that 
using an allergen challenge model of the nose would be a useful surrogate to 
test potential new anti-inflammatory therapies for asthma without having to carry 
out inhaled allergen challenge nor bronchoscopy with their associated risks. 
1.2.3 COPD 
1.2.3.1 Cigarette smoke composition 
Cigarette smoke has been estimated to contain some 10" oxidant molecules 
per inhalation, and there is considerable evidence that oxidative stress is 
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increased in patients with COPD (128-132). The lungs have a large epithelial 
surface area that is exposed to reactive oxygen and nitrogen species (ROS and 
RNS) within cigarette smoke, further oxidants are generated during 
inflammatory processes, and an oxidant/antioxidant balance is thought to be 
important in the pathogenesis of COPD (133). Cigarette smoke is a 
heterogeneous aerosol generated by incomplete burning of tobacco leaves. It is 
composed of gaseous, volatile and particulate components with up to 95% of 
the weight of smoke in the gaseous phase. More than 400 substances are 
present in cigarette smoke including oxidants; pharmacologically active 
compounds such as nicotine, mutagens and carcinogens; as well as antigenic 
and cytotoxic components. Nicotine is a toxic plant alkaloid that stimulates 
acetylcholine receptors at autonomic ganglia of both the sympathetic and 
parasympathetic systems as well as having stimulant activities at 
neuromuscular receptor sites and in the central nervous system. Carbon 
monoxide interferes with oxygen transport and utilisation due to formation of 
carboxyhaemoglobin (COHb). Carcinogens include aromatic hydrocarbons, 
amines, and nitrosamines. 
Both the gas phase of cigarette smoke and the tar component can lead to the 
generation of ROS (134-136) (Figure 1.2). In addition to direct inhalation of 
ROS from cigarette smoke, the inflammatory process that occurs in smoker's 
lungs can lead to further generation of oxidants by nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase in leukocytes drawn to the site of 
inflammation. Neutrophil death and necrosis leads to high concentrations of 
neutrophil elastase and ROS in sputum (137). ROS may also be important 
mediators in asthma (138). 
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Reactive oxygen species (ROS) include superoxide anion (02'"), hydrogen 
peroxide (H202) and hydroxyl radicals (OH). Most of the oxygen we inspire is 
reduced within the mitochondrial electron transport chain in a reaction catalysed 
by cytochrome oxidase to produce water (133). To allow continued electron 
transport and ATP generation, cytochrome oxidase donates its electron to 
oxygen to generate ROS such as 02'". In addition, 02' is generated by NADPH 
oxidase found in neutrophils and monocytes/macrophages. O2*" is relatively 
unstable and does not readily cross cell membranes. O2*-may be converted to 
H202 by superoxide dismutase (SOD), and the H2O2 may itself be oxidised by 
myeloperoxidase (MPO) or eosinophil peroxidase (EPO) to hypochlorous acid 
(HOCI). Alternatively, O2' and H202 may interact in the presence of ferrous ions 
(Fe 2+) to form the highly reactive -OH, which is thought to be a major mediator of 
ROS damage. 
Free radicals can also react with polyunsaturated fatty acid side chains that are 
present in membrane or lipoproteins, leading to the formation of lipid 
peroxidation products such as isoprostane which is a marker of oxidant stress 
but may have important effects as a mediator of disease (139). Oxidants also 
activate the transcription factor for NF-KB which then promotes the transcription 
of many other pro-inflammatory mediators, while hydrogen peroxide causes an 
increase in histone acetylation (140). Herne oxygenase-1 (HO-1) is a stress 
response protein induced by oxidants (141). 
Reactive nitrogen species (RNS) include nitric oxide (-NO) and its derivatives 
such as nitrogen dioxide (NO2) and peroxynitrite (ONOO") (142) (Figure 1.3). 
NO is itself a gaseous radical and has complex regulatory actions in a variety of 
inflammatory and infectious conditions. Nitric oxide synthase (NOS) converts L- 
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arginine to L-citrulline and generates NO. 02 can react with NO to form 
ONOO", a very unstable and highly reactive molecule that mediates many of the 
damaging effects of oxidative stress (142). When ONOO" becomes protonated it 
isomerises to trans-peroxy nitrous acid, which leads to the formation of 'OH. 
ONOO" reacts with tyrosine residues within certain proteins to form stable 3- 
nitrotyrosines which may be detected immunologically. Increased levels of 3- 
nitrotyrosines have been detected in sputum macrophages from patients with 
COPD (143). Nitrite (N02") is a major end product of NO metabolism that is 
rapidly metabolised to nitrate (N03) and has been shown to promote tyrosine 
nitration by reaction with hypochlorous acid (HOCI). Myeloperoxidase has the 
capacity to produce nitrating oxidants and may also nitrate tyrosine residues 
(144; 145). 
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1.2.3.2 Oxidant stress in COPD 
The lungs are unique because they have a large epithelial surface area that is 
exposed to oxidants or generators of oxidant stress such as cigarette smoke or 
airborne pollutants. There is considerable evidence that oxidative stress is 
increased in patients with COPD (128-130; 132; 146). The major oxidants in 
airways are reactive oxygen and reactive nitrogen species (ROS/RNS). ROS 
include superoxide, hydrogen peroxide and hydroxyl radicals. RNS include nitric 
oxide and its derivatives such as nitrogen dioxide and peroxynitrite. Each puff of 
cigarette smoke contains in the order of 1017 ROS molecules. In addition to 
direct inhalation of ROS from cigarette smoke, the inflammatory processes that 
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occur in smokers lungs can lead to further generation of oxidants by 
nicotinamide adenine dinucleotide phosphate (NADPH) in leukocytes drawn to 
the site of inflammation. Neutrophil death and necrosis leads to high 
concentrations of neutrophil elastase and ROS in sputum (137). 
Superoxide radicals can combine with nitric oxide to form peroxynitrite; this is a 
very stable molecule which increases its ability to diffuse through a cell to find a 
target. When peroxynitrite becomes protonated it isomerises to trans-peroxy 
nitrous acid, which leads to the formation of hydroxyl radicals, a further oxidant 
stress. Peroxynitrite reacts with tyrosine residues within certain proteins to form 
3-nitrotyrosines which may be detected immunologically. Increased levels of 3- 
nitrotyrosines have been detected in sputum macrophages from patients with 
COPD (143). Nitrite is a major end product of nitric oxide metabolism, and has 
been shown to promote tyrosine nitration by reaction with the inflammatory 
mediators hypochlorous acid or myeloperoxidase an enzyme found in 
neutrophils (144). 
Assessment of oxidant and antioxidant status may be performed in a non- 
invasive manner by analysis of exhaled breath condensate (147-152). Markers 
of oxidative stress measured in exhaled breath of patients with COPD include 8- 
isoprostane (153; 154), ethane (155; 156) and aldehydes (157). There is an 
increase in these markers during exacerbations (154; 158). However, concerns 
have been expressed about the reproducibility of some of these oxidative stress 
biomarkers assessed in breath condensate, sometimes due to sensitivity of 
assays in relation to low concentrations (159-161). A problem with 
measurement of exhaled hydrogen peroxide in COPD is that there must be a 
properly matched control group with matched smoking status and age 
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(158; 162). Markers of oxidative stress are also increased in smokers with 
normal lung function, but to a lesser extent than in COPD patients (151). 
The lungs have protective antioxidant mechanisms, and damage can occur 
when this equilibrium is disturbed either by depletion of antioxidants or excess 
production of ROS or RNS (133). Superoxide dismutase (SOD) acts to protect 
the lungs from increased oxidative stress by catalyzing the formation of H202, 
which is then degraded by catalase to water and oxygen (163). Glutathione 
(GSH) is a ubiquitous tripeptide that contains a suifhydryl (-SH) group that 
enables it to protect cells against oxidants (164; 165). Oxidant stress induces 
glutathione synthesis in human bronchial epithelial cells (166). H202 can be 
rendered less toxic by reacting with reduced glutathione under the action of 
glutathione peroxidase. Glutathione peroxidase is present within cells and is 
also secreted into the epithelial lining fluid. It has been shown that bronchial 
epithelial cells, alveolar macrophages and interstitial cells are potential sources 
of pulmonary extracellular glutathione peroxidase (167). Nonenzymatic 
antioxidants also exist; these include vitamin E, vitamin C, ß-carotene, uric acid, 
glucose, bilirubin, taurine, albumin, and cysteine and cysteamine. 
It has been shown that plasma antioxidant capacity is significantly reduced in 
healthy smokers and in patients with COPD compared with non-smoking 
healthy subjects (168). These changes were present in patients with COPD who 
were ex-smokers suggesting that at least a component of the oxidative stress 
comes from endogenous inflammation rather than the direct effects of cigarette 
smoke. Sputum concentrations of glutathione disulphide (GSSG) and nitroso 
thiols are increased in sputum supernatants of patients with COPD (169). The 
ability of epithelial lining fluid (ELF) to provide antioxidant protection to lung 
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parenchymal cells has been evaluated by assessing the response of cells in 
culture in response to hydrogen peroxide (170). It was demonstrated that ELF 
does provide protection against H202, and this is mainly due to the presence of 
catalase. Oxidants cause a variety of cell signalling events including activation 
of adenylate cyclase, IKB kinases and NF-KB, p38 MAPK and PI-3Ky. These 
cause inflammatory gene activation and release an upregulation of cytokines, 
chemokines, adhesion molecules and proteases. 
1.2.3.3 Inflammatory cells in COPD 
Neutrophils 
Neutrophils have been found in increased numbers in the sputum and BAL fluid 
of patients with COPD (171-175). An increased level of sputum neutrophils is 
associated with a rapid decline in FEV1 in smokers, indicating that neutrophils 
may play a role in disease progression (176). It is also interesting to note that 
induced sputum from ex-smokers show similar neutrophil levels suggesting that 
inflammation may persist once established (176-178). However increases levels 
of neutrophils are not seen in bronchial biopsies from patients with COPD 
(171; 179; 180). This may be due to the neutrophils being in a location other than 
the subepithelial zone obtained in biopsies or rapid transit of neutrophils through 
the lung parenchyma into the lumen. There are a number of chemotactic stimuli 
that may lead to neutrophil accumulation including LTB4 and IL-8 and increased 
levels of IL-8 have been found in the BAL fluid of smokers susceptible to COPD 
(181). Neutrophil recruitment to the airways involves vascular adhesion and E- 
selectin has been shown to be upregulated on the bronchial epithelium in 
COPD (182). 
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Neutrophils secrete serine proteases including neutrophil elastase, cathepsin G, 
and proteinase-3, as well as matrix meta Iloproteinase (MMP) 8 and MMP-9. 
The observation that increased neutrophils are not found within biopsy 
specimens is consistent with the observation that there is a negative correlation 
between number of neutrophils and amount of alveolar destruction (183). These 
enzymes are however potent mucus stimulants and excess mucus production is 
a feature of COPD. 
Macrophages 
Macrophages are thought to play a significant role in the development of COPD. 
Macrophage numbers are increased in BAL fluid of patients with COPD (184), 
and numbers of macrophages in the airways correlates with the amount of 
parenchymal destruction in emphysema (179). In addition macrophages are 
concentrated in the centriacinar zones where emphysema is most marked 
(179). The number of macrophages also correlated with disease severity (185). 
Increased levels of MCP-1 and GROa have been found in the sputum and BAL 
fluid of COPD patients providing a mechanism for macrophage recruitment 
(186; 187). Macrophages release inflammatory mediators and elastolytic 
enzymes when stimulated with CSCM in vitro and this provides a mechanism 
for the inflammatory changes seen in COPD (188-190). 
T lymphocytes 
Increased numbers of CD45+ cells (total leukocytes) and CD3+ cells (T 
lymphocytes are found in chronic bronchitis with a greater proportional increase 
in CD8+ (cytotoxic/suppressor) cells (191-193). The increase in CD8+ cells is 
associated with a decline in lung function (180). It is not yet clear how T cells 
are attracted to the lung although it has been suggested that there is chronic 
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immune stimulation via antigens presented via the HLA class 1 pathway (194). 
It also remains unclear how the CD8+ cells contribute to the pathological 
features of COPD, although their ability to cause apoptosis of alveolar cells may 
playa role (195; 196). 
Epithelial cells 
In normal lung the airway epithelial cells act in a protective manner by 
producing anti-oxidants, defensins and anti-proteinases. However airway 
epithelial cells may be important in the initiation and propagation of 
inflammation in COPD as they are stimulated by cigarette smoke to produce 
TNF-a, IL-1 P, GM-CSF and IL-8 (197-199). 
Eosinophils 
Whilst eosinophils are characteristically thought to be a feature of allergic 
disease there is some evidence for their role in the pathogenesis of COPD, 
although this remains controversial. It has been noted that the presence of 
eosinophils in the sputum predicts a response to treatment with corticosteroids, 
and it has been proposed that this indicates co-existing asthma (200). It has 
been noted that there are increased numbers of eosinophils present during 
acute exacerbations of COPD and this is due to upregulation of RANTES in the 
epithelium and sub epithelium (201). 
1.2.3.4 Cytokines and chemokines 
Increased levels of IL-6, HAP, TNF-a and IL-8 have been found in sputum 
samples from patients with stable COPD (174). Levels of TNF-a, IL-1ß, IL-6, IL- 
8 and MCP-1 are increased in BAL taken from smokers compared with non- 
smokers (202). The CC chemokine macrophage chemotactic peptide-1, MCP-1, 
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is increased in BAL of COPD patients (187). MCP-1 is a potent chemoattractant 
for monocytes, and acts via CCR2. MCP-1 causes T-cell and monocyte 
migration, and this may lead to the accumulation of these cells into the airways 
in COPD. GRO-a (growth related oncogene-a) is elevated in COPD (186) and 
is chemotactic for monocytes as well as neutrophils and may therefore 
contribute to the increased numbers of macrophages that are derived from 
blood monocytes in COPD. Elevated expression of MCP-1, TGF-ß and IL-8 and 
their mRNA has been seen in the bronchiolar epithelium in smoker with COPD 
compared with smokers without COPD (203). 
There are increased amounts of LTB4, a potent chemoattractant of neutrophils, 
in the sputum of patients with COPD (204). LTB4 is probably derived from 
alveolar macrophages and neutrophils themselves. Alveolar macrophages from 
patients with al-anti-trypsin deficiency secrete greater amounts of LTB4 (205). 
IL-8 is a chemoattractant for neutrophils present in high concentrations in 
induced sputum of patients with COPD (174; 206), and found in increased 
amounts in BAL fluid (206; 207) IL-8 is secreted by macrophages, neutrophils 
and by airway epithelial cells (208) and signals through two receptors: a low 
affinity CXCR1 specific for IL-8 that is involved in neutrophil activation, and a 
high affinity CXCR2 that is activated by a range of CXC chemokines including 
IL-8, growth related oncogene (GRO-(x, -ß, -y), and epithelial-derived neutrophil 
activating peptide, ENA-78. CXCR2 is involved in the chemotaxis of neutrophils 
and monocytes. Higher levels of IL-6 and IL-8 are found in the induced sputum 
from patients with increased numbers of exacerbations (209). 
TNFa is present in high concentration in the sputum of COPD patients (174), 
especially during exacerbations (210). TNFa may activate the transcription of 
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NF-x6, which switches on the transcription of inflammatory genes, including 
chemokine (IL-8) genes and proteases, in macrophages and epithelial cells 
(211). Serum concentrations of TNFa and stimulated TNFa production from 
peripheral blood monocytes are increased in weight losing COPD patients 
(212). 
Transforming growth factor-ß1 has increased expression in small airway and 
alveolar epithelial cells in COPD, and participates in the fibrotic processes that 
take place in the small airways (213; 214). As fibrosis has been shown to be a 
component of COPD pathogenesis then extrapolation of the processes that 
occur in fibrotic lung disease may be relevant. TGF-ß, connective tissue growth 
factor, platelet-derived growth factor and IL-13 have all been shown to be 
involved in the pathogenesis of idiopathic pulmonary fibrosis (215). IL-13 and 
interferon-7 are overexpressed in a murine form of emphysema that is mediated 
by increased expression of MMPs and cathepsins (216; 217). Endothelin-1 
levels are increased in the sputum of patients with COPD, particularly during 
exacerbations (218; 219). ET-1 may be important in pulmonary vascular 
remodelling in severe pulmonary hypertension (220). Cigarette smoke extract 
has been shown to induce COX-2 with concurrent synthesis of prostaglandin E2 
by normal human lung fibroblasts producing a pro-inflammatory environment 
(221). 
1.2.3.5 Protease-Antiprotease Balance 
The key to the pathogenesis of emphysema is believed to be an imbalance of 
proteases and antiproteases in the lung (222). An excess of proteases capable 
of degrading extra-cellular matrix components, in comparison to their inhibitors, 
leads to the destruction of the extracellular matrix seen in emphysema. Elastin 
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degradation may be particularly important in the pathogenesis of emphysema 
since elastin cannot be regenerated in an active form (223). 
Proteases are also potent stimulators of mucus secretion. Neutrophils and 
macrophages are producers of proteases and are present in increased numbers 
in COPD. Matrix metalloproteinases (MMPs) are a group of over 20 closely 
related endopeptidases produced by both neutrophils and alveolar 
macrophages as well as airway epithelial cells (224). Activities of collagenase 
(MMPs-1 & 8) and gelatinase B (MMP-9) are elevated in BAL fluid in 
emphysema in comparison to healthy controls (225; 226). Whilst neutrophil 
elastase and gelatinase B activities may be increased as a direct result of 
smoking, increased collagenase activity seems to be more specific for COPD 
(227). Alveolar macrophages cultured from BAL fluid express increased levels 
of mRNA transcripts for MMP-9 in emphysema, but no differences are seen 
between disease and health for MMP-1 or MMP-12 mRNA transcript levels 
(228). Increased MMP-9 levels and activity have also been demonstrated in 
induced sputum in COPD (229). Increased MMP-1 levels and activity have also 
been demonstrated in emphysematous lung parenchyma, suggesting that 
MMP-1 may play a key role in the pathogenesis of emphysema. 
1.2.3.6 Receptors, kinases and transcription factors 
The cytokines and chemokines discussed in section 1.2.3.4 act through a series 
of receptors. IL-8 binds to both CXCR1 and CXCR2. CXCR2 is also activated 
by other mediators relevant to the development of COPD (230). CD8+ cells 
show increased expression on CXCR3 in the airways of patients with COPD. 
(231) Mitogen-activated protein (MAP) kinases are associated with chronic 
inflammation and the p38 MAP kinase pathway is activated by cellular stress 
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and regulates the production of inflammatory cytokines, including IL-8, TNF-a 
and MMPs. (232; 233). In a murine macrophage model of oxidant stress 
generated by ischaemia leads to activation of p38 MAPK is an Src-dependent 
manner and P38 does not have a direct role in inducing oxidant dependent NF- 
KB translocation (234). 
The transcription factor NF-KB regulates the expression of IL-8, TNF-a and 
some matrix meta Iloproteinases. Acute exposure to cigarette smoke causes 
expression of NF-KB through a superoxide dependent mechanism, which 
results in neutrophil accumulation in the airways (235). NF-KB has been shown 
to be activated in the macrophages and epithelial cells of COPD patients and 
this is particularly pronounced during exacerbations (236; 237). It has been 
shown that smoke induced activation of human monocytes and macrophages to 
produce IL-8 is oxidant mediated via the activator protein-1 pathway, but not the 
NF-KB pathway (238). Toll-like receptors (TLRs) are essential for the immune 
response to invading micro-organisms, and they may have a significant role to 
play in the development of the chronic inflammation that is seen in COPD (239). 
TLRs are a pattern recognition receptor (PRR) and are part of the innate 
immune system and bind to molecules that are shared by pathogens but are 
distinct from host molecules, collectively referred to as pathogen-associated 
molecular patterns (PAMPs). Thirteen types of TLRs have been discovered in 
humans, and activation triggers a series of signalling pathways that results in 
the activation of transcription factors such as NF-KB (240). The TLRs of 
particular interest in COPD are TLR2 and TLR4 as they have been shown to be 
involved in the response to cigarette smoke challenge, LPS and oxidant stress 
(241; 242) 
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Figure 1.4 shows the inflammatory changes that occur in COPD as a result of 
cigarette smoke exposure. 
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1.2.3.7 Nasal disease in COPD 
Epidemiological studies have shown that rhinosinustits occurs in COPD and 
may be associated with significant nasal symtptoms (112; 112). The severity of 
nasal obstruction is proportional to the severity of airway obstruction and hence 
disease severity (243). Nasal inflammation is also seen to increase in parallel to 
bronchial inflammation at the time of exacerbations of COPD (244). There is 
also a direct link between the development of nasal symptoms, including 
rhinorrhoea, nasal congestion and sneezing, and cigarette smoking (245; 246). 
Passive exposure to cigarette smoke also causes inflammation of the nasal 
mucosa (247), and nasal obstruction as measured by rhinomanometry (248). 
The mechanism of the nasal inflammation is not clear, although it is likey to be 
similar to that found in the lungs. Patients with COPD have increased numbers 
of neutrophils in both nasal and bronchial biopsy specimens (249). It has also 
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been shown that patients with COPD have increased nasal neutrophil activity 
and increased mucinous secretory responsiveness (250). Some of the effects of 
smoking may also be due to the deleterious effect of cigarette smoke on 
mucociliary clearance (251) 
1.3 Current treatment and potential new therapeutic agents for allergic 
rhinitis, asthma and chronic obstructive pulmonary disease 
1.3.1 Allergic rhinitis 
Current pharmacological treatment of allergic rhinitis involves anti-histamines, 
steroids and immunotherapy. Oral H1 antihistamines are taken daily and are 
rapidly effective on some nasal and eye symptoms but are only moderately 
effective on nasal obstruction. Intranasal glucocorticoids are the most effective 
therapy for allergic rhinitis and are effective on nasal congestion. The maximal 
effect is seen after a few days of use, and their use is recommended in the 
weeks preceding the pollen season. If symptoms are particularly severe then a 
short course of oral glucocorticoids may be necessary. 
Allergen avoidance is a part of the management of allergic disease. Severity of 
asthma is related to the level of allergen exposure (252; 253). However the 
relationship between levels of exposure and asthma symptoms is complex, with 
differing levels of allergen required to trigger symptoms (254). Atopic asthmatics 
who are exposed to high levels of house dust mite or dog allergens but are not 
sensitized to these allergens as determined by skin prick testing have increased 
airway reactivity (255). 
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There are significant difficulties in obtaining a randomised blinded trial removing 
bias in assessing allergen avoidance and several studies have provided 
conflicting evidence on the benefits of removing allergens from the home (256). 
Removing the allergen can be difficult, with domestic pets it has been shown 
that removal of the cat from living room and bedroom areas and the use of a 
HEPA (high efficiency particulate air) filtration can reduce airborne levels of Fel 
d1 in homes. (257). A randomized trial of the use of air filters and HEPA vacuum 
cleaners in 30 sensitized asthmatics who shared a home with cats or dogs 
resulted in a small but significant improvement in bronchial hyper-reactivity or a 
reduction in treatment by one step on the British Thoracic Society guidelines. 
There were however no changes in lung function or levels of airborne pet 
allergen (258). 
The removal of house dust mite allergen is a lot more problematic. The use of 
vacuum cleaners can actually lead to an increase in allergen exposure, and 
HEPA cleaners do not reduce the level of allergen exposure. The use of 
special bed lines has been proposed to reduce exposure to house dust mite 
allergen, however this intervention has not been shown to bring about symptom 
control in adults, but children showed an improvement in asthma control(259). A 
large study of the use of allergen-impermeable bed covers in asthmatic patients 
has shown no clinical benefit as determined by the success of a steroid 
weaning programme (260). 
Allergen avoidance should bring about significant improvement in seasonal 
allergic rhinitis as patients do not suffer any symptoms outside of the pollen 
season. However avoidance of pollen can be difficult but there is evidence that 
nasal filters reduce both the nasal and ocular symptoms associated with pollen 
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exposure (261). The many trials of allergen avoidance are reflected in the 
recent British Society for Allergy and Clinical Immunology guidelines suggest 
advising allergen avoidance for allergy to domestic pets, horses and 
occupational allergens such as latex (262). 
Leukotriene receptor antagonists have a role to play in the treatment of 
seasonal allergic rhinitis (263), although not all patients show benefit (264). A 
recent systematic review and meta-analysis of the use of montelukast in allergic 
rhinitis has concluded that montelukast does reduce nasal symptom scores , 
but is not as effective as topical nasal steroids and when used it should be in 
combination with an anti-histamine (265). 
Nasal douching with saline is simple procedure that can be used as an adjunct 
to pharmacological therapies in allergic rhinitis (266; 267). Topical cromones 
have an undefined mechanism of action, and are particularly effective for eye 
symptoms however their intranasal use is less effective. Sodium chromoglycate 
only has very limited activity in the treatment of allergic rhinitis (268). 
Oral decongestants are sympathomimetic drugs that act to reduce the 
symptoms of nasal congestion. They are often poorly tolerated as they have a 
poor side effect profile and have no effect on the other symptoms of rhinitis. 
1.3.2 Asthma 
The aim of asthma treatment is to minimise asthma symptoms and to limit its 
effects on activities of daily living. Avoiding triggers is important, especially in 
atopic asthma. A stepwise approach to the treatment of asthma has been 
recommended by the Global Initiative for Asthma (GINA) work group (7; 269). 
The latest issue of the guidelines emphasise control of asthma symptoms. The 
following table summarises the advice given in the GINA guidelines. Patients 
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should be reviewed regularly, and if stable for a three month period then 
treatment should be stepped down. 
A proportion of patients will continue to have persistent symptoms despite being 
on maximal therapy as defined by GINA. Attempts have been made to reduce 
the dose of oral corticosteroids by using other anti-inflammatory therapies such 
as methotrexate and cyclosporine. There is limited evidence that these 
therapies achieve that goal but they are associated with a significant side effect 
profile (270; 271). Specific targeting of the CD4 T cell population using a 
monoclonal antibody has also been trialled in the treatment of severe 
corticosteroid dependent asthma (272).. 
A major change in the way asthma medication is prescribed has been achieved 
by a regimen known as SMART (Symbicort Maintenance And Relief Therapy). 
Symbicort is a combined inhaler consisting of an Inhaled CorticoSteroid (ICS) 
and Long-Acting ß2-Agonist (LABA) that has a licence to be taken as a regular 
maintenance treatment and as needed in response to symptoms There have 
been 8 published large RCTs that have assessed the impact of SMART 
compared with fixed doses of ICS and showed a reduction in severe 
exacerbations and a lower total ICS dose (273-280). 
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i awe i-z - aummar oT b11VH uiaeiines Tor [ne mans ement OT astnma 
Level of severity 
Daily Controller Other treatment 
Medications options 
STEP 1 Intermittent None necessary As need bronchodilator 
Sustained release 
STEP 2 Mild persistent 
Low dose Inhaled theophylline or 
CorticoSteroid (ICS) Cromone or 
Leukotriene modifier 
Medium dose ICS plus 
sustained release 
Low to medium theophylline OR 
STEP 3 Moderate dose ICS plus long Medium dose ICS plus 
persistent acting ß2 -agonist LABA OR 
(LABA) High dose ICS OR 
Medium dose ICS plus 
leukotriene modifier 
High dose ICS plus 
LABA one or more 
of the following 
STEP 4 Severe Sustained release 
persistent 
theophylline 
Leukotriene modifier 
Long acting oral ß2 - 
agonist 
Oral corticosteroid 
1.3.3 New treatments for allergy and asthma 
There is a need for new treatments as although corticosteroids are very effect 
they are associated with side effects which limit compliance, and there is a 
group of patients with severe asthma who do not respond to treatment with 
corticosteroids (281). 
There have been two main new therapies in the treatment of allergic disease in 
recent years. A humanised anti-IgE monoclonal antibody (Xolair, Novartis- 
Genentech) has a licence for the treatment of severe persistent asthma not 
responding to high dose inhaled corticosteroids and long acting beta agonists 
(282). A novel immunotherapy agent using sublingual immunotherapy (SLIT) 
involving grass pollen is now available, and hopefully will improve access to this 
type of therapy that was previously given by subcutaneous injection (283). 
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Previous attempts at directed anti-inflammatory therapies have been 
disappointing. Soluble IL-4 receptor (Nuvance, Immunex) failed to show clinical 
efficacy in large scale trials after promising results in early phase trials 
(284; 285). An anti-IL-5 antibody has been shown to reduce blood eosinophils 
but does not remove eosinophils from airway walls (286) and has been shown 
to have limited efficacy in moderate (287) and severe asthma (58). However 
anti-IL-5 has been shown to reduce eosinophil numbers and tenascin deposition 
in allergen challenged human atopic skin (59), as well as extracellular matrix in 
bronchial subepithelial basement membrane (59). Although disappointing in 
asthma and eczema anti-IL5 has been shown to be effective in 
hypereosinophilic syndrome with skin manifestations (288-290), eosinophilic 
oesophagitis (291). Anti-1L5 has also been shown to reduce the size of nasal 
polyps in 50% of patients (292). A soluble TNFa receptor construct has been 
shown to be effective in a small group of patients with severe asthma (n=10) 
(293), while an antibody directed against TNF-a (Remicade, Centocor) has 
been shown to decrease exacerbation rate in moderate asthma (294). 
Dendritic cells have a role to play in asthma as they present antigen to Th2 cells 
and their activity is stimulated by thymic stromal Iymphopoietin (TSLP) (295). 
Hence blocking the effects of TSLP may have significant effects on the 
development of allergic disease. Regulatory T cells also have a role in 
modifying the immune response, and it has been shown that immunotherapy 
increases IL-10 production by regulatory T cells (296). Hence therapies that 
enhance T regulatory cells function and increase IL-10 production are being 
developed. IL-12 acts to suppress Th2 cells, and administration of IL-12 
reduces levels of blood eosinophils, but does not reduce responsiveness to 
inhaled allergen and has a poor side effect profile (297). Administration of T cell 
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peptides has the potential to achieve the same effects as immunotherapy but 
with an improved safety profile (298). 
Targeting cytokines is also likely to yield new agents to target allergic disease, 
although as discussed above clinical trials have so far been disappointing. IL-9, 
IL-15, IL-17, IL-18 and IL-21 are all potential targets to modulate responses in 
allergic disease. All of the mediators of allergic disease act through receptors 
which in turn trigger intra-cellular signalling. The commonest signalling 
pathways in allergic disease are NF-KB and P38 MAP kinase and inhibitors of 
these are available (299; 300). A major limitation is that these enzymes are 
ubiquitous in human cells and hence may need to be given by inhalation to 
prevent unacceptable side effects. At a protein synthesis level, antisense- 
oligodeoxynucleotides and interference RNA (RNAi) can inhibit the production 
of inflammatory mediators (301; 302). 
1.3.4 COPD 
The most important therapeutic intervention is smoking cessation and patients 
should be given enough encouragement and pharmacological support to 
achieve this. Vaccination against influenza and pneumococcus also play an 
important preventive role in the treatment of COPD. The GOLD guidelines 
provide a stepwise approach to treatment based on lung function determined 
severity (303). Mild COPD with an FEV1 of z 80% predicted can be treated with 
an inhaled short acting bronchodilator when needed. For moderate COPD with 
an FEV1 < 80% predicted but z 50% predicted a long acting bronchodilator 
should be added and the patient considered for a pulmonary rehabilitation 
program. For severe COPD with an FEV, < 50% predicted but ; >- 30% predicted 
the management should be as for moderate COPD but inhaled corticosteroids 
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(ICS) should be added if there are frequent exacerbations (304). Very severe 
COPD is defined as and FEV, < 30% predicted or < 50% predicted with chronic 
respiratory failure, and should be managed as for severe COPD with the 
addition of long term oxygen therapy if there is chronic respiratory failure and 
surgical treatments including lung transplantation should be considered. 
Bronchodilators have been shown to improve exercise capacity independently 
of their effects on lung function (305; 306)., and combinations of bronchodilators 
with differing mechanisms of action leads to a synergistic effect (307; 308). 
Development of new therapies to aid in smoking cessation or improved 
bronchodilators and inhaled corticosteroids are all areas of great interest to 
pharmaceutical companies working towards improvements in the management 
of COPD. 
As the pathophysiology of COPD becomes more defined and the precise 
cellular pathways involved in inflammation then potential new targets for drugs 
can be identified. There is also considerable evidence that oxidative stress 
plays a large role in the development of COPD (146), and it has been 
suggested that targeting this would bring benefits (309). However studies with 
oral N-Acetyl Cysteine (NAC) have shown a small but significant reduction in 
exacerbation frequency (310), and more effective antioxidants may bring about 
greater clinical effects. Selective inhibitors of NOS have been developed and 
these may result in reduced production of free radicals in the airways (311). 
Phosphodiesterase (PDE4) is the predominant PDE in neutrophils, CD8 T cells 
and macrophages (312) and hence is a logical choice to target to reduce 
inflammation in COPD. The PDE4 inhibitor Cilomilast (GSK) has been shown to 
reduce CD8+ and CD68+ cells in the airways of patients with COPD, however 
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this did not result in any changes to sputum parameters or FEV, (313). However 
in a larger study Cilomilast did cause a reduction in trough FEV1, although the 
reduction was small and quality of life outcome measures were unchanged 
(314). The main draw back with the PDE4 inhibitors is that the dose is limited 
by the gastro-intestinal side effects of nausea and loss of appetite. 
Leukotriene B4 is a potent chemoattractant for neutrophils and is increased in 
the sputum of patients with COPD (204) and a receptor antagonist has been 
shown to inhibit the neutrophil chemotactic activity of COPD sputum (315). The 
CXC chemokines IL-8 and GRO-a are increased in COPD and act via the 
CXCR2 receptor, hence antagonists of this are potential new therapies. The CC 
chemokine MCP-1 is also implicated in the pathogenesis of COPD suggesting 
that CCR2 receptor antagonists may also be useful. TNF-a is also raised in 
COPD and early phase trials of a TNF-a antibody in asthma have been 
promising (294). However a study of the use of a monoclonal antibody against 
TNF-a (Remicade, Centocor) did not show any benefit in moderate to severe 
COPD and there were increased rates of malignancy in the treatment group 
(316). 
The protease, anti-proteinase balance is also a potential site for drug 
development either through delivery of inhibitors of proteases or administration 
of anti-proteases such as a1-antitrypsin of secretory leukoproteinase activity. 
The recruitment of inflammatory cells into the airways is dependent on the 
presence of adhesion molecules on the surface of the cells and hence inhibitors 
of these molecules would seem to be a good target for an anti-inflammatory 
treatment. However these adhesion molecules also form an essential part of the 
defence mechanism against invading pathogens and hence may be associated 
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with an unacceptable level of immunosuppression. p38 MAP kinase is involved 
in the intra-cellular cascade that leads to the expression of inflammatory 
cytokines and chemokines and inhibitors of these have been developed and 
may have useful anti-inflammatory effects (317). Attempts at regeneration of 
lung tissue using retinoic acid has been disappointing (318), but stem cell 
regeneration has the potential to be used in lung regeneration (319). 
1.4 Non-invasive assessment (biomarkers), challenge models, and early 
clinical trials of novel anti-inflammatory drugs 
A biomarker is a molecular indicator of a specific biological property that can be 
detected ex vivo and can be used to measure the progress of disease or the 
effects of treatment. Biomarkers can be used as an indicator of normal 
biological processes, pathogenic processes, and pharmacologic responses. 
Biomarkers are surrogate markers that may correlate with a clinical endpoint 
(320). It has been argued that waiting for clinical endpoints to be measured can 
lead to long delays in the introduction of new drugs and the use of a surrogate 
biomarker can expedite the introduction of a new drug (321). Due to the burden 
of respiratory disease, there is a need for new therapeutic agents. Based on the 
numerous potential new anti-inflammatory drugs, there is the need for models to 
allow rapid assessment of new molecular entities. Translational medicine is a 
rapidly expanding field and aims to speed the process between new scientific 
insights, drug target identification, and clinical trials to assess novel treatments, 
that permit new drugs to become licensed for use in patients. 
To improve safety of phase 1 trials it is vital to have in vitro methods of 
assessing effects in human models. Because of species differences it is not 
always possible to transfer safety data from animal studies to humans. This is 
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particularly relevant in the development of human monoclonal antibodies the 
effects of which cannot be reliably carried across species. The catastrophic 
events that occurred during the testing of the monoclonal antibody (MoAb) 
against CD28, TGN 1412 in March 2006 at The Parexel research unit located at 
Northwick Park Hospital only re-enforce the need to be sure of a drugs full 
range of effects before administration to volunteers. The drug was given by 
rapid IV infusion to 6 previously healthy volunteers, and they went on to develop 
multi-organ failure due to a cytokine storm (322). At high doses TGN 1412 
becomes a superagonist causing T cell cytokine release, and we require human 
blood in vitro safety tests to identify potential toxic effects of biological therapies 
such as TGN 1412 (323) To aid assessment of new therapies, it would be 
useful if a model could be developed that allowed effect to be determined after 
a single dose of some drugs. This would also have the benefit of limiting patient 
exposure to drug. If a compound showed limited effects in these early studies 
then it would not be worth pursuing in larger scale trials. It is important however 
to note that efficacy in the pre-clinical models does not guarantee clinical effects 
in the target patient group. 
Animal allergic models are generally based on murine ovalbumin sensitisation 
which allows small amounts of new molecular entities to be assessed for anti- 
eosinophilic effects. The study of seasonal allergic rhinitis is affected by the 
short pollen season which make cross-over studies impossible to carry out, and 
the pollen exposure can vary daily hence relying on the naturally occurring 
disease state can be difficult. It is advantageous to have a model that 
challenges with a quantified allergen dose out of the pollen season to allow for 
cross over design trials. To mimic allergen exposure it is possible to utilise a 
Vienna chamber, which is a closed unit where allergen is introduced and the 
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subjects are exposed in a way that mimics their normal allergen exposure. This 
has the advantage of allowing a large number of subjects to be exposed at 
once. It is also possible to directly apply allergen to the mucosa via a nasal 
spray; this is a quick and reliable way to apply allergen specifically to the area of 
interest. An alternative human model is intradermal administration of allergen 
which has proved to be a useful model of immune response to allergen 
(324; 325). 
To mimic the allergic responses in asthma the inhaled allergen challenge is 
used, where subjects inhale an antigen they are allergic to and then undergo 
airway sampling either by inducing sputum or obtaining samples 
bronchoscopica Ily. However this can sometimes provoke dramatic fall in lung 
function, and repeated challenge and airway sampling at frequent intervals is 
not possible. Alternative models of asthma have been developed such as 
inhaled methacholine, which is a non-selective muscarinic receptor agonist 
acting on bronchial smooth muscle.. There was a death in a healthy volunteer 
who inhaled hexamethonium, an acetylcholine receptor antagonist, as part of a 
study investigating the inflammatory responses in asthma. Careful review 
following this death concluded that there had been some data presented in the 
1950's that had indicated a problem with this challenge model and one paper 
failed to include details of problems in subjects because breathlessness and 
cough had been attributed to viral infections (326). 
Challenge models for COPD are either currently animal models such as the 
smoking mouse model or in vitro human models such as cigarette smoke 
conditioned medium or LPS challenge of isolated human lung macrophages. 
There is currently no safe, reliable in vivo human model of COPD. It has been 
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suggested that inhaled LPS would be a good model for testing new drugs in 
COPD, however very careful consideration must be given to the safety of this. It 
is important to remember that patients with COPD are considerably older than 
subjects undergoing allergen challenge, and as a consequence of this and their 
smoking history often have co-existing disease. Therefore any challenge 
models in this group of patients must be the least invasive possible and ideally 
avoid the need for any procedures which may cause a reduction in lung 
function. 
It can be seen that it would be extremely useful to have human blood and nasal 
challenge models to assess new therapies for allergic disease and COPD. For 
allergic disease it is relatively easy to mimic the acute and late phase reactions 
by administering allergen. However the situation with COPD is much more 
complex as the disease arises from chronic exposure to a stimulus, most 
commonly cigarette smoke, over a long period of time hence developing an 
acute model is much more difficult. The stimulus is also much more complex, 
allergen can be extracted and purified, but the components of cigarette smoke 
are too numerous to study individually. So in this Thesis the stimulus was either 
cigarette smoke or systems which generate oxidative stress to reproduce the 
oxidative stress component of COPD. 
The nasal mucosa is very similar to the respiratory mucosa lining the lungs and 
is in continuation with it. This means that the nasal mucosa could potentially be 
utilised as a surrogate for inhaled challenge models. The main differences are 
that the nasal sub-epithelium has a large network of blood vessels and is devoid 
of smooth muscle. Table 1.3 shows the advantages of the nasal challenge 
model over inhaled challenge models. 
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Table 1-3 Comparison of sinale inhaled and nasal allergen challennn mnrinls 
Inhaled Nasal 
Requires inhalation from a nebuliser Single nasal spray 
Single inhaled allergen challenge is Single NAC is generally repeated at 2 generally repeated at 3 weekly weekly intervals. Can be given daily intervals 
Limited number of airway samples Nasal samples can be taken every 5 
can be collected. e. g. sputum at 24h minutes 
Potential for decline in lung function, Minimal potential for allergen to reach safety concerns over anaphylaxis and the lungs decreased lung function are greater 
Requirement for allergic asthmatics 
off inhaled corticosteroids (ICS) can 
Patients with hayfever out of season 
lead to study recruitment difficulties. can 
be readily recruited 
Whole blood stimulation assays can be used early in drug development to 
determine pharmacological activity of new drugs. This can be done purely as an 
in vitro assay whereby drug is added to whole blood and responses measured, 
or as an ex vivo model whereby subjects are given the drug and 
responsiveness to whole blood challenge measured at time intervals following 
drug ingestion. A combination of these methods allows assessment of drug 
efficacy and provides information about pharmacodynamic properties. 
1.5 Aims 
Asthma and COPD are common illnesses seen in both primary and secondary 
care. Currently the main treatment is bronchodilators and inhaled steroids. 
There is considerable evidence that there is ongoing inflammation in both of 
these conditions and novel therapeutic agents could be developed to target this 
inflammation. The development of new drugs requires robust models for testing 
their efficacy. Conventionally new drugs for respiratory disease have been 
tested using inhaled challenge models, which are invasive and have limited 
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opportunities to obtain samples following challenge. This thesis develops a 
nasal challenge model for testing novel therapeutic agents for allergic disease 
and nasal and blood challenge models of COPD. 
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2 GENERAL METHODS 
2.1 Clinical 
2.1.1 Subject selection 
Subjects with allergic rhinitis were generally recruited from newspaper 
advertisements. Subjects with COPD were recruited from outpatient clinics at 
The Royal Brompton Hospital and St Mary's Hospital, Paddington. Subjects 
were also recruited from local smoking cessation courses and through 
advertisements placed in local newspapers. All studies received ethical 
approval and all subjects gave informed consent. 
2.1.2 Medical and smoking history 
All patients had a full medical history taken by a research physician on the 
Clinical Studies Unit, with particular note taken of previous respiratory illness 
and any recent viral illnesses. Patients were carefully questioned regarding any 
drugs taken including any over the counter preparations. Details of smoking 
habits were taken and a calculation of "pack years" made. 
2.1.3 Lung function 
Spirometry was performed using a computerised dry bellows Vitalograph 
spirometer which was calibrated at the start of each day. The patient was asked 
to take a full inspiration and form a tight seal around the mouthpiece and to 
perform a full forced expiration. The best of three attempts was used. 
Comparison was made to the predicted values from the European Coal and 
Steel workers (327). 
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2.1.4 Skin prick testing 
Intra-epidermal challenge with an allergen extract was used to determine 
sensitivity to Timothy grass extract. The tests were performed on the volar 
aspect of the forearm. Test sites were marked, and a single drop of negative 
control, positive control and Timothy grass solution was placed on the skin. A 
sterile lancet was introduced into the epidermis through the solution, and the 
remaining solution blotted off with a tissue. After 15 minutes the wheal size was 
measured using a transparent ruler. A positive result was taken to be a wheal 
z3mm more than the negative control. 
2.1.5 Nasal symptom scores 
Subjects completed symptom score cards supplied during the study and graded 
their symptoms as detailed. Subjects were not allowed to ask for guidance from 
the clinical staff when completing the forms. An example of a symptom score 
card is included in the appendix. A grading from 0-3 was given to the four 
symptoms of nasal blockage, rhinorrhoea, sneezing and nasal itch giving a 
maximum possible score of 12. This was recorded prior to nasal challenge and 
at time points following challenge as detailed in the study protocol. 
2.1.6 Nasal lavage collection 
Nasal lavage was performed using a modified nasal pool technique (328). Nasal 
lavage was performed using a nasal olive attached to a 10ml syringe containing 
5mis of PBS at room temperature. A nasal olive of appropriate size was placed 
gently into the anterior nares to make a close fitting seal to prevent leakage of 
lavage fluid. The subject was seated with the neck flexed to 500 from the upright 
position to prevent fluid reaching the nasopharynx. The PBS was slowly instilled 
in to the left nasal cavity and allowed to remain there for several seconds. This 
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was repeated 20 times to maximise collection for cell phase data. The volume 
of PBS recovered after lavage was noted and the sample placed on ice and 
transported to the laboratory where it was processed immediately. To ensure 
comparable baseline nasal lavage, an initial lavage was carried out in both 
nostrils prior to collection of baseline lavage and filter paper samples and the 
lavage fluid recovered discarded. 
2.1.7 Nasal filter paper technique 
A modified "matrix method" was used adapted from Alam and Sim 
(95; 329; 330). Two strips (7x 30 mm) of filter paper with rounded edges 
(Whatman No. 40; Whatman paper Ltd, Maidstone UK) were placed onto the 
lateral wall of the right nasal cavity and left for 2 minutes. After removal from the 
nose the strips were placed into a labelled eppendorf® containing 500NL of 
Luminex® assay buffer. This was then placed on ice and transferred 
immediately to the laboratory for processing. 
2.1.8 Blood collection for flow cytometry studies 
Blood was taken from an antecubital arm vein using a tourniquet. Blood was 
slowly withdrawn into a syringe using a 0.6mm internal diameter butterfly 
needle. (Venisystems). The blood was then placed immediately into a 
collection tube containing EDTA. A 0.25M solution of EDTA was used. 100NL 
was added for each 3mis of blood collected for incubations up to 30 minutes. 
For more prolonged incubations 200NL EDTA was added for each 3mls of blood 
collected. In experiments using washed cells 3mls whole blood was made up to 
12mIs using PBS and spun at 400g for 10 minutes. The supernatant was 
removed taking care not to disturb the bully coat; the cell suspension was then 
made up to 3mis using PBS. 
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2.1.9 Blood collection for cytokine/chemokine analysis 
An 18G cannula was inserted into an ante-cubital vein and flushed with 2.5mis 
normal saline to ensure patency. 5mls of blood was withdrawn and discarded 
prior to study blood sampling. 4.5mls blood was withdrawn using a vacuum 
collection system into a tube containing powdered EDTA and placed 
immediately on ice. This was then spun at 1 000g at 4°C for 10 minutes and the 
plasma removed taking care not to disturb the buffy coat. The plasma was 
aliquoted into labelled cryo tubes. 5ml blood was collected into a SST tube and 
left to stand for 30 minutes at room temperature. This sample was then spun at 
1000g for 20 minutes at room temperature and the serum carefully removed 
and aliquoted into labelled cryo tubes. The plasma and serum samples were 
stored at -20°C until analysis. 
2.2 Laboratory 
2.2.1 Nasal Lavage processing 
The total volume of nasal lavage recovered was centrifuged at 4°C for 10 
minutes at 400g. The supernatant was then aliquoted using a 3ml disposable 
wide bore pipette into a 15 ml polypropylene centrifuge tube and this was mixed 
using a vortex to ensure that the sample was homogenous. Three 500pL 
aliquots were transferred to labelled cryo tubes; these were stored at -80°C for 
latter analysis. The remaining cell pellet was resuspended in 5mls of 0.1 % DTT 
prepared fresh daily from a1% stock. This cell suspension was gently aspirated 
with a3 ml disposable wide bore plastic pipette. The sample was gently 
agitated on a rolling mixer for 10 minutes. The nasal lavage was again 
centrifuged at 4°C for 10 minutes at 400g. The DTT containing supernatant was 
removed using a 3ml disposable wide bore pipette and discarded. The 
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remaining pellet was resuspended in PBS to make a total volume of 21 Old. 1 0µI 
of sputum cell suspension was added to 101I of trypan blue (1 in 2 dilution). 
1 0µI of the mixture was placed under the microscope for cell counting using an 
improved Neubauer haemocytometer. If the cells were too dense for an 
accurate count, the procedure was repeated with additional dilution until 
satisfactory for an accurate count. The dilution was noted. Cells are counted in 
the bottom left, middle and top right quadrants of the haemocytometer grid. The 
total leukocyte count per ml is calculated, taking into account the dilution factor 
of trypan blue, by using the following formula: 
Total leukocyte count (cells/ml) = (Average no of viable + dead leukocytes) X 
trypan blue dilution factor X 2000 
One cytospin block was prepared, using the remaining 200µI resuspended cell 
pellet. The cytospin slides are produced by spinning at 450 rpm, medium 
acceleration, for 3 minutes. The slides were left to air-dry for 30 min, and then 
fixed in methanol. The slides were stained with Diff-Quik® stain, mounted using 
size 0 cover slip and DPX, and stored at room temperature. A BSA solution was 
added to the lavage supernatant to give a final 2% concentration, the lavage 
supernatants were then centrifuged through a 0.22pm pore size cellulose 
acetate filters (Costar spin-X (D) at 4°C for 30 min at 2000G to remove residual 
mucus before analysis. 
Nasal lavage samples were not corrected for variations in recovery rate, as it 
has been shown that levels of eotaxin recovered in nasal lavage fluid was 
unchanged when corrected for albumin concentration in lavage fluid (98). 
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2.2.2 Nasal filter paper processing 
The papers in assay buffer were mixed using a vortex for 15 seconds and then 
placed on the rolling mixer for 10 minutes to allow mediators to elute. After 
centrifugation at 4°C for 10 minutes at 400g, the eluate was collected and 
stored at -70°C for later analysis. A BSA solution was added to the eluate to 
give a final concentration of 2% and the eluate was then centrifuged through a 
0.22pm pore size cellulose acetate filter (Costar spin-X ®) at 4°C for 30 min at 
2000G to remove residual mucus before analysis. 
2.2.3 Quantification of cytokine and chemokine levels using Luminex® 
multiplex analysis 
Cytokine and chemokine analysis of nasal and sputum samples was carried out 
on the Luminex10°ISTM analyser (Luminex Corporation, Austin, Texas) 
Multiplexed bead array systems were used (Upstate Biotechnology, Milton 
Keynes, UK). A standard curve in duplicate was used for each sample run. Data 
was analysed with either Luminex or STARstation software. 
The Luminex bead array system enables multiple cytokines and chemokines to 
be analysed on a single 50pL sample. The system works by coupling a capture 
antibody against the cytokine to be tested to one of a hundred uniquely colour 
coded polystyrene microspheres. Then a detection antibody labelled with the 
flurochrome phycoerythrin is added and the sample passed through a flow cell 
and exposed to a laser with surrounding detectors. The quantification of 
antigen-antibody reactions that occur on the microsphere surface can be 
performed by measurement of the relative fluorescence intensity. This can then 
be read against a standard curve to give concentrations of the cytokine under 
study(331). It is the presence of the uniquely coloured microspheres that allows 
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for mutitple cytokines to be measured. Comparative experiments have shown 
that cytokine multiplex assays are comparable in sensitivity, accuracy and 
reproducibility to Enzyme Linked Immunosorbant Assays (ELISAs) (332) (333). 
It has been proposed that multiplexed assays could be used as a screening tool 
that could be used to identify a promosing marker that could then be analysed 
in future experiments using a specific ELISA (334). 
2.2.4 Statistical analysis 
All graphs and statistical analyses were generated by using the GraphPad 
Prism® 4 graphing and statistical package. 
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3 Single dose nasal allergen challenge: repeatability and 
dose response of nasal allergen challenge on symptom 
scores, eosinophils and inflammatory mediators 
3.1 Abstract 
Introduction: Nasal allergen challenge (NAC) is a simple method for the 
investigation of the inflammatory response that occurs following allergen 
challenge. Multiple samples can be obtained following a single challenge. The 
challenge can be repeated after a 14 day washout period to determine 
repeatability and dose response effects. 
Aims: This study aims to determine the dose response and degree of 
repeatability of nasal allergen challenge with regard to detectable levels of 
inflammatory mediators and to enable power calculations for future studies with 
new therapies. 
Methods: Patients with grass pollen seasonal allergic rhinitis (n=8) outside the 
pollen season were given topical NAC with 500 BU of Timothy grass pollen on 2 
consecutive visits with a two week washout period. A separate cohort of 
patients (n=8) were challenged with 50BU, 250BU and 500 BU in a randomly 
assigned order to assess dose response. 
Results: All subjects had symptomatic nasal allergic responses following NAC. 
In nasal filter paper eluate there were not consistent significant changes in 
levels of interleukin (IL)-4, IL-5 and IL-13, and there were generally high and 
variable background levels compared with a previous published study. In a 
similar manner, nasal lavage did not contain consistently elevated levels of IL-4, 
IL-5 and IL-13 in the late phase. Elevations in lavages levels from baseline in 
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the first 60 min may have been due to a falsely low baseline immediately after 
washing, followed by a leaking back of cytokines into the nasal lining fluid. In 
contrast, nasal C3a and PGD2 were elevated in nasal paper eluates during the 
early phase, however they were poorly repeatable. There was a dose response 
for C3a in the early phase. 
Conclusion: The main endpoint in this study was to determine levels of IL-4, II- 
5 and 11-13 in the late phase, and there was failure to detect consistent late 
phase responses in both filter paper eluate and nasal lavage. The reasons for 
this disappointing result were thought to be methodological and the subject of a 
detailed review. In a later study steps were taken to increase the allergen dose 
(x3) and employ a new type of synthetic absorptive matrix (SAM) instead of 
Whatman's filter paper (See Appendix 2). 
3.2 Introduction 
3.2.1 Use of nasal allergen challenge 
Inhaled allergen challenge has been used in clinical studies to study the 
inflammatory response in the allergic asthmatic reaction and to assess the 
response to treatment (335). The respiratory tract in the nose shares many 
features with the lung as part of the "one airway hypothesis" (336; 337). The 
use of a nasal challenge model has several advantages over inhaled allergen 
challenge including ease of recruitment, subject safety and the ability to obtain 
samples at multiple time points. This ability to obtain repeated samples allows 
both the early and late phase levels of mediators to be determined. Symptom 
scores can be collected following NAC using a questionnaire completed by 
subjects. The nasal mucosa can be lavaged with physiological saline to obtain 
fluid for analysis (328). This nasal lavage yields both a fluid phase for mediator 
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analysis and also a cell phase for determination of eosinophil influx. Mediators 
can also be detected in nasal secretions using a modified matrix filter paper 
method (329). This has the advantage over nasal lavage samples given that 
dilution of the mediators does not occur. Allergen challenge of the nasal 
epithelium could be used to test new therapeutic agents in the treatment of 
allergic rhinitis and potentially also new anti-inflammatory therapies for asthma 
due to their similar pathogenesis. 
3.2.2 Nasal responses following allergen challenge 
Symptom scores have been studied following nasal allergen challenge (NAC). 
There is a well defined early phase of sneezing, rhinorrhoea and blockage. In 
contrast to inhaled allergen challenge there is not a well defined late phase 
symptom response (338). Allergen challenge of allergic individuals has been 
shown to produce nasal symptoms and increase levels of histamine and 
tryptase in nasal lavage fluid, and these changes are not seen in non-allergic 
subjects (44). Topical corticosteroids have been shown to reduce symptom 
scores in relation to allergen challenge (100; 101). 
Prostaglandin D2 (PGD2) is produced by mast cells and has been detected in 
high concentrations at the site of allergic inflammation (46; 47). It has been 
shown that PGD2 stimulates the production of IL-4, IL-5 and IL-13 by human 
Th2 cells at levels found at the site of allergic inflammation, and gene 
transcription peaks at 2 hours (77). ß-Tryptase is a serine protease that is 
released from degranulating mast cells and has inflammatory actions through 
PAR-2 activation (48). In addition tryptase may also contribute to airway 
oedema through microvascular leakage (49). In a NAC study a reversible ß- 
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tryptase and trypsin inhibitor has been shown to reduce symptoms, eosinophils, 
and levels of IL-5 following NAC (50). 
The production of TH2-type cytokines such as IL-4 and IL-5 are characteristic of 
allergic diseases. A study of nasal biopsies at 6 hours following nasal allergen 
challenge has shown that the levels of eosinophils (but not T-cells) increase in 
nasal mucosa. Co-localisation studies showed that the majority of the IL-4 and 
IL-5 mRNA was associated with eosinophils (94). This is important because it 
suggests that eosinophils are the source of early phase cytokines that lead to 
the development of a late phase response. IL-5 levels have also been shown to 
increase in nasal filter paper samples during the early and late phase following 
nasal allergen challenge; however IL-4 was not detected in this study (95). 
Another biopsy study has shown that NAC induces a significant tissue 
eosinophilia with an associated increase in IL-8, IL-13 and RANTES mRNA- 
positive cells and that increased levels of IL-13 mRNA-positive cells are still 
present 1 week following single NAC (96). A co-localisation study has 
determined that the majority of RANTES mRNA-positive cells following NAC are 
macrophages, followed by eosinophils (97). 
Following NAC there are parallel increases in eosinophil counts, eosinophil 
protein X, and eotaxin concentrations in nasal lavage fluid (98). Nasal allergen 
challenge has been shown to increase levels of the cytokines IL-4, IL-5 and IL- 
13 in filter paper samples collected during the late phase. The chemokines 
eotaxin, RANTES, MCP-1, MIP-1a, IL-8 and IP-10 were also produced during 
the late phase. Pre-treatment for a week with topical fluticasone, a 
corticosteroid inhibited this response to nasal allergen challenge. Fluticasone 
also reduced symptom scores and eosinophil influx into nasal lavage samples 
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following nasal allergen challenge (100). Using an anti-IL-5 antibody, it has 
been shown in a guinea pig model of allergic rhinitis that IL-5 is essential for 
eosinophil migration from the bone marrow to the nasal airway. However neither 
IL-5 nor eosinophils are required for the development of nasal symptoms and 
nasal hyperresponsiveness in this animal model (99). Interestingly levels of TH1 
cytokines (IL-2, IL-3, IL-7, IL-12, IL-15, TNF-a, IFN-y, GM-CSF) were not. It has 
also been shown that a single dose of nasal steroid has the ability to abolish the 
IL-5 and IL-13 responses following nasal allergen challenge (101). Inhalation of 
IL-4 increases levels of airways eosinophils (102). Intranasal administration of 
IL-4 to nonallergic individuals increased levels of IL-6, eosinophils, and 
neutrophils in nasal lavage fluid 24 hours following challenge (103). This is an 
important study as a sign of allergic inflammation, increased eosinophils, was 
seen in nonallergic individuals. Unfortunately this study did not collect any 
samples at earlier time points, and it would have been very interesting to see if 
there was any induction of cytokines and chemokines during the early phase. 
3.2.3 Aims 
The aim of this study is to determine if nasal allergen challenge is a repeatable 
technique for the technique of cytokine and chemokine detection in nasal 
lavage fluid and nasal filter paper (FILT P) samples. The dose response 
characteristic of nasal allergen challenge is also determined. 
3.3 Methods 
3.3.1 Subjects 
The study was approved by the Ethics Committee of The Royal Brompton and 
Harefield NHS Trust, and all subjects gave written informed consent. 2 cohorts 
of 8 subjects were recruited for the repeatability and dose response arms of the 
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trial. The study cohort consisted of male and female, non-smoking subjects with 
a history of seasonal (intermittent) atopic rhinitis, aged between 18 and 40 
years. All subjects had a positive skin prick test to Timothy grass pollen (wheal 
difference Timothy grass pollen - negative control z 2mm). Subjects were 
studied outside of the UK hay fever season, i. e. not between May and July. The 
subjects were all otherwise healthy with no medical problems that might have 
risked their participation in the study. All subjects had no history of other 
significant allergies or any respiratory disease other than a history of mild stable 
asthma not requiring treatment and associated with normal lung function. All 
subjects had a physical examination with particular attention to the nose to 
exclude any subjects with structural nasal abnormalities or nasal polyps. 
Subjects were excluded if they had had an upper respiratory tract infection in 
the week prior to screening. All subjects were non-smokers and not taking any 
regular medication. Subjects were not allowed to take any medication for the 
duration of the trial apart from paracetamol. Table 3.1 below shows the 
demographic details of the subjects in each group. 
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Table 3-1 Subject demoaraohics 
Repeatability Dose response 
N 8 8 
Age (median and range) 24 (20-28) 23 (20-39) 
Gender M: F 5: 3 3: 5 
Cauc 6 Cauc 6 
Black 0 Black 1 
Ethnicity Asian 1 Asian 0 
Hispanic 1 Hispanic 0 
Oriental 0 Oriental 1 
3.3.2 Nasal challenge 
Subjects received their nasal challenge using a Bidose delivery device (Valois, 
UK) which delivers 100NI of allergen solution to each nostril. The nasal allergen 
challenge was performed with freeze-dried extract of Timothy grass pollen 
(Aquagen, phleum pratense, ALK freeze dried extract). For the repeatability part 
of the study total dose of 1000 biological units was given as 500BU to each 
nostril (0.33pg Phleum P5 antigen). For the dose response part of the study 
doses of 50BU (0.033pg Phleum P5 antigen), 250BU (0.165pg Phleum P5 
antigen) and 500BU (0.33pg Phleum P5 antigen) were given. The Timothy 
grass pollen extract was initially dissolved in a diluent solution containing phenol 
before being dissolved in physiological saline to achieve the final concentration. 
3.3.3 Nasal procedures 
Nasal symptom scores were carried out as detailed in section 2.1.5 using the 
nasal symptom score card shown in the appendix, the subjects gave a score of 
0-3 for each of the 4 symptom questions giving a maximum score of 12. 
Subjects were excluded if they had a nasal symptom score of >2 at baseline. 
Nasal lavage was carried out using the modified pool technique as detailed in 
section 2.1.6. The nasal lavage was processed to obtain a cytospin preparation 
for cell analysis and a supernatant sample was reserved for future cytokine 
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analysis. Filter paper samples were collected using Whatman 42 filter paper as 
described in section 2.1.7 and the eluates reserved for future cytokine analysis 
3.3.4 Mediator detection 
Cytokines in nasal filter paper eluates and nasal lavage were detected using the 
highly sensitive multiplex Luminex® bead assay as described in section 2.2.3. A 
standard curve was run in duplicate. The detection limits are shown in the table 
below. 
Table 3-2 Detection limits for cvtokines In na/ml 
Cytokine Nasal filter paper eluates Nasal lavage 
IL-4 2.14 5.31 
IL-5 1.13 4.66 
IL-13 3.52 4.58 
Eotaxin 10.14 23.3 
IFN-y 1.47 3.29 
The measurement of PGD2 and complement factor C3a on in filter paper 
eluates was by commercially available assay kits. Samples for PGD2 required 
treatment with methyl oximating agent to stabilise PGD2 which was added in 
accordance with the assay kit manufacturers' recommendations immediately 
after thawing. 
3.3.5 Study schedule 
All subjects were studied outside of the pollen season. 8 subjects received 
nasal challenge with 500BU of Timothy grass pollen on 2 consecutive visits with 
a2 week washout period. A separate cohort of 8 subjects with seasonal allergic 
rhinitis were challenged with 50BU, 250BU, and 500BU Timothy grass pollen in 
a randomly assigned order with a2 week washout period between each 
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challenge. Assessments were made at baseline and at 5,10,15,30,45,60, 
120,240,360 and 480 minutes post challenge. 
3.3.6 Statistical analysis 
The data was assessed for normality by assessing data distributions and also 
comparing the mean and median of the data sets. Formal statistical testing of 
normality was not carried out as small sample sizes almost always pass a 
normality test. Since there were frequent non-detectable levels of mediators, the 
data was not normally distributed; hence box-whisker plots, which show the 
median, interquartile ranges and the range of the data, represent the data. Plots 
are also shown of individual subject data, where there is consistency of a colour 
for a particular subject throughout the graphs. This enables the signal for each 
cytokine to be compared for each individual subject, and allows response rates 
to challenge to be assessed 
Initially the results from Visit 1 were analysed to determine if there had been a 
response following NAC by comparing the response at individual time point 
compared to baseline using the Wilcoxon matched pairs test. If a significant 
increase was found following challenge then repeatability was assessed. Intra- 
subject repeatability between 2 visits following NAC with FILT P and nasal 
lavage sampling was assessed by the calculation of the median % change in 
Area Under the Curve (AUC) between visits. This is the percentage change 
from the minimum to the maximum (maximum-minimum -- maximum, as a 
percentage). This was calculated for the early phase and the late phase at 
TNSS, eosinophils and early phase mediators and cytokines and chemokines 
for each of the 8 subjects and a median percentage change (with range) was 
expressed as the summary statistic. The direction (+/-) of this change was not 
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considered in the analysis of repeatability, since this will distort the median 
value. When the AUC was zero at both visits, these results were excluded from 
the analysis. The early phase was considered to be from time 0 to 30 min 
(inclusive) post NAC, while the late phase was taken from 120 to 480 minutes 
(inclusive) post NAC. The Bland-Altman method of repeatability measures the 
coefficient of variability between measures by comparing the average of the 
difference between the two measures. Initially the bias is calculated which is the 
difference between the two measures, if the average of this bias is not close to 
zero it indicates that the results are different on the two occasions. The 
standard deviation of the differences is used to calculate the limits of agreement 
which are 1.96 x SD on either side of the mean (339; 340). Bland-Altman 
characteristics are shown for the symptom response and PGD2 in filter paper 
samples obtained at visit 1. 
In the dose response arm differences between doses were tested using the 
Kruskal-Wallis non-parametric ANOVA test comparing all 3 doses. A p-value of 
<0.05 was considered significant. 
3.4 Results 
The following graphs show the results obtained following nasal allergen 
challenge 
Figures 3-1 and 3-2 show the results for nasal symptoms and eosinophils in 
nasal lavage. 
Figures 3-3 and 3-4 show the results for PGD2 and C3a. 
Figures 3-5 - 3-7 show the results for IL-4. 
Figures 3-8 - 3-10 show the results for IL-5. 
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Figures 3-11 - 3-13 shows the results for IL-13. 
Figures 3-14 and 3-15 show the results for eotaxin IFN-y. 
Page 90 of 293 
Visit 1 Visit 2 
12 12- 
11 11 Subject 1 
ö 
10 CO ö 
19 Subject 2 
g8N8 -- Subject 3 7 7- E6E6 Subject 4 
6«5- Subject 5 
E3 E" 3 -- Subject 6 
2 2. Subject 7 
1P 
I. 
0.. . =_ - Subject 8 0 
1ý1 r-r r" 
0 10 20 30 40 60 60 120 240 360 480 0 10 20 30 40 50 60 120 240 360 480 
Minutes post challenge Minutes post challenge 
12 * 12 11 * 11 
a 10 **y 10 ö9ö9 
N6**N6 
E6Eg 
«6 
E2H, 
3 
13 1 aaö1 6e 66 10 15 30 46 60 120240380480 06 10 15 30 45 60 1202iWi04iO 
Minutes post challenge Minutes post challenge 
60 60 
Subject 1 
40 N 40 Subject 2 
rL -ý Subject 3 CL 30 0 30 
- Subject 4 cc 
20 $ 20 - Subject 5 
-. - Subject 6 
10 10 
- Subject 7 
00 -Subject 8 
ýrrw---r-r 
0 10 20 30 40 60 60 120 240 360 480 0 10 20 30 40 60 60 120 240 360 480 
Minutes post challenge Minutes post challenge 
60 50 
40 40 
Lt 
ä 30 c 30 
ec 
20 $ 20 
" 10 0 
_ý. -- ist 
10 
J-_-I s 1u 
05 10 15 30 46 60 120240360480 06 10 15 30 46 60 120240360480 
Minutes post challenge Minutes post challenge 
Figure 3-1 Repeat challenge with 500BU Timothy grass pollen. Effects on nasal symptom 
scores and eosinophils in nasal lavage. Data shown as median, interquartile range and 
range There was an increase in symptoms that was maximal at 15 minutes and had 
returned to baseline by 480 minutes. Only one subject had an eosinophil response in 
nasal lavage. 
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Figure 3-2 Dose response effects following challenge with 50BU, 250BU and 500BU 
Timothy grass pollen on nasal symptoms and eosinophils in nasal lavage. Data shown as 
median and interquartile range. Dose response effects for nasal symptoms were seen in 
the late phase but this did not achieve statistical significance. 500BU Timothy grass 
pollen was required to produce an increase in eosinophils in nasal lavage. 
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Figure 3-3 Repeat challenge with 500BU Timothy grass pollen. Effect on PGD2 and C3a in 
nasal filter paper eluate. Data shown as median, interquartile range and range. Levels of 
PGD2 peak at 5 and 10 minutes. Levels of C3a peak between 5 and 30 minutes. There is 
also an increase in C3a at 480 minutes. 
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Figure 3-4 Dose response effects following challenge with 50BU, 250BU and 500BU 
Timothy grass pollen on PGD2 and C3a. Date shown as median and interquartile range. 
Early and late phase dose effects were seen with PGD2 and C3a but these did not 
achieve statistical significance. 
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Figure 3-5 Repeat challenge with 500BU Timothy grass. Effects on IL-4 in nasal filter 
paper eluate. Data shown as median, interquartile range and range There was a 
significant increase at Visit 1 at 45 minutes. 
Page 95 of 293 
Visit 1 Visit 2 
40 
30 
ao 
Subject 1 
ä 
20 30 Subject 2 
a -Subject 3 
10 
$ 
20 -Subject 4 
---Subject 5 
" io - Subject 6 
p -Subject 7 
oSubject 8 
0 10 20 30 40 50 60120 240 360 480 
0 10 20 
4050 
60 120 240 360 
Minutes post challenge Minutes post challenge 
40 * 40 
30 
* 
30- 
r= 
20 -6 20 
aa 
10 10 
O 
ýaäý 
00 
05 10 15 30 45 60 120240360480 05 10 15 30 45 60 120240360480 
Minutes post challenge Minutes post challenge 
Figure 3-6 Repeat challenge with 500BU Timothy grass. Effects on IL-4 in nasal lavage. 
Data shown as median, interquartile range and range There were significant increases at 
Visit 1 at 5- 45 minutes. 
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Figure 3-7 Dose response effects following challenge with 50BU, 250BU and 500BU 
Timothy grass pollen on IL-4. Date shown as median and interquartile range. 
Page 97 of 293 
Visit 1 Visit 2 
60 
40 
30 
1001 -' Subject 1 
00 Subject 2 
20.40 -Subject 3 
-Subject 4 30 
10 a Subject 5 
20 --- Subject 6 
p 10 Subject 7 
_y I0 -Subject 
8 
0 10 20 30 40 60 60 120 240 360 480 ý-ý-ý--ý+ -ý--ý-ýý 0 10 20 30 40 60 40120 240 310 400 
Minutes post challenge Minutes post ohaHeng. 
60 
180 
40 
60 
30- 40 
20 30 
20- 
10 
C6 
6a6 
0 llýg 
p 
16ý 
0 
05 10 16 30 45 60 120240360480 06 10 15 30 45 60 120240360480 
Minutes post challenge Minutes post challenge 
Figure 3-s Repeat challenge with 500BU Timothy grass pollen. Effect on IL-5 in filter 
paper eluate. Data shown as median, interquartile range and range There were non- 
significant increases following challenge at Visit 1. 
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Figure 3-9 Repeat challenge with 500BU Timothy grass pollen. Effect on IL-5 in nasal 
lavage. Data shown as median, interquartile range and range There were significant 
increases at 30 and 45 minutes at Visit 1. 
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Figure 3-1o Dose response effects following challenge with 50BU, 250BU and 500BU 
Timothy grass pollen on IL-5. Date shown as median and interquartile range. 
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Figure 3-11 Repeat challenge with 500BU Timothy grass pollen. Effect on IL-13 in nasal 
filter paper eluate. Data shown as median, interquartile range and range There were no 
increases in IL-13 following nasal allergen challenge. 
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Figure 3-12 Repeat challenge with 500BU Timothy grass pollen. Effect on IL-13 in nasal 
lavage. Data shown as median, interquartile range and range There were increased levels 
following challenge that were significant at 60 minutes post challenge. 
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Figure 3-13 Dose response effects following challenge with 50BU, 250BU and 500BU 
Timothy grass pollen on IL-13. Date shown as median and interquartile range. 
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Figure 3-14 Repeat challenge with 500BU Timothy grass pollen. Effects on eotaxin and 
IFN-y in nasal filter paper eluates. Data shown as median, interquartile range and range 
There were no increases in eotaxin and IFN-y following challenge. 
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Figure 3-15 Repeat challenge with 500BU Timothy grass pollen. Effects on eotaxin and 
IFN-y in nasal lavage. Data shown as median, interquartile range and range There were 
significant increases in eotaxin and IFN-y at 45 and 60 minutes following challenge. 
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Table 3-5 Bland-Altman data on symptom scores 
Time point Bias Limits of agreemen t 
0 0.37 -0.64 1.38 
5 -0.62 -5.30 4.05 
10 0.25 -5.17 5.67 
15 -0.12 -4.50 4.25 
30 0.25 -3.02 3.52 
45 -1.12 -7.87 5.62 
60 -0.50 -6.52 5.52 
120 -1.0 -5.80 3.80 
240 -0.75 -5.63 4.14 
360 -0.62 -2.70 1.45 
480 -0.25 -1.56 0.66 
Table 3-6 Bland Altman data on PGD2 in filterpaper eluate 
Time oint Bias Limits of agreemen t 
0 -2.68 -20.9 15.59 5 22.19 -239.08 283.46 10 49.64 -166.69 265.98 
15 1.77 -188.33 191.87 
30 1.15 -65.53 67.83 
45 -3.08 -75.55 69.39 
60 9.99 -21.27 41.25 
, 
120 2.84 -10.06 15.74 
240 -0.95 -18.03 16.12 
, 
360 1.81 -33.77 37.41 
480 9.10 -22.08 40.27 
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3.4.1 Results summary 
3.4.1.1 Nasal symptom scores and eosinophils in nasal lavage 
Following nasal allergen challenge there was an immediate increase in 
symptoms that was maximal up to 15 minutes and had returned to baseline by 8 
hours following challenge. Bland-Altman analysis showed that symptom scores 
were repeatable. Dose response effects were seen in the symptom scores and 
this achieved statistical significance (p=0.042). There was no significant 
increase in eosinophils in nasal lavage following challenge with 500 BU of 
Timothy grass. Repeat challenge with 500 BU of Timothy grass resulted in a 
median absolute change (range) in AUC from visit 1 to visit 2 of 23% (8-32) for 
total nasal symptom scores during early response (0-30 min). For late phase 
(120-480 minutes) responses, the median absolute change (range) in AUC from 
visit 1 to visit 2 was 69% (9-100). Dose response effects were not seen for 
levels of eosinophils in nasal lavage following NAC. 
3.4.1.2 Early phase mediators 
Levels of PGD2 detected in filter paper (FILT P) eluates peaked at 5 and 10 
minutes post NAC, and for C3a the peak is seen between 5 and 30 minutes, 
and again at 480 minutes. Repeat challenge with 500 BU of Timothy grass 
resulted in a median absolute change (range) in AUC from visit 1 to visit 2 of 57 
(28-96) for PGD2 and 39 (3-76) for C3a as sampled by FILT P during early 
response. Bland-Altman analysis showed that measured of PGD2 was poorly 
repeatable. Dose response effects for PGD2 and C3a were seen during both 
the early and the late phase responses and this achieved statistical significance 
for C3a in the early phase (0-30 minutes), (p=0.01). 
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3.4.1.3 Cytokines and chemokines 
Levels of cytokines and chemokines detected in filter paper (FILT P) eluates 
were generally higher than those in nasal lavage. 
There was a significant increase in IL-4 in lavage during the early phase and for 
IL-5 in nasal lavage at the end of the early phase. There was a significant 
increase in IL-13 in nasal lavage at 60 minutes post challenge. 
The filter paper eluates did not yield increases in cytokine levels, with no clear 
early or late responses and dose response calculations were not made. Levels 
of IL-4 were generally <50pg/m (Fig 3-5) levels of IL-5 were generally <20pg/ml 
(Fig 3-8), and IL-13 levels <150pg/ml (Fig 3-8). The same individual had high 
levels of IL-4, IL-5 and IL-13 in nasal FILT P eluate at 45 min. Repeat challenge 
with 500 BU of Timothy grass resulted in a median absolute change (range) in 
AUC from visit 1 to visit 2 of 44 (16-74) for IL-4,32 (5-100) for IL-5 and 16 (2- 
61) for IL-13 as sampled by nasal lavage during the early phase. Repeat 
challenge with 500 BU of Timothy grass resulted in a median absolute change 
(range) in AUC from visit 1 to visit 2 of 48 (27-100) for IL-4,100 (34-100) for IL- 
5 and 50 (25-85) for IL-13 as sampled by nasal lavage during the late phase. 
3.5 Discussion 
A single nasal allergen challenge (NAC) model is potentially a very efficient 
study design for drug development as it is possible to obtain serial 
measurements of biomarkers that relate to inflammation in the eight hours 
following challenge (68), which is not a feature of inhaled or skin allergen 
challenge. In this NAC model we measure symptoms, levels of lavage 
eosinophils, and our primary end-point was to focus especially on late phase 
levels of IL-4, IL-5 and IL-13 measured in FILT P eluates. 
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However, in the current repeat part of the nasal allergen challenge (NAC), that 
employed the higher allergen dose of 500BU, in the 8 individuals there were no 
significant changes in levels of IL-4, IL-5 and IL-13 at 2h, 4h, 6h and 8h when 
comparing with baseline for nasal lavages and for filter paper eluates. This was 
despite subjects having symptomatic responses to grass pollen challenge. 
This failure to detect significance in the current study may partly have been due 
to only 8 subjects being studied, and these being low producers of IL-4, IL-5 
and IL-13 in the late phase. However, it is important to stress that in our study 
levels of these cytokines in FILT P eluate were very variable and were generally 
higher in terms of medians compared to a previous study that measured FILT P 
eluates (68). The failure to elicit a significant response in terms of levels of IL-4, 
IL-5 and IL-13 with the high 500BU dose renders assessment of a dose 
response invalid. 
It is important to compare these results with those previously found using this 
NAC model from our group. In 3 published studies from the NHLI Clinical 
Studies Unit this NAC model has been found to cause significant changes in 
levels of IL-5 in nasal lavage in the late phase (4 to 8h post NAC) when 
comparing with baseline. The first of these studies employed a single dose of 
topical nasal corticosteroid (101), and measured nasal lavage IL-5 and IL-13 in 
32 subjects. The second study employed 7 days of dosing with a topical 
corticosteroid (100); and measured IL-4, IL-5 and IL-13 in both nasal lavages 
and filter paper eluates in 13 subjects. Finally, a single dose of a topical 
combined beta-tryptase/trypsin inhibitor (50) was used in 16 subjects to assess 
levels of IL-5 in nasal lavage fluid. In all 3 of these studies significant changes in 
levels of cytokines (IL-5 with sometimes IL-4 and IL-13) were detected in the 
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late phase when comparing with baseline. In addition, in the 3 studies 
significant effects of therapy on these mediators were noted compared to 
placebo. 
Of the 3 studies, the study with 7 days of nasal corticosteroid was the only one 
to assess levels of IL-4, IL-5 and IL-13 in both nasal lavages and eluates from 
Whatman's filter paper number 42 (100). This study established that higher 
levels of all 3 of these mediators were detectable in filter paper eluates 
compared to nasal lavages (Figure 2 of (100). However, when scrutinising data 
for individual subjects from this study (poster at the American Thoracic Society) 
it was noted that high levels of IL-5 and IL-13 were detected in filter paper 
eluates in just 2 of 13 subjects. In this situation, there is the need to use non- 
parametric methodology to analyse and present the data. In graphical 
presentation this should have involved whisker plots to show 
median/interquartile range/range (non-parametric data summary statistics), 
rather than mean and SEM (parametric data summary statistics). Hence it could 
be argued that the results achieved in this study depended on those 2 
individuals that were responders in terms of IL-4, IL-5 and IL-13 in nasal filter 
paper eluates. Therefore, another reason why we failed to detect significant 
changes in levels of IL-4, IL-5 and IL-13 in the late phase may have been 
because we did not recruit "responders" in terms of IL-4, IL-5 and IL-13. 
Despite not seeing changes in levels of IL-4, IL-5 and IL-13 after NAC; it was 
interesting to note that a single subject with a very high eosinophil response 
also had high IL-5 levels in the late phase suggesting a possible mechanism for 
the appearance of eosinophils in nasal lavage. In addition, 2 subjects (numbers 
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4 and 7) had higher levels of IL-5 in the late phase measured in nasal filter 
paper and nasal lavage on both visits. 
In the current study, complement factor 3a (C3a) and prostaglandin D2 (PGD2) 
were significantly increased from baseline in the acute phase (up to 60 min) for 
both nasal lavage and nasal filter paper levels. PGD2 levels peaked at 5-10 
mins, and C3a peaked at between 5 and 30 min. The increase of mediators in 
the early phase may be due to the release of pre-formed mediators from cells 
such as degranulating mast cells, and PGD2 can be rapidly synthesised 
through the arachidonic acid pathway. In contrast, increase in interleukin levels 
during the late phase could represent new synthesis of protein. The early phase 
mediators PGD2 and C3a are poorly repeatable and large sample sizes would 
be needed to detect changes in response to treatment. The variability in these 
mediators could be due to the presence of proteases in nasal secretions, and 
this in an area that could be investigated in future studies. The early phase C3a 
levels varied with the allergen dose, but the upper dose level for allergen was 
not defined in this study. Further studies should be carried out with higher doses 
of allergen, as this may lead to increased numbers of responders to challenge. 
There was considerable inter-subject variability that was consistent over the 2 
visits. 
The choice of dose for allergen challenge studies is clearly of crucial 
importance. With regard to inhaled allergen challenge there is a careful balance 
between a dose high enough to produce a response but no so high as to 
produce a dangerous reduction in FEV1. Using skin prick titration in 
combination with PC20 for histamine has been shown to be useful for guiding 
the dose of inhaled allergen challenge (341; 342). However it has been shown 
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that whilst there is a correlation between skin test threshold and inhaled 
response in some subjects this relationship is inconsistent (343). In a study 
comparing responses in the nose following house dust mite challenge, the 
wheal diameter following skin prick challenge correlated with the nasal allergen 
challenge threshold (344). However by the using the nasal allergen challenge 
method the concern about maximal dose is not as great as with inhaled 
challenge with regards to fall in lung function. However we would not wish to 
use a supramaximal dose as this may not be able to be overcome by any of the 
drugs under study. The dose used in the studies presented in this Thesis is 
based on the work of Professor Durham, although his group apply the allergen 
to the nose using paper disks rather than the nasal spray used in these studies. 
A dose of 500BU given by nasal spray has also been shown to cause 
consistent symptom responses in three published studies (50; 100; 101). 
In addition to recording symptoms another physiological measure of nasal 
response following allergen challenge is rhinomanometry which is a measure of 
the physical changes that occur post allergen challenge. Nasal obstruction can 
be measured by anterior and posterior rhinomanometry and is generally 
accepted as the standard measure of nasal airways resistance (345). Other 
methods used to measure nasal patency include acoustic rhinometry (346), and 
CT scanning. (347). Nasal peak flow is a very simple method for assessing 
nasal patency but does have the disadvantage of also being affected by 
changes in pulmonary function(348). These methods could be utilised in future 
studies to guide the allergen dose, by selecting a dose for an individual patient 
that couased a 50% reduction in the airway on objective monitoring and then 
using this dose when measuring cytokine levels. 
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In this study the levels of mediators in filter paper eluates were not corrected for 
the weight of the sample obtained as the original methodology paper does not 
suggest that this is necessary (329). Similarly the levels of mediators in nasal 
lavage were not corrected for the volume of nasal lavage recovered as nasal 
lavage recovery volumes were generally consistent (98). 
The levels of mediators were higher in nasal filter paper eluates than in nasal 
lavage and it likely that this is due to the dilutional effect of the 5. Omls of saline 
employed in nasal lavage. However it is important to recognise that the filter 
paper eluates may represent different signals. The presence of filter paper may 
lead to cells becoming adherent and undergoing lysis and hence giving a signal 
of intracellular and extracellular mediators. However during collection of lavage 
there should not be any cell lysis and hence the detectable levels should 
represent only the extracellular component of the signal. Both nasal filter paper 
eluate and lavage are dependent on the mediators being soluble and released 
into nasal epithelial lining fluid. Where tissue analysis is required samples can 
be obtained by biopsy, curettage or brushing. 
A comparative analysis technique was employed to consider the factors that 
may have caused the failure to see significant increases in levels of IL-4, IL-5 
and IL-13 in the late phase filter paper eluates when comparing with the 
published studies (100) (101) (50). In this analysis all the potential causes are 
first listed, and then the most likely factors considered, so that those causative 
factors can then potentially be remedied. 
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Table 3-7. Potential Factors to Account for the Failure to Detect Significant Increases In 
Late Phase Nasal Filter Paper levels of IL-4, IL-5, and IL-13 after Nasal Allergen Challenge 
(NAC). Single dose NAC and repeat dose NAC studies were compared to a published 
study (349). 
Study Component Descripton 
Different hay fever sufferers, out of season, with 
Timothy grass pollen sensitivity (confirmed by skin 
Patients prick test) were used in the 3 studies. In the published 
study only 2 of 8 subjects had prominent IL-4 and IL-13 
responses, and it is possible that in the more recent 
studies there were less responders. 
There was a change from the Bidose (Valois) to the 
Dolphin (Valois) device form the single dose to the 4 
day repeat NAC model. However, this is unlikely to be 
Nasal delivery device a factor: since both devices actuate reliably when 
checking by weight, and the vials and stoppers that 
contain the actual allergen within he device are 
identical. 
Aquagen SQ Timothy Grass Pollen (ALK, Denmark) 
(500 BU/nostril) was used in both studies, always 
within the manufacturer's expiry date. However, 
different allergen batches were used, and the allergen 
Timothy Grass Pollen dose may be too low. The potency of the allergen is 
allergen established by the manufacturer (ALK) on in vitro 
assays, and it would be ideal to have a full dose 
response for NAC with each batch in patients. In a 
given study a single batch of allergen should be 
employed. 
Diluents used for Manufacturer's (ALK) diluent (with 1% phenol) and 
Timothy Grass saline (0.9%) was used in identical reconstitution 
allergen for NAC protocols in both studies 
Storage of dilute 
allergen in nasal 
The diluent was stored at 4°degrees C for up to 4 
delivery device weeks in stoppered vials in all studies. 
Ed Erin took part in the published study, while I (Helen Clinicians performing Neighbour) carried out the single dose and repeat dose procedure NACs. 
Application of nasal The same filter paper size (30mm by 7mm) and same paper, and paper application time (2 min) were employed. size 
Clinical response TNSS levels were as expected across the studies, with 
assessed by total early and late phase response observed in subjects on 
nasal symptom no drug (study 1) or placebo (study 2), and reduced 
scores (TNSS) response in the active treatment group (study 2) 
LABORATORY 
PHASE 
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Ed Erin performed the processing of samples in the 
Personnel published study, while I and Grant Nicholson 
processed them in the single and repeat dose NAC 
studies 
Whatman's No 42 filter paper was used in both studies, 
Filter paper as specified in the study protocol, but different batches 
were employed. 
The same elution buffer was used in both studies, 
Elution buffer namely Beadlyte Assay Buffer, containing BSA 1%, 
azide, tween 20 
Supplied by Upstate, 20m1 (CAT 43-002) 
Bovine serum 
albumin (BSA) 
Unchanged between the studies: thus not a factor 
Elution methodology Not a factor 
Storage of samples 
Samples were stored at -80-C in both studies, with a 
single cycle of freeze-thawing. 
This was not found to be a factor, on checking filters 
with control samples. 
Centrifugal filtration was performed using Corning Filter 
Membranes in both studies. 
Centrifugal filtration Ed Erin employed Corning cellulose acetate filters 
procedure (defined by the manufacturer as very low protein 
binding ) 
I used Corning nylon filters 
(defined by the manufacturer as low to moderate 
protein binding) 
Sample tubes and Eppendorfs and cryo tubes were used in both studies containers 
Luminex procedure; 
Including incubation Identical procedure in both studies 
times 
Software to Luminex for published studies and single dose download 
Manual checks on Performed downloads 
Sample application to Random in both studies microtitre plate 
Control curves on Equivalent Luminex 
Paired samples Good fit 
In summary, a number of elements need to be considered, and some protocol 
and methodological alterations made in order to be able to detect higher levels 
of IL-4, IL-5 and IL-13 in nasal lining fluid. 
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It is important to have sufficient responder subjects, and it might be possible to 
perform a screening NAC in order to be able to select IL-4/5/13 responders. 
A particular concern is that there may be batch variability for Whatman's No. 42 
filter paper, especially since this material is not designed to absorb biological 
fluids and efficiently release the contained proteins. One could either perform 
spiking experiments to select a batch of Whatman's FILT P that is efficient at 
releasing proteins, or one could consider alternative synthetic absorptive 
matrices (SAM). On contacting Pall Gellman, the international manufacturers of 
electrophoretic media and support material for laboratory protein assays, we 
found that they had a range of SAMs with specifications for extremely low 
protein binding. They recommended Accuwik Ultra because this is extensively 
used in urine pregnancy kits and in automated immunoassay machines to 
absorb and release reagents containing proteins. 
Results are shown in Appendix 2 for further studies performed to assess a SAM 
in comparison to Whatman's filter paper No. 42, in relation to detectable levels 
of IL-4, IL-5 and IL-13. I was involved in the design of these experiments, but 
did not carry out the clinical and laboratory procedures (Ed Erin with Grant 
Nicholson). The conclusion from this series of experiments was that Whatman's 
filter paper is inferior to the synthetic absorptive matrix (SAM) (Accuwik Ultra) in 
terms of absorption and release of nasal lining fluid cytokines. In addition the 
dose of allergen used for NAC should be increased to increase the likelihood of 
achieving higher detectable levels of IL-4 IL-5 and IL-13 in the late phase. 
In a NAC study carried out on the CSU in the first quarter of 2007 (Linda 
Brinkman on clinical procedure, Grant Nicholson on laboratory aspects), the 
dose of allergen was increased from 500BU (0.3pg of Phleum pratense 
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allergen) to 1.0Ng of Phleum pratense and the Accuwik Ultra SAM was 
employed. These modifications enabled high levels of IL-4, IL-5 and IL-13 to be 
detected in SAM eluates in the late phase: levels were higher than any 
previously found in studies performed on the CSU. In 8 of 12 individuals, levels 
of IL-5 and IL-13 were consistently >100pg/ml in the late phase. The raw data is 
shown in Appendix 2 (Figure 11.4). 
3.6 Conclusions 
1. Single dose NAC causes an increase in nasal symptoms and is safe and well 
tolerated. 
2. There was no late phase response for IL-4, IL-5 and IL-13 in nasal filter paper 
eluates or nasal lavage samples. 
3. The early phase mediators C3a and PGD2 are poorly repeatable. 
4. Whatman's 42 is not the optimum filter paper for measuring cytokines in 
nasal secretions. 
3.7 Future study 
1. One should only employ Whatman's filter paper if it has appropriate elution 
characteristics for a particular batch demonstrated by spiking with commercial 
standards and nasal samples. Given the complexities of this approach there is a 
need to identify and validate novel preferably synthetic absorptive matrices 
(SAM) with reproducible and efficient elution characteristics. 
2. There is still a need to determine the optimum dose of NAC and also in the 
context of repeat daily NAC. 
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4 Repeat dose nasal allergen challenge (NAC): development 
of a model that mimics natural seasonal exposure and 
exhibits priming 
4.1 Abstract 
Introduction: Single dose NAC does not reproduce the allergen exposure 
during the pollen season. Topical nasal steroids have been shown to inhibit the 
early and late phase reactions, with single doses inhibiting the late nasal 
reaction, and 6 weeks of therapy inhibiting the early and late nasal reactions. 
Aims: To determine if repeated daily nasal allergen challenge will cause 
sensitisation in terms of increased levels of symptoms, eosinophils and 
inflammatory mediators. 
Methods: A total of 14 patients with Timothy grass pollen seasonal allergic 
rhinitis were recruited out of season; receiving a total of 6 nasal challenges 
over a2 week period, with 4 of these challenges on consecutive days. 8 
subjects were challenged with 500BU Timothy grass pollen to each nostril 
without prior fluticasone, 4 received 100pg fluticasone to each nostril prior to 
repeat nasal challenges, and 2 subjects received placebo challenge and no 
therapy. Symptom scores were recorded following nasal challenge, and nasal 
lavage and nasal filter paper samples were taken for cell and 
cytokine/chemokine analysis respectively. 
Results: Repeated NAC caused a trend for priming in terms of increased 
symptoms that did not reach significance. With repeated NAC there was an 
increase in levels of eosinophils detectable in nasal lavage at 1h at visits 5,6 
and 7 (p<O. 05). There was evidence of priming for IL-5 levels in nasal lavage at 
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1h at visit 5 and 6h at visit 9 (p<0.01). In addition, levels of IL-13 in nasal lavage 
showed evidence of priming at 6h post NAC at visit 7 and 9 (p<0.01). Of the 4 
individuals in the fluticasone arm, there were very low responses to NAC at 
baseline, and priming and effects of fluticasone could not be commented on. 
For the 2 individuals receiving placebo challenge there was no symptomatic or 
eosinophil response, and levels of lavage chemokines and cytokines were 
generally very low. 
Conclusions: This study of repeat NAC on 4 consecutive days demonstrated a 
trend for increased symptoms, with evidence of priming in terms of increased 
levels of eosinophils, and nasal lavage IL-5 and IL-13. Levels of chemokines 
and cytokines in nasal FILT P eluate were low and this may be due to batch 
variability in Whatman's filter paper, with potential for cytokines and chemokines 
binding to the paper and failing to elute. Effects of topical nasal fluticasone 
could not be seen, while placebo challenge did not cause symptoms nor 
appreciable eosinophil or chemokine/cytokine responses. 
4.2 Introduction 
4.2.1 Use of nasal allergen challenge 
The use of a nasal challenge model has several advantages over inhaled 
allergen challenge including ease of recruitment, subject safety and ability to 
obtain samples at multiple time points. However the single dose challenge 
model has limitations; since it does not accurately model the exposure that 
occurs during the hay fever season. The aim of the model developed in this 
Chapter aims to replicate seasonal exposure to allergen by giving NAC on 4 
consecutive days and hence more accurately model the changes that occur in 
seasonal allergic rhinitis. It is also hoped that there will be priming and hence 
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increased levels of cytokine will be detected. It would be possible to challenge 
subjects with seasonal allergic rhinitis during the allergen season during which 
the nasal mucosa will be primed however it is not possible to quantify the exact 
level of allergen exposure and hence is difficult to make valid comparisons. The 
higher the level of cytokines following allergen challenge, the more likely an 
effect of a novel therapeutic will be statistically significant. 
The Vienna chamber is the challenge model that most accurately mimics the 
allergen exposure in seasonal allergic rhinitis generally for a period of up to 8 
hours. 6 to 8 subjects with hay fever are placed in a sealed room outside the 
grass pollen season, and are challenged with an accurately quantifiable amount 
of allergen which is added via the air-conditioning system with a proven 
homogenous distribution of pollen grains, in conditions of allergen exposure that 
mimic those of a hot summer day. (350). This NAC can then be repeated over 
several days. Generally, subjects remain within the Vienna chamber, but 
samples can be obtained from the subjects at set time points following the 
challenge. 
In a variation of this form of challenge, Environmental Challenge Rooms can 
seat up to 100 subjects, and allergens are delivered via nebulisers within the 
room (Applied Clinical Research, Toronto). One of the advantages is that it 
allows a large number of subjects to be challenged with the same dose of 
allergen at the same time. However, repeated sampling with rapid processing of 
specimens is not practical in this context. The nasal spray challenge model 
shown here can be carried in smaller research units as subjects can be 
challenged individually and a series of samples processed immediately. 
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4.2.2 Priming 
Priming is the increased levels of inflammation seen following repeated allergen 
exposure compared with a single large dose of allergen (351); (352). There is a 
cumulative effect of serial challenges. Repetitive allergen challenge might cause 
an accumulation of inflammatory cells and their mediators in the nasal mucosa 
and hence increase the response to subsequent challenges. It has been shown 
that local accumulation of eosinophils, neutrophils and mononuclear cells 
persists for 48 hours and is accompanied by release of ECP, MPO, LTB4 and 
histamine. (353). Additionally there might be effects on circulating cells or the 
airway epithelial cells themselves that might modify subsequent responses. In 
contrast to effect of repeat challenge on airways mucosa there is no increase in 
response to repeated allergen challenge using skin prick testing. However if the 
allergen in injected into the skin then priming is seen (324). These findings may 
indicate that the priming seen in repeat airways challenge may be due to 
changes in the epithelial barrier function (354). It has been shown that unilateral 
repeated nasal allergen challenge causes priming, that is not seen in the 
contralateral nostril suggesting that priming is due to changes in the local 
mucosa rather than a systemic effect (351). 
Priming also occurs during seasonal exposure to allergen, and this effect 
persists for several weeks following the end of the allergen season (352). 
Priming of the symptom response has been demonstrated in the nasal mucosa 
using a ragweed model of seasonal allergic rhinitis. There is an influx of 
inflammatory cells prior to each of the challenges (355). The use of the Vienna 
chamber has shown that a specific nasal response in increased by 
environmental priming, as demonstrated by exposing grass pollen sensitive 
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individuals with other sensitivities to the allergen other than grass pollen to 
which they are sensitive and then challenging with grass pollen. There was 
augmentation of the response to grass pollen challenge following prior 
challenge with other allergens (356). Eosinophils release major basic protein 
(MBP) and other granule proteins, which can damage the mucosal barrier which 
may allow the allergen to reach submucosal cells more readily (357). MBP can 
also reduce ciliary activity and hence increase the time the nasal mucosa is 
exposed to pollen allergens (358). 
4.2.3 Repeated allergen challenge 
Studies of the consequence of repeated allergen challenge and the effect of 
priming have been carried out previously. A study comparing the effect of a 
large single allergen challenge compared with the same dose spread over 4 
days on the inflammation seen in asthmatic airways showed that 2 consecutive 
days of lower dose allergen produced the same degree of sputum eosinophilia 
as a single large dose challenge (359). Studies have shown that the priming 
response in the nose to allergen is specific to the side of the nose challenged, 
disappears when the exposure is stopped, occurs during seasonal exposure 
and is not specific for the antigen used (351). Nasal responses to repeated 
doses of ragweed have been determined by measuring levels of histamine, 
TAME-esterase activity and kinins in nasal lavage fluid and by symptom scores. 
92.7% of subjects had an early phase reaction in both mediators and 
symptoms, 47% of subjects developed a late increase in symptoms. The levels 
of late phase mediators could not be predicted by skin test response or serum 
IgE measurement. On re-challenging subjects 21% had an increase in mediator 
levels during the early phase reaction (360). In birch pollen allergic subjects it 
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has been shown that repeated nasal challenge over 7 days resulted in a 
gradual increase in nasal symptoms. There was also a priming effect on the 
number of eosinophils in the nasal mucosa, and the levels of eosinophils 
correlated with the symptom score (361). 
Interestingly when non-asthmatic subjects with allergic rhinitis received inhaled 
allergen challenge there was an increase in eosinophils in induced sputum 
without any in respiratory symptoms, and with repeated challenge priming was 
not observed. However the doses used in this study were significantly lower 
than those used in other studies (362). The time interval required for priming 
has also been assessed, when subjects received nasal allergen challenge 
(NAC) 3 days, 1,2 and 4 weeks following initial nasal challenge. The 3 day 
interval group showed an increased response, the 1 and 4 week interval group 
showed a similar response to baseline; while the 2 week group showed a 
reduced response when compared to baseline (363). The reduced response 
seen at 2 weeks may involve a mechanism similar to that of immunotherapy. 
It has also been shown that placebo nasal challenge does not cause nasal 
symptoms or decrease in nasal patency in allergic subjects (352). This suggests 
that the changes seen following allergen challenge are immune mediated rather 
than due to physical effects of nasal challenge. Repeat allergen challenge has 
also been studied in asthmatic airways. Repeated inhaled allergen challenge 
causes airway eosinophilia and increased IL-5, associated with airway hyper- 
responsiveness as determined by methacholine challenge without the 
development of marked acute bronchoconstriction or the development of a late 
response (364). 
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A cumulative dose trial of inhaled allergen challenge in asthmatics has shown 
an increase in IL-4 IL-5 and IL-13 mRNA expression in bronchoalveolar cells. 
(365; 366). This increase in cytokines is a possible mechanism for the priming 
seen in repeat dose allergen challenge models. In addition eosinophils form 
subjects with allergic asthma exhibit priming, probably as a result of their 
interaction with cytokines in peripheral blood. The priming enhances migration 
into the airways due to increased chemotaxis and endothelial adhesion 
response. (367-370). 
The priming effect in skin has be used to test a novel therapeutic agent, the 
anti-IgE Omalizumab prevents the repeat dose priming effect of increased 
inflammatory cells in skin with repeated allergen challenge (325). This suggests 
that a model of allergen priming can be used to test a novel therapeutic agent. 
4.2.4 Effects of steroids on nasal response to repeated allergen 
challenge 
This study also investigates the effects of a topical nasal steroid, fluticasone, on 
repeat dose allergen. When budesonide is given 30 minutes prior to allergen 
challenge there was no effect on nasal symptoms, but nasal filter paper eluate 
levels of GM-CSF and IL-5 were inhibited during the late phase (371). In a 
repeat dose allergen model budesonide has been shown to inhibit the increase 
in symptoms and also levels of TAME in nasal lavage (372). It has been shown 
that repeated nasal allergen challenge can increase levels of eotaxin in nasal 
lavage and this can be reduced by topical budesonide started 2 weeks prior to 
first challenge (373). Pre-treatment with topical nasal steroids for a week prior 
to challenge decreased symptom scores and levels of histamine, TAME, and 
kinins in the early, late and re challenge reactions (374). 
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Topical nasal budesonide has been shown to reduce early phase symptoms if 
started for a week prior to a repeat dose allergen challenge study (375). Topical 
steroids have also been shown to reduce the early reduction in nasal peak 
inspiratory flow in a repeat dose allergen challenge study (376). However oral 
glucocorticoids inhibit the late phase of an allergic reaction but not the early 
phase (377). Inhaled budesonide has been shown to reduce allergen induced 
sputum eosinophilia and at higher doses reduces airway hyperresponsiveness 
following repeat low dose allergen challenge in atopic asthmatics (378). 
4.2.5 Aims 
The aim of this study was to develop a nasal allergen challenge model that 
more closely resembles the natural pollen exposure that occurs during the hay 
fever season and leads to increased levels of cytokines in nasal filter paper 
eluates. 
4.3 Methods 
4.3.1 Subjects 
The study was approved by the Ethics Committee of The Royal Brompton and 
Harefield NHS Trust, and all subjects gave written informed consent. The study 
cohort consisted of male and female, non-smoking subjects with a history of 
seasonal (intermittent) allergic rhinitis, aged between 18 and 40 years. All 
subjects had a positive skin prick test to Timothy grass pollen (wheal difference 
Timothy grass pollen - negative control z3 mm). Subjects were studied outside 
the UK hay fever season, outside May to July. The subjects were all otherwise 
healthy with no medical problems that might have risked their participation in 
the study. All subjects had no history of other significant allergies as 
environmental priming has been described (356). The subjects did not have 
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respiratory disease other than a history of mild stable asthma not requiring 
treatment and associated with normal lung function. All subjects had a physical 
examination with particular attention to the nose to exclude any subjects with 
structural nasal abnormalities or nasal polyps. Subjects were excluded if they 
had had an upper respiratory tract infection in the week prior to screening. All 
subjects were non-smokers and not taking any regular medication. Subjects 
were not allowed to take any medication for the duration of the trial apart from 
paracetamol. 
Table 4.1 below shows the demographic and baseline details of the subjects in 
each group. Data is represented as the median and the range. As the placebo 
group only contains 2 subjects individual patient data is shown. 
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Table 4-1 - Subiect demoaraehics 
Allergen Fluticasone Placebo 
n 8 4 2 
Age 26 (20-40) 24 (19-26) 22-28 
Gender M: F 4: 4 1: 3 2: 0 
Cauc 1 
Ethnicity Cauc 5 Afro-caribbean 1 Cauc 1 Afro-caribbean 3 Asian 1 Oriental I 
Hispanic 1 
Total IgE 191 (21-788) 142 (43-539) 56,130 
Timothy grass 
IgE 35 (6-860 20 (8-33) 6,8 
4.3.2 Nasal challenge 
Subjects received their nasal challenge using a Dolphin delivery device (Valois, 
UK) which delivers 100pl of allergen solution to each nostril. The nasal allergen 
challenge was performed with freeze-dried extract of Timothy grass pollen 
(Aquagen, phleum pratense, ALK freeze dried extract). A total dose of 1000 
biological units was given as 500BU to each nostril (0.33pg Phleum P5 
antigen). The Timothy grass pollen extract was initially dissolved in a diluent 
solution containing phenol before being dissolved in physiological saline to 
achieve the final concentration. Therefore the placebo nasal challenge was 
made by diluting the same volume of diluent used to dissolve the allergen in the 
same volume of saline to ensure that the allergen and placebo challenges 
contained equal amounts of phenol. The fluticasone was administered using a 
commercially available nasal spray delivering 1 00pg to each nostril. 
4.3.3 Nasal procedures 
Nasal symptom scores were carried out as detailed in section 2.1.5 using the 
nasal symptom score card shown in the appendix, the subjects gave a score of 
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0-3 for each of the 4 symptom questions giving a maximum score of 12. 
Subjects were excluded if they had a nasal symptom score of >2 at baseline. 
Nasal lavage was carried out using the modified pool technique as detailed in 
section 2.1.6. The nasal lavage was processed to obtain a cytospin preparation 
for cell analysis and a supernatant sample was reserved for future cytokine 
analysis. Filter paper samples were collected using Whatman 42 filter paper as 
described in section 2.1.7 and the eluates reserved for future cytokine analysis 
4.3.4 Cytokine detection 
Cytokines in nasal filter paper eluates were detected using the highly sensitive 
multiplex Luminex® bead assay as described in section 2.2.3. A standard curve 
was run in duplicate and all samples were run in duplicate and the mean taken 
of the two values. The detection limits for each cytokine are shown in the table 
below. 
Table 4-4-2 Detection limits for cvtokines 
Cytokine Detection limit (pg/ml) 
IL-4 1.3 
IL-5 0.9 
IL-13 5.4 
Eotaxin 11.7 
IFN-y 14.6 
The cytokine levels in the nasal lavage samples were measured using the Meso 
Scale Discovery Ultra sensitive cytokine detection assay which has a detection 
limit of 0.6pg/ml. 
4.3.5 Study schedule 
Arm 1: Nasal allergen challenge (n= 8) 
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I Challenge week 
Day -7 -8 12345 11 12 
Screening V2 V3 V4 V5 V6 V7 V8 V9 V10 
Arm 2: Fluticasone and NAC (n= 4) 
I Challenge week 
Day -7 -8 12345 11 12 
Screening V2 V3 V4 [VflFV6 V7 V8 V9 V10 
FFFFF 
Arm 3: Placebo challenge (n=2) 
Challenge week 
Day -7 -8 12345 11 12 
Screening V2 V3 V4 J V5 V6 V8 V9 V 10 
The schedule, days and visit numbers for the study are presented. The red 
arrows indicate the timing of an allergen challenge, the letter F indicates when 
fluticasone was given. The white arrows indicate the timing of placebo 
challenge. Visits 3,8 and 10 were performed at 24 hours following the 
challenge, and symptom score data and nasal filter paper and lavage samples 
were collected. Nasal filter paper samples and symptom scores were collected 
prior to challenge and at 15 minutes and 1 and 6 hours post challenge. Nasal 
lavage samples for eosinophils and cytokine analyses were collected prior to 
challenge and 1 and 6 hours post challenge. Blood samples for IgE and IL-13 
measurement were collected at V2 and V10. 
Page 131 of 293 
4.3.6 Statistical analysis 
The data was assessed for normality by looking at data distributions and also 
comparing the mean and median of the data sets. Since there were many zero 
values in the data set, the data was not normally distributed, with the mean and 
median being disparate. Hence box-whisker plots, which show the median, 
interquartile ranges and the range of the data, represent the data. Plots are also 
shown of individual subject data, where there is consistency of a colour for a 
particular subject throughout the graphs. This enables the signal for each 
cytokine to be compared for each individual subject, and allows response rates 
to challenge to be assessed. Priming was determined by comparing responses 
at the first challenge visit (V2) with the response at the same time point in the 
subsequent challenge visits (V4, V5, V6, V7, V9) using the Wilcoxon matched 
pairs test. 
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4.4 Results 
4.4.1 Symptom score responses to nasal challenge with allergen, 
allergen and fluticasone and placebo challenge 
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Figure 4-1 Effect of repeated nasal challenge on total nasal symptom score. Data shown 
as median, interquartile range and range There was an increase in pro-challenge 
symptoms between V2 and V7 in the allergen arm, however this did not achieve 
statistical significance. There was no evidence of priming at 1 or 6 hours post allergen 
challenge. Administration of fluticasone before allergen challenge did not modify the 
symptom response to allergen challenge. Placebo challenge did not cause nasal 
symptoms. 
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4.4.2 Change in % eosinophils in nasal lavage in response to nasal 
challenge with allergen, allergen and fluticasone and placebo challenge. 
Allergen challenge 
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Figure 4-2 Effect of repeated nasal challenge on % eosinophils recovered from nasal 
lavage. Data shown as median, interquartile range and range 
Repeated nasal allergen challenge caused an increase in the % eosinophils in nasal 
lavage. There was no evidence of priming at baseline or at 6 hours post challenge with 
repeated allergen challenge. However at 1 hour post allergen challenge there was a 
statistically significant increase in the response at V5 (p=0.03), V6 (p=0.03) and V7 
(p=0.05), but not visit 9. Fluticasone did not reduce levels of eosinophils in nasal lavage 
following nasal allergen challenge. Placebo challenge did not increase the % of 
eosinophils in nasal lavage. 
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4.4.3 Levels of cytokines in nasal samples following repeated nasal 
allergen challenge 
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Figure 4-3 Effect of repeated nasal allergen challenge on IL-4. Data shown as median, 
interquartile range and range 
In general, IL-4 levels are higher in lavage than paper, and it is noted that lavage levels 
do not seem correlate with paper levels. There was a non-significant increase in IL-4 in 
nasal lavage at V9 6 hours compared with V2 6 hours in nasal lavage. There was no 
evidence of priming of the IL-4 response in nasal lavage to repeated allergen challenge. 
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Figure 4-4 Effect of repeated nasal allergen challenge on IL-5. Data shown as median, 
interquartile range and range 
In general, IL-5 levels are higher in lavage than paper, and it is noted that lavage levels 
do not seem correlate with paper levels. There was no evidence of priming at baseline. 
There was evidence of priming in nasal lavage at 1 hour at V5 (p=0.01), however this 
priming effect was not sustained across the challenge week. There was evidence of 
priming at 6 hours at V9 (p=0.008). 
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Figure 4-5 Effect of repeated nasal allergen challenge on IL-13. Data shown as median, 
interquartile range and range 
In general, IL-13levels are higher in lavage than paper, and it is noted that lavage levels 
do not seem correlate with paper levels. There was no evidence of priming at baseline or 
1 hour post challenge. There was evidence of priming at 6 hours post challenge at V7 
(p=0.01) and V9 (p=0.008). 
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Figure 4-6 Effect of repeated nasal allergen challenge on eotaxin. Data shown as median, 
interquartile range and range 
There were non-significant increases in eotaxin in nasal lavage following repeated nasal 
allergen challenge and there was no evidence of priming. 
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Figure 4-7 Effect of nasal allergen challenge on IFNy. Data shown as median, interquartile 
range and range 
There was no increase in nasal lavage levels of IFN-gamma following nasal allergen 
challenge and there was no evidence of priming. 
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The following table summarises the effect of repeated nasal allergen challenge 
on cytokine levels in nasal lavage fluid. 
Table 4-3 Cvtokines in nasal lavaae followina reheated nasal allergen challenge 
IL-4 IL-5 IL-13 
Detection limit pg/ml 0.6 0.6 0.6 
Magnitude of maximum signal pg/ml 
(median) 8.8 31.2 94.2 
Number of subjects out of 8 with consistent 
response 
5 4 6 
Priming at baseline No No No 
Priming at 1 hour No No No 
Priming at 6 hours No Yes Yes 
The maximum signal for all cytokines was seen at V9 6 hours post challenge. 
The graphs of individual subject data allow the signal to be tracked across the 
challenge week and determine the number of subjects who have a consistent 
response to repeated challenge. 
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4.4.4 Effect of fluticasone administration prior to repeated nasal allergen 
challenge on nasal cytokine levels 
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Figure 4-8 Effect of fluticasone on IL-4 response to nasal allergen challenge. Data shown 
as median and interquartile range. 
There was no IL-4 response to nasal challenge at baseline which makes assessment of 
priming difficult. There was an increase in levels of IL-4 in nasal lavage post challenge at 
V9, but this was not statistically significant. 
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Figure 4-9 Effect of fluticasone on IL-5 response to nasal allergen challenge. Data 
shown as median and interquartile range. 
There was no response to nasal challenge at baseline, which makes assessment of 
priming difficult. There was not an increase in levels of IL-5 in nasal lavage at V9. 
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Figure 4-10 Effect of fluticasone on IL-13 response to nasal allergen challenge. Data 
shown as median and interquartiler range. There was no response to nasal challenge at 
baseline which makes assessment of priming difficult. There was an increase in IL-13 
levels in nasal lavage at 6 hours post challenge at V9, but this did not reach statistical 
significance. 
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Figure 4-11 Effect of nasal fluticasone on eotaxin response to allergen challenge. Data 
shown as median and interquartile range. 
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Figure 4-12Effect of fluticasone on IFNy response to nasal allergen challenge. Data shown as median and interquartile range. There was no response to single or repeated nasal allergen challenge for eotaxin or IFNy. 
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Figure 4-13 Effect of repeated nasal challenge with placebo on nasal cytokines in filter 
Paper eluate and nasal lavage (n=2 ). 
Repeated nasal challenge with placebo did not cause increases in cytokine levels in 
nasal lavage. The nasal filter paper data did cause some increases in cytokines in one of 
the subjects. 
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4.4.6 Results summary 
Nasal allergen challenge caused an increase in nasal symptoms that was 
maximal at 15 minutes post challenge. This effect was not abolished by the 
prior administration of fluticasone. Placebo challenge of the nose did not cause 
nasal symptoms. Nasal allergen challenge caused an increase in nasal 
eosinophils in nasal lavage. Priming was assessed by using the Wilcoxon 
matched pairs test to compare responses across the challenge week at 
comparable time points, comparing response to allergen challenge at visit 2. 
The baseline did not increase across the challenge week, however at 1 hour 
post challenge there were significant increases in the % eosinophils in nasal 
lavage at 1 hour post challenge at visit 5 (p=0.03), visit 7 (p=0.03) and visit 7 
(p=0.05) when compared with the response at visit 2. When the subjects 
returned a week later at visit 9 this priming effect was no longer present (p=0.3). 
At 6 hours post challenge there was not a significant increase in response when 
compared with visit 2. 
In the fluticasone group there was no increase in the % eosinophils in nasal 
lavage following initial challenge. However levels of eosinophils were increased 
in nasal lavage 1 hour post challenge in subsequent challenges despite the pre- 
administration of fluticasone. Challenging the nose with placebo allergen did not 
increase the levels of eosinophils in the subjects studied. 
When considering detectable levels of cytokines and chemokines it was striking 
that detectable levels were generally higher in nasal lavage supernatants than 
in filter paper eluates. This finding was contrary to our previous studies, where 
filter paper eluate levels were always higher than those in nasal lavage 
supernatants. Repeated nasal allergen challenge did not cause a significant rise 
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in IL-4 levels in nasal lavage. There was an increase in IL-4 in nasal lavage 
consistently across subjects at V9 6 hours post allergen challenge. There was a 
trend (non statistically significant) for an increase in IL-4 in nasal lavage 
following repeated nasal allergen challenge in the fluticasone treated group. 
Nasal challenge with placebo did cause an increase in IL-4 at one challenge 
that did not fall back to baseline and as such is anomalous data. The filter paper 
data did not show any consistent patterns of priming with progressively 
increasing levels of cytokines and chemokines post nasal allergen challenge 
performed on consecutive days. 
There was an increase in IL-5 at 6 hours post challenge at V9, and this was 
significantly increased when compared to initial challenge at V9. There was no 
increase in IL-5 in nasal lavage at any of the challenge visits in the fluticasone 
treated group. Placebo nasal challenge did not cause an increase in IL-5 levels 
in nasal lavage. 
Repeated nasal allergen challenge caused elevated levels of IL-13 in nasal 
lavage. There was no evidence of priming pre-challenge or 1 hour post 
challenge. There was evidence of priming at 6 hours at V7 (p=0.01) and V9 
(p=0.008). There was an increase in IL-13 in nasal lavage at 6 hours post 
challenge at V9, but this did not achieve statistical significance. The fact that 
there was a response seen at 6 hours post challenge at V9 suggests that 
priming has occurred. There was a trend within individual subjects for levels of 
IL-13 to be increased during the final challenge. In the placebo group one 
subject did have increased levels of IL-13 in nasal lavage during the challenge 
week, but this was not sustained at the following challenge. 
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In all the groups and for all of the cytokines the filter paper eluate paper did not 
show any consistent patterns. 
Systemic effects of repeated nasal allergen challenge 
The following table summarises the changes in blood levels of IgE (total and 
specific) and IL-13 at baseline and at study completion. Data shown is median 
and range. 
Tnhlp 4-4 Blood InE and IL-13 levels 
Allergen 
n=8 
Fluticasone 
n=4 
Placebo 
n=2 
Total Ig E baseline 191 (21-788) 142 (43-539) 56,130 
Total IgE follow up 214 (52-857) 343 (42-622) 55,152 
Timothy grass IgE baseline 35 (6-86) 20 (8-33) 6,8 
Timothy grass IgE follow up 36 (13-87) 28 (8-100) 7,5 
Plasma IL-13 baseline 2.9 (0-116) 9(5-13) 94,0 
Plasma IL-13 follow up 2.5 (0-116) 9(0-12) 87,0 
This table shows that plasma levels of IgE and IL-13 were not increased 
following repeated allergen challenge, and hence systemic inflammation was 
not detected. 
Regression analysis did not yield any link between baseline levels of total, IgE, 
Timothy grass specific IgE and plasma IL-13 and subsequent response to nasal 
allergen challenge. 
4.5 Discussion 
The aim of the development of a clinical model of repeated daily dosing with 
allergen was to mimic the exposure that occurs naturally in the allergen season. 
Many animal models of allergen challenge employ this priming, and novel 
therapeutics are often effective in the context of inhibiting priming reactions. A 
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therapeutic that inhibits priming in an animal model can then be assessed in a 
related human model, which is also similar to natural allergen challenge. 
The late phase reaction associated with release of IL-4, IL-5 and 11-13 is of 
particular interest when assessing new drugs. The best model of the allergen 
exposure that occurs during the hay fever season is the Vienna chamber, but 
access to these is limited and the model is not generally employed in the 
context of repeated sampling. 
It is possible that repeated allergen dosing could cause tolerance and hence a 
reduced response over the course of the challenge week. However the doses of 
allergen used in immunotherapy shows a dose dependent effect and the doses 
used to achieve clinical benefit are in the range of 15-20pg (379), this is in 
comparison to the much lower dose of 0.33pg used in this study hence 
tolerance is unlikely to have occurred. 
One of the limitations of this study was that samples were collected up to 6 
hours post challenge and then at 24 hours post challenge. There may have 
been a greater magnitude of response at 8 hours. There was no evidence of 
increased eosinophils or cytokines prior to allergen challenge on each of the 
study days suggesting that priming was not due to an increase in inflammatory 
cells or mediators that were amenable to collection by nasal lavage, it is 
possible however that there were changes in inflammatory cell numbers in the 
mucosa or indeed changes in the nasal epithelium cells that lead to the priming 
effects seen. This could be investigated further by sampling the mucosa using a 
nasal scraping technique such as the Rhinoprobe®. 
Previous studies from other groups have shown that eotaxin levels are 
increased in nasal lavage samples following single allergen challenge (98), and 
Page 149 of 293 
following repeated nasal challenge and this effect can be reduced by the 
administration of a nasal steroid (373). However, eotaxin levels did not increase 
in this model following single or repeated challenge. The levels of IL-4 in nasal 
lavage were comparable to the levels presented in the single challenge model 
in chapter 3; however the levels of IL-5 and IL-13 found following repeated 
challenge were higher. The raw data plots enable responses for individual 
subjects to be visualised and demonstrates the contribution of an individual 
subject to the pooled data. This is important because these results show that it 
is the same individual having a response to challenge across the study rather 
than random contributions from numerous subjects. In this study it was found 
that responder rates for IL-4, IL-5 and IL-13 were 5,4 and 6 out of 8 subjects 
respectively. This responder rate after repeat dose allergen challenge is higher 
than the responder rate following single allergen challenge reported in Chapter 
3. If it could be predicted prior to the study the response rate then this would 
allow subjects to be selected for the study, however regression analysis has not 
shown that levels of IgE or serum IL-13 at screening can predict who is going to 
respond. This is an important point for drug development however as carrying 
out trials on selected patients as this type of selection of reactive individuals 
may make generalisation of such treatment difficult and would have to be 
confirmed by larger more inclusive protocols. With the ever expanding field of 
pharmacogenetics the future of drug development is tailoring treatments to 
individuals. 
Subjects were treated with fluticasone as a positive control group. A single dose 
of topical nasal steroid has been shown to reduce symptoms at 8 and 24 hours, 
with no effect on acute symptoms (101). This is consistent with the findings of 
this study. A reduction in the early phase symptoms has been seen following a 
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week of fluticasone treatment prior to allergen challenge (380). A similar model 
to the one used in this study where subjects were given allergen challenges for 
7 days following 7 days of nasal steroid and, and this was shown to reduce 
symptoms and inflammatory mediators in nasal lavage (381). This is not directly 
comparable with the results of this study as subjects did not receive pre- 
treatment with nasal steroid prior to the challenge week. In addition the subjects 
in that study did not have an allergen challenge prior to receiving nasal steroids 
so it is possible that they were non-responders to allergen challenge. 
The main problem with the fluticasone group is that there was not any increase 
in cytokine levels in response to initial challenge which makes it impossible to 
detect inhibition of response in subsequent challenges. It is possible that by 
chance the 4 subjects selected at random for the fluticasone treatment were 
non-responders to allergen challenge, and this again underlines the need for 
larger sample sizes. Repeated placebo challenge did not cause increases in 
levels of cytokines in nasal lavage. This is important because the allergen is 
stabilised in phenol and it is essential to determine that this does not cause a 
non-specific increase in vascular permeability and hence increase levels of 
cytokines in nasal lavage by a non-immune mechanism. This was further 
clarified by the measurement of IFNy in the nasal lavage sample, as this would 
not usually be released following allergen challenge, but may be increased in 
generalised capillary leak. However it is important to note that the subjects in 
the placebo group did have lower levels of IgE and hence may be considered to 
be less atopic. 
One of the main limitations of this exploratory study was the small number of 
subjects in the fluticasone and placebo groups, but unfortunately this was a 
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fixed part of the protocol and further funding could not be obtained to increase 
the sample size. 
This study did not show any systemic effects of repeated allergen challenge and 
determined by blood levels of IgE and 11-13. It has previously been shown that 
nasal allergen challenge does not increase levels of eosinophils in the blood or 
sputum (382). Safety of subjects participating in research is extremely important 
and tolerability of a model is important. There were no serious adverse events 
reported during this study, there were several adverse events of subjects 
reporting frontal headaches during the challenge week that were similar in 
nature to the headaches they suffer during the hay fever season. These 
headaches were treated with paracetamol and no subject withdrew from the 
study as a result. 
The detectable filter paper eluate levels of cytokines were consistently low in 
this study, and showed no relation to the levels found in the nasal lavage. There 
was an increase in nasal symptoms, eosinophils and cytokines in nasal lavage 
following challenge suggesting that there was not a problem with the allergen or 
its delivery device. The Whatman 42 filter paper is designed as a cellular filter 
and is not designed for protein work. However Whatman 42 is the paper used in 
the original description of the method (329). 
In preliminary experiments, an absorptive synthetic matrix that is designed for 
protein elution use was assessed by members of the Clinical Studies Unit 
(results presented in Appendix 2). Accuwik Ultra® (Pall Gellman) was used in 
spiking experiments and shown to have improved protein recovery compared to 
Whatman's FILT P. Therefore in any subsequent clinical studies the Accuwik® 
paper could be used, although batch validation is also recommended for this 
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product. Also in the appendix is the results of a study subsequently performed 
using the Accuwik® paper in a nasal allergen challenge study that shows 
increased levels of IL-13 following nasal allergen challenge with an increased 
dose of Timothy grass. In general, the levels in lavage are lower due to 
dilutional effects; hence it is preferable to use an absorptive matrix to obtain a 
bigger signal. 
4.6 Conclusions 
This repeat dose NAC model does cause significant priming of the IL-5 and IL- 
13 late phase response in nasal lavage, with a trend for increased symptoms 
and eosinophils. 
Repeat NAC is feasible for recruitment and the protocol is safe and well 
tolerated by subjects. 
Repeated NAC could be used as a model for the assessment of new drugs, 
especially those therapies that target 11-4, IL-5 and IL-13. 
4.7 Future study 
1. It would be beneficial to determine subjects' responsiveness to allergen 
challenge at screening prior to inclusion in the study, with documentation of 
serial nasal cytokine and chemokine responses. 
2. One should only employ Whatman's filter paper if it has appropriate elution 
characteristics for a particular batch demonstrated by spiking with commercial 
standards and nasal samples. Otherwise there is the need to identify and 
validate novel absorptive matrices with reproducible and efficient elution 
characteristics. 
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3. The dose of allergen employed should be characterised, since greater doses 
may cause higher detectable cytokine responses. 
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5 Cigarette smoke nasal challenge in patients with COPD 
5.1 Abstract 
Introduction: Cigarette smoke is the commonest cause of COPD, and has 
been shown to have inflammatory effects in animal models and in in vitro 
human models. For ethical reasons an in vivo human cigarette smoke challenge 
model has not been developed. Nasal challenge has been used effectively to 
show the inflammatory changes in allergic disease and could potentially be 
used to demonstrate the inflammatory effects of smoking. 
Aims: The aim of this exploratory study was to assess whether there will be an 
inflammatory response (detectable as changes in nasal inflammatory 
mediators) following exhalation of cigarette smoke through the nose. 
Methods: A total of 8 smokers with COPD and 8 smokers with no evidence of 
lung disease as determined by symptoms and spirometry were recruited. They 
abstained from smoking for 12 hours and then smoked a cigarette with the 
smoke being exhaled through the nose. Nasal filter paper and nasal lavage 
samples were collected prior to challenge, and at time intervals up to 8 hours 
following challenge for cytokine/chemokine and cell analysis respectively. 
Samples of blood were also collected for cytokine/chemokine analysis of 
plasma. 
Results: There was a trend for cytokine/chemokine levels to be higher in nasal 
filter paper samples and plasma samples in the subjects with COPD. In nasal 
filter paper samples there was a statistically significant difference for IL-8 and 
IL-12p70 at baseline after washing. In nasal lavage samples cytokine and 
chemokine levels were similar for both groups; however there was an increase 
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in MCP-1 8 hours following challenge. There was a pattern of increased 
neutrophils in nasal lavage following challenge in 3 out of 8 COPD subjects. In 
plasma samples there was a statistically significant difference for IFN-y and 
MIP-1a. None of the cytokines or chemokines measured in nasal filter paper 
eluate samples or plasma were increased in response to nasal cigarette 
challenge, but based on the NAC studies the FILT P is likely to have been 
inadequate for detection of inflammatory mediators in nasal secretions. 
Conclusions This pilot study suggests that further development of this model is 
justified. It should be repeated with more subjects who are more carefully 
screened to exclude the presence of respiratory disease. Attention should also 
be paid to length of abstinence from smoking prior to challenge and also to 
continued collection of samples beyond 8 hours. The nasal filter paper samples 
should be collected using a SAM designed for protein absorption and release 
such as the Accuwik® paper. 
5.2 Introduction 
5.2.1 The role of smoking in the pathogenesis of COPD 
Cigarette smoking is by far the commonest cause of COPD worldwide, 
accounting for more than 95% of cases in industrialised countries. Usually there 
is a smoking history of greater than 20 pack years. Smoking causes both mucus 
hypersecretion and progressive airflow obstruction. Smoking cessation 
decreases respiratory symptoms and slows the rate of decline of lung function 
(383-387). Passive smoking is associated with the development of COPD (388- 
390) and smoking during pregnancy may be a risk factor for the development of 
COPD as this may affect foetal lung growth (391). As discussed in Chapter 1, 
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there is considerable evidence from in vitro and in vivo models that the 
development of COPD as a result of cigarette smoking is biologically plausible. 
5.2.2 Nasal disease in patients with COPD 
Whilst the name COPD suggests a disease affecting the lungs, it has been 
apparent that there are effects on the body distant from the lungs (392). The 
nasal mucosa is continuous with the respiratory mucosa and also is exposed to 
cigarette smoke. It is therefore not surprising that nasal disease is present in 
smokers with COPD. A study of patients with COPD has shown that raised 
nasal levels of IL-8 are seen in patients with COPD and this correlates with 
levels of IL-8 present in sputum and nasal wash leukocyte concentration (393). 
A study comparing nasal and bronchial biopsies in smokers with and without 
COPD has that nasal and bronchial inflammation coexists in smokers and is 
characterised by infiltration of CD8 T lymphocytes. In smokers with COPD this 
is associated with an increased number of neutrophils in both nasal and 
bronchial biopsy specimens (249). Markers of inflammation have been shown to 
be increased in nasal wash samples at the time of exacerbation suggesting that 
COPD exacerbation is associated with pan-airway inflammation (244). In a very 
interesting study patients with COPD showed and increase in markers of 
neutrophil but not eosinophil inflammation following challenge with histamine 
and this was greatest in subjects who complained of nasal symptoms prior to 
challenge (250). The same study also showed that COPD patients with nasal 
symptoms had increased mucinous secretory hyperresponsiveness. 
5.2.3 Nasal challenge models 
The nasal epithelium is histologically similar to and in continuation with the 
respiratory epithelium and has the advantage of being easily accessible. 
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Therefore the nose has been used to study the effects of various stimuli. As 
discussed previously in this Thesis the nose can be used to study responses to 
allergen challenge. Lipopolysaccharide nasal challenge has been shown to 
increase GM-CSF in nasal lavage fluid four hours after challenge in atopic and 
non-atopic subjects (394). LPS has been shown to cause a release of IL-6 into 
nasal lavage 6 hours following challenge. IL-1 P, 11-6,11-8 and TNFa, and 
neutrophils are all increased in nasal lavage fluid at 6 hours post nasal 
challenge with Iipopolysaccharide. Ozone is an environmental pollutant that has 
oxidant properties, and has been shown to have inflammatory properties in 
human airways(395; 396). Exposure to ozone causes a central regulator of 
epithelial function, epidermal growth factor receptor, to be increased in nasal 
biopsy specimens following exposure to ozone (397). 
5.2.4 Cigarette smoke challenges 
It is possible to generate cigarette smoke extracts by bubbling cigarette smoke 
through liquid which can then be added to cell culture lines or other tissue 
preparations and then measure the inflammatory response. It is also possible to 
investigate the effects of single components of cigarette smoke such as nicotine 
or acetaldehyde, although this method has limitations due to the complex 
chemical nature of cigarette smoke. It has been suggested that some of the 
effects seen in cigarette challenge models is due to the effect of 
lipopolysaccharide present in the tobacco, however it has been shown that 
cigarette conditioned medium does not contain significant amounts of 
Iipopolysaccharide using the Limulus assay (398). 
Similarly in vivo animal models of cigarette smoking can be divided into those 
that look at the effect of cigarette smoke or those that look at specific 
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components of cigarette smoke. Animals can be exposed to cigarette smoke by 
using smoking machines that deliver a constant rate of smoke to their cages, 
and the design can be modified to create models of mainstream or sidestream 
passive smoking. These models have been used to show the effects of 
exposure to cigarette smoke in animals (399; 400). It has been shown that 
inflammatory changes similar to those seen in COPD can be induced in mice by 
intranasal application of cigarette conditioned medium (401). 
In humans there are considerable ethical issues when planning a cigarette 
smoke challenge model. It is not ethical to expose non-smokers to cigarette 
smoke. Similarly it is not ethical to expose smokers to individual components of 
cigarette smoke as the exact levels reached in the tissues cannot be accurately 
known and hence subjects may be exposed to levels much higher than those 
reached during normal smoking and hence suffer form greater toxicity. In a 
human smoking model were samples were collected following smoking there 
was and increase in sputum neutrophils and lymphocytes and greater 11-8 
release from stimulated blood cells (402). This model allows subjects to be 
exposed to levels of cigarette smoke associated with normal smoking, and also 
allows multiple samples to be taken following the exposure. 
5.2.5 Aims 
The aim was to develop a model for the testing of new anti-inflammatory drugs 
for the treatment of COPD. Patients with COPD often have reduced respiratory 
reserve so the aim was to develop a model that avoided the need for invasive 
procedures such as bronchoscopy. It was hoped that using a challenge model 
would increase the inflammatory signal to increase the power of any future 
studies with new therapeutic entities. 
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5.3 Methods 
5.3.1 Subject selection 
This study received approval from a local ethics committee. Subjects were 
recruited from the database at the Clinical Studies Unit and by advertisements 
placed in local newspapers. Subjects underwent a full medical and smoking 
history, physical examination and lung function as detailed in section 2.1.1- 
2.1.3. Subjects in the COPD group were given a subject number from 101-108, 
and the "healthy" group were given a number from 201-208. 
5.3.2 Nasal sample collection 
Nasal lavage and filter paper samples were collected as detailed in section 
2.1.5 and 2.1.6. Briefly nasal lavage samples were obtained by instilling 5 mis of 
PBS into the left nostril with the subjects' neck flexed. The PBS was flushed 
slowly in and out of the nose 20 times. The lavage sample was then centrifuged 
and a cell pellet obtained for cell counting and the supernatant retained for 
cytokine and chemokine analysis. The right nostril had 2 pieces of filter paper 
inserted for 2 minutes. These were then placed into Luminex® assay buffer and 
the eluate retained for cytokine and chemokine analysis. 
5.3.3 Plasma collection 
Blood was collected for cytokine analysis as detailed in section 2.1.8. 
5.3.4 Measurement of cytokines and chemokines 
Nasal lavage supernatant, nasal filter paper eluate and plasma were analysed 
using the Luminex® multiplex analyser. All samples were stored at -80°C from 
time of collection until analysis. 
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5.4 Results 
5.4.1 Subject clinical data 
There were 8 subjects with COPD and 8 subjects with no clinical evidence of 
lung disease who continue to smoke at least 5 cigarettes a day were recruited 
for this study. Their clinical details are summarised in Table 5.1. Subjects were 
excluded if they had allergic rhinitis or within two weeks of an upper respiratory 
tract infection. 
Table 5.1 Subiect demoaraohics 
COPD Healthy smokers 
Age (mean, range) 64 (48-75) 55 (42-71) 
Gender (% Female) 50 37.5 
Ethnicity All Caucasian All Caucasian 
Smoking history: pack years (mean, 
range) 
43.5 (17.5-67) 35.91 (16.8-82.5) 
Current smoking: number of 
cigarettes/day (mean, range) 
17.75 (12-20) 19.94 (7.5-35) 
FER pre bronchodilator (mean, range) 49.13 (27-63) 77.50 (73-84) 
FEV1: % predicted ( mean, range) 58.5 (26-78) 99 (94-105) 
5.4.2 Nasal lavage cytology 
Nasal lavage cytology results are expressed as % neutrophils per ml of lavage 
fluid. This is calculated by multiplying total cell count from a Neubauer chamber 
by % neutrophils on a cytospin stained with Diffquick®. This was then corrected 
for the amount of lavage recovered from the patient. 
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Figure 5-1 Neutrophils/ml of nasal lavage fluid following challenge with one cigarette in 
COPD and healthy smokers. 
Figure 5.2 shows the results for COPD and healthy subjects following nasal 
challenge with one cigarette. It can be seen that healthy smokers had low levels 
of neutrophils at baseline, whereas three of the COPD subjects had raised 
neutrophils at baseline. One subject in the COPD had remarkably high levels of 
neutrophils at baseline. It is possible that the pre-lavage was not performed 
adequately. Three subjects in the COPD group and one subject in the healthy 
group showed some increase in neutrophil levels in nasal lavage following nasal 
cigarette challenge. 
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5.4.3 Nasal filter paper cytokines and chemokines 
COPD Healthy Median + IQR 
IL-la 
-101 
_ ,0 
-,. 4 
105 
_ 106 
_ , 01 
i08 
oiz4snze 
Hour. poet chaIII. ng. 
S0 zu. 
so. -207 
-204 
-205 
- 208 
207 
-208 
oita45ere 
Hours post chMIU. np. 
50 
.0« 
lo 
oz*; 
h, 
Houn polt Nrllbnp. 
IL-1b 
- 1J1 
l0 102 
10] 
20 10 
105 
10 00 
107 
0J 
108 
0127IS676 
Houn po. t ch. lll. ng. 
: 02 
203 
0 +-2 p 
S -105 
ýo + Zue 
-207 
- ON 
01231S67D 
Hours po. t ch. Ybng. 
M 
n 
o+ a+ý snýe 
Houn poft cl. I n9e 
I L-2 
15 - 
101 
02 
X 103 
75 104 
-105 
106 
25 - 107 
0 X108 
0I234597e 
Hours post challlsngs 
125- --- mi 
202 ao 203 
75 204 
-205 
OB 
25- 
_Y77 
- 
208 
01234sere 
Huun post chaIU. np. 
,e 
tl ý 
nI f 
o, a, sete 
Hours po+l ch. m. ng. 
I L-3 
ý- 101 
102 
ß-10J 
- 104 
t05 
m +-106 
-107 
n +. 
108 
01x34sare 
Hours po8l chal1Mnq 
7s 
zo. 
24 
- . 05 
1 
-207 
-2otl 
o, sa4se7e 
Hours post challbnp 
ý0 " ýY 
b 
H1 
a1])ese/e 
Noun peil t dWq . 
Page 163 of 293 
COPD Healthy 
Median + IQR 
IL-13 
p -101 
102 
-103 
104 
--705 
06 
10 
+- 107 
X 108 
oIZ345678 
Hours post chaIIINngs 
202 
-203 
25 -204 
-205 
-206 
-207 
-208 
ot234567e 
Hours post chaIII. o . 
. 14a1TY 
1 
l. 
_ 
0 
1A1 
Hourf yofl 0.111. rgf 
IL-15 
ro 
- 101 
102 
-103 
-104 
105 
0 2 -ý 106 
10 - 107 
X 100 
01234597a 
Hours pool challlsng. 
GM-CSF 
50- 02 
40- 03 
105 
20^ 
ý- 106 
,0 
0 
-107 
+108 
01234567E 
Hours post of IIIengs 
IFNy 
100 - 101 
102 
75 -r 103 
04 1 
a 
6 `50 - 105 
ý- 106 
2p 5º! 
T 107 > 
108 T1 
127456r0 
Noura post ch6NNrgs 
70 
e0 -201 CO D 
y0 202 FbaMy 
¬ eo x- 
203 
204 
208 
z0 205 
1 
r_. 1 . 
'07 
0 208 
012le597601I1ase 
Mours post ch III. np* Noun post clvllbrp+ 
-201 
202 
-203 
24 
- : us 
209 
wX 207 
o -- Zoe 
oI2aes6Ie9 
Hours post chaiII.. c. 
Sao - zoi 
-02 
75 203 
20 
ý: OS 
25 . O6 
: OI 
p (M 
012J159/e 
H........ t l4rqý 
1 
1. ýbaß. 'I 
e ot zý dseie Nourý noel ch&kq, 00 
. IM. ßýy 
$. 
1]14seie 
"-1. nu. t cn. wu " 
Page 164 of 293 
COPD 
I L-8 
IL-10 
250 
101 
zoo 102 
ý t00 
X 10 ton 
$'. 
- tos 
-toa 
- too 
0 r tae 
ottl4; e/ 
Hoors poft chaill-p. 
15 
-ý 101 
102 
10 --103 
X 104 
- 105 
107 
- 108 
ot234561e 
Hours post cha1114rps 
IL-12p4O 
IL-12p70 
101 
Opp 102 
, Oa 
t 
lw 105 
06 
100 101 
-108 
o1234567e 
Hours post choIII. g. 
,8 
-101 
Z: 03 
75 - 04 
pý +1a8 
a, zý" saýe 
HOOrs post <hUl.. g. 
Healthy 
ow, 
- mý 
: os 
- oe so. 
Median + IQR 
1ý 
0I1a45e/en111a5nn 
Hours post eMNbnge II...... ..... ., I, IIk u. 
15 
-201 
202 
10 - 203 
-204 
S%ý ? n5 
5 
ý/ /, 208 
x: 07 
01T]1SR/0 
Hours {wsl chall6nps 
-ma 
' -207 a /ý _ -me 
01734567e 
Hoo,. pool ch. I6. ng. 
txs 
t : 02 
i : oa $ zoe 
VS 
206 
n 
ß: a7 
-td1 ý-. 'oe 
ptz34se r$ 
Hours post cMNMnps 
5 
-- ýl'Il 
eyEýý 
I' t 
n 
o tý s n+ s 1 
Hour. yo+l c1r1114rq. 
. 14nITY 
.. r_ . TJ 01 týý sarý hour. Iw. l rhMIMng. 
MaT'r 
orriesers 
H- poet chMMpe 
Page 165 of 293 
COPD Healthy Median + IQR 
TNFa 
101 
102 
- 103 
- 104 
a 
s - 105 
zs - toe 
x 107 
-108 
ota; 4ser 
Hours post challl. np. 
Eotaxin 
175 
-ý 1 01 
150 102 
125 103 
100 10 
75 05 
50 108 
25 107 
0 108 
0127! 5878 
Hours poal cM11Mrq. 
MCP-1 
15 50 
. 102 
, Y5 103 
10 - 104 
IS 105 
5p + 106 
Z5 107 
Hour, post clulIYrg0 
RANTES 
1]1 
01zsae 
Hours poet ch. 10-g. 
ýs 
702 
so -203 
204 a 
d -205 
7 
--: ae 
208 
1234se1e 
Hours post challbngs 
1T5 
x : 01 
150 
: 02 
125 
T `, ýJ E Iý 
ý: OA 
7s : 05 
25 - 207 
0 -208 
0123456re 
Mourn poet chdllvp. 
Irs 01 
50 
" 202 
203 
75 205 
so 2206 
75 207 
0 208 
01234567 
Mourn post ch. I0. nga 
50- 202 
204 
-:, 5 -206 
10. =17 
o, a; ý sei 
Moue pmt ch lunge 
A Mn. Fhv 
I10 lI` 
01eiýsere 
ý1.,. ý.. no. 1 cn. xr. ýu. 
H.. ny e-- 
o I}i T 
orr yý n r. 
ýtrýýýn no. r dýwtx. ou. 
i3 
, no 
1iI4Seia 
Houn p,. I chNlbna. 
10 . IIII !I a124s e/$ Noun po. I Ch. I$np. 
- . -wn 
ýýsamr 
Page 166 of 293 
COPD 
MI P-1 a. -101 
, OZ 
03 
-104 
J-105 
00 x-106 
01 
-108 
01i]4581B 
Nov. p0.1 ch. III. n9. 
Healthy Median + IQR 
ýroa "m, F ý: oa 
,ý -roe 
207 
o Mme a 
H-. p. .t cMNbrpý Hoým p- ch4M 01 
P-10 
aý -moo 
zs --, oe zs ro 
07 -ro7 za 
"ob a +: 09 
a 
o ,: ieseia a , aý asere oarr 
Hours post chaNkrga Hours post chu ng. Hours post chSk. lo. 
Figure 5-2 Levels of cvtokines/ chemokines in nasal filter naner eluates from smo rs 
with COPD and healthy smokers following nasal cigarette smoke challenge. Date shown 
as median and interquartile range. Baseline levels were compared using a Mann-Whitney 
test. There were significant differences between COPD and healthy subjects at baseline 
for IL=8 (p=0.01) and IL-12p70 (p=0.02). 
Page 167 of 293 
5.4.4 Nasal lavage cytokines and chemokines 
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Figure 5-3 Levels of cytokines/ chemokines in nasal lavage from smokers with COPD and 
healthy smokers following nasal cigarette smoke challenge. Date shown as median and 
interquartile range. Baseline levels for the 2 groups were compared using a Mann- 
Whitney test, and showed no differences. Responses at 8 hours compared with baseline 
in each group were compared with the Wilcoxon signed rank test. There was an increase 
in MCP-1 following challenge in both COPD and healthy subjects. 
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5.4.5 Plasma cytokines and chemokines 
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Figure 5-4 Levels of cytokines/ chemokines in plasma samples from smokers with COPD 
and healthy smokers following nasal cigarette smoke challenge. Date shown as median 
and interquartile range. Baseline levels were compared using a Mann-Whitney test. There 
were significant differences at baseline between COPD and healthy groups for IFN-y 
(p=0.01) and MIP-la (p=0.05). 
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5.4.6 Results summary 
In the analysis if the filter paper eluates there are a trend for levels of cytokines 
and chemokines to be elevated at baseline in the COPD subjects when 
compared to the healthy controls. However this only reaches statistical 
significance for IL-8 (p= 0.01) and IL-12p70 (p=0.02). It would appear that none 
of the cytokines or chemokines increases in nasal filter paper samples in 
response to nasal cigarette smoke challenge. 
For the nasal lavage data baseline levels of cytokines and chemokines were 
similar for each of the groups. There was a response following nasal cigarette 
challenge for MCP-1 in both groups. This reached statistical significance at 8 
hours for both COPD and healthy subjects (p=0.02) 
There is a trend for increased plasma levels in COPD smokers for IL-6, IL-7, IL- 
12p70, IL-13, GM-CSF, IFN-y, eotaxin and MIP-la. There is a significant 
difference between COPD smokers and healthy smokers at baseline for IFN-y 
(p=0.01) and MIP-1 a (p=0.05). None of the cytokines or chemokines measured 
in plasma were increased in response to nasal cigarette smoke challenge. 
5.5 Discussion 
This was a pilot study to investigate if a signal of inflammation could be 
detected following nasal cigarette smoke exposure as a potential model for the 
testing of new drugs for COPD. 
Traditionally sputum leukocyte counts are calculated by assessing leukocyte 
numbers using a Neubauer chamber and then performing a leukocyte 
differential on a cytospin preparation. In sputum preparations the distinction 
between squamous epithelial cells and leukocytes in a Neubauer chamber is 
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clear. However in nasal lavage preparations there are large numbers of 
respiratory epithelial cells in addition to squamous epithelial cells. On this 
unstained preparation it is very difficult to distinguish between a leukocyte and a 
small respiratory epithelial cell, relying on granularity differences can be 
misleading as macrophages may have limited granularity. Similarly on a 
cytospin preparation there are epithelial cells of intermediate size that are 
difficult to classify into squamous or respiratory epithelial types. Therefore the 
most robust way to interpret the cytology of nasal lavage in this population is to 
determine the neutrophil % of total cells on a cytospin preparation stained with 
Diffquick® and then multiply this by the total cell count obtained on a Neubauer. 
This can then be corrected for the number of mis of lavage recovered from the 
subject. This is in contrast to nasal lavage cell counting following an allergen 
challenge where it is easier to determine the leukocyte sub-types, and the 
eosinophil is usually absent at baseline and rises to approximately 30% of the 
leukocyte total. There also appears to be less contamination of the post- 
allergen challenge slides with indeterminate epithelial cells. 
Modification of the staining methodology may lead to more accurate expression 
of the neutrophil count. Use of the May-Giemsa-Grunwald stain may 
differentiate the leukocyte subtypes more clearly. However the optimal method 
would be immunohistochemistry, using CD68 to identify macrophages and 
cytokeratin 10 to distinguish the squamous cells. Vimentin would not be suitable 
as it has been shown to be present on cytokeratin positive cells in addition to 
the ciliated or goblet type cells (403). 
This pilot data shows that there is some merit in repeating this study with a 
larger number of subjects. It would also be interesting to repeat lavages more 
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frequently in the first hour, at 10,20 and 30 minutes. This study could 
incorporate a control group who did not smoke a cigarette to determine if 
repeated washing had an effect of nasal lavage cell counts and mediator levels. 
It is interesting to note that even with the small numbers present in this study 
there were differences in nasal filter paper and plasma cytokines and 
chemokines between smokers with COPD and healthy smokers. There was the 
suggestion that some of the mediators were different but these did not reach 
statistical significance, which may be a reflection of the small number of 
subjects. This study did not have a control group of non-smokers and this would 
be a useful group to compare with the smokers, but would not be possible to 
study for ethical reasons. There is a problem interpreting the nasal filter paper 
data, as in the previous chapter we have shown that Whatman's 42 paper may 
cause degradation of cytokines and chemokines. Therefore any future studies 
should be carried out with a paper such as the Accuwik Ultra® that has had its 
elution characteristics established using commercially available cytokine and 
chemokine standards. 
There was not a stimulatory response to nasal cigarette smoke in nasal 
samples or plasma samples, with the exception of MCP-1 in nasal lavage 
samples. The filter paper used in this study was of the same batch as was used 
in the repeat dose allergen model and hence the results should be reviewed 
with caution. However the nasal lavage data should give an accurate 
representation of the changes occurring in the nose following challenge. There 
are two possible explanations for this. It is likely that abstinence for 12 hours 
followed by a single nasal cigarette is not a potent enough stimulus to detect a 
change, and levels may not have fallen from the cigarette the previous evening. 
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It is also possible that 8 hours is an insufficient time period for inflammation to 
develop, and that an inflammatory response may have been seen if samples 
were taken at a later time point. COPD develops over a prolonged period of 
time with repeated cigarette exposure and this model does not replicate the 
pathogenesis of COPD. 
It is also possible that the so-called "healthy" smokers actually do have an 
inflammatory process that was not detected in the screening for this study. 
Subjects were defined as healthy in this study if they were free from respiratory 
symptoms and had normal FEV, and FVC on spirometry. In future studies it 
might be beneficial to characterise the healthy subjects further by performing full 
lung function testing to assess MEF25-75 to assess any small airways disease 
and transfer factor to suggest any early emphysema. A high resolution CT scan 
of the thorax could also indicate the presence of emphysema or another 
smoking related lung disease such as respiratory bronchiolitis- interstitial lung 
disease. 
5.6 Conclusions 
This model of nasal cigarette challenge has the potential to be used to 
characterise the inflammatory changes that occur in smoking related lung 
disease and also to be used for the evaluation of new anti-inflammatory 
therapies for the treatment of COPD. 
5.7 Future study 
Use an increased number of subjects in each group and use SAM to obtain 
nasal samples. 
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Characterise subjects further at screening with CT scans and full lung function, 
to ensure that "healthy" group are free of any respiratory disease. 
Collect samples at time points beyond 8 hours. 
Refine laboratory techniques of nasal lavage cytology and also determine the 
elution characteristics of an alternative matrix for the collection of nasal filter 
paper samples. 
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6 The effects of cigarette smoke conditioned medium (CSCM) 
and oxidants (menadione and xanthine/xanthine oxidase) 
on neutrophil CD1I b upregulation in human whole blood. 
6.1 Abstract 
Introduction: Cigarette smoke is the main cause of COPD, and contributes to 
cardiovascular disease and malignancies. Cigarette smoke is a rich source of 
oxidants, and further oxidant stress is caused by accumulation of inflammatory 
cells. Cigarette smoke conditioned medium (CSCM) has been shown to 
stimulate the release of inflammatory mediators from human cells in vitro, and is 
a source of oxidants, tar, lipopolysaccharide and other molecules. As a more 
specific oxidant stimulus, menadione crosses cell membranes and leads to the 
generation of reactive oxygen species intracellularly, whereas the xanthine/ 
xanthine oxidase system leads to the extracellular generation of reactive 
oxygen species. 
Aims: To develop a short term stimulation model of whole blood with CSCM 
and oxidants through flow cytometric quantification of neutrophil CD11 b 
upregulation. 
Methods: Whole blood short term stimulation systems were developed with (i) 
CSCM (ii) menadione and (iii) xanthine/xanthine oxidase. Following stimulation, 
cells were fixed prior to labelling, and CD11b upregulation on leukocytes was 
measured using flow cytometry. In experiments designed to inhibit the effect of 
oxidants, reduced glutathione and N-acetylcysteine were used as anti-oxidants. 
Results: Fresh CSCM and oxidants caused human neutrophil levels of CD11 b 
to become upregulated in a dose dependent manner. The effect of CSCM could 
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not be inhibited by anti-oxidants, but there was loss of CSCM stimulation on 
storage on the bench. There was no significant difference in the CD11 b 
response to CSCM stimulation of neutrophils between "healthy" smokers and 
COPD smokers. In contrast, menadione caused a dose dependent increase in 
CD11 b expression on neutrophils that could be inhibited by the presence of 
reduced glutathione. Xanthine/ xanthine oxidase required plasma to be 
removed from whole blood before a dose dependent increase in CD11 b on 
neutrophils could be demonstrated, and these effects could again be inhibited 
by glutathione. 
Conclusions: CSCM, menadione and xanthine/xanthine oxidase all cause 
neutrophil CD11 b upregulation. These whole blood models have the potential 
for use pre clinically to screen in vitro new anti-oxidants and anti-inflammatory 
treatments for COPD. 
6.2 Introduction 
6.2.1 Role of oxidative stress in COPD 
There is considerable evidence that oxidative stress in increased in patients 
with COPD (128; 130-132). This arises because of the reactive oxygen species 
(ROS) present in cigarette smoke and also the inflammatory processes 
triggered by inhaling cigarette smoke. Therapies targeted at oxidant stress 
should offer an anti-inflammatory treatment for COPD and developing a 
preclinical human model to test potential new therapies could lead to enhanced 
development in this area. Human whole blood assays can be used pre clinically 
(in vitro), but can also be employed to assess pharmacodynamics in clinical 
pharmacology studies during phase I//II clinical studies ex vivo. It has been 
shown that the pharmacodynamics of a specific p38 mitogen-activated protein 
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kinase inhibitor can be assessed by measuring cytokine production from ex-vivo 
stimulated polymorphonuclear blood cells in a phase one clinical trial (404). 
Pharmaceutical companies are keen to shorten timelines for drug development 
and an ex-vivo model for testing new compounds in a model of oxidant stress 
could reduce the time it takes potential new therapies to proceed to clinical 
testing. 
6.2.2 Effects of CSCM on biological systems 
Cigarette smoke medium is produced by passing the smoke from a burning 
cigarette though cell medium and then applied to the target cells. Cigarette 
smoke can stimulate human cells in vitro to release inflammatory mediators 
(189). It has been shown that CSCM is toxic to an alveolar type II cell-derived 
line, and this toxicity could be inhibited by aldehyde dehydrogenase and N- 
acetyl cysteine (405). 
CSCM triggers stress responses in cultured fibroblasts by the induction of haem 
oxygenase and a significant decrease in intracellular glutathione (406). When c- 
fos is used as an indicator of cellular response against oxidative stress, it's 
expression in fibroblast cells can be inhibited by superoxide dismutase and 
catalyse or the NO-scavenger oxyhaemoglobin (407). The mechanism by which 
cigarette smoke causes these changes in vivo has yet to be well characterised. 
CSCM induces IL-8 release and expression in human airway smooth muscle 
cells, without effect on eotaxin or RANTES, while TNFa enhances CSCM 
induced IL-8 release and expression The effects of CSCM on IL-8 release can 
be inhibited by glutathione and associated with the induction of the oxidant 
sensing protein, haem oxygenase-I (408). This effect on IL-8 without effect on 
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eotaxin or RANTES may explain why the inflammation in COPD is 
predominantly neutrophilic. 
CSCM has been shown to stimulate production of IL-8 in human macrophages, 
and this can be inhibited by the addition of N-acetyl cysteine and this is 
mediated by AP-1 but not NF-KB (238). The role of NF-KB in CSCM mediated 
cytokine release is controversial as it has been shown that smoke can activate 
(409), inhibit the activation (410), or not affect NF-KB (411). Similarly 
contradictory results have been found with regard to AP-1 (410; 412; 413). Some 
of these differences may be explained by different methods of preparation, and 
different concentrations of CSCM being used, as there is no universally agreed 
standardisation method. 
6.2.3 Oxidants and Toll-Like Receptors (TLRs) 
The recent discovery of the TLR family has increased our understanding of the 
innate immune system, especially the way that the TLRs act as sensors for 
infection, TLRs are pattern recognition receptors (PRRs) for "pathogen 
associated molecular patterns" (PAMPs), acting as surveillance receptors for 
microbial products and oxidants (414; 415). Gram positive bacterial and fungal 
lipopeptides bind to TLR2, which forms heterodimers with either TLR1 or TLR6. 
In contrast, Gram negative Iipopolysaccharide (LPS) binds to TLR4 in 
association with CD14 (239). It has recently been shown that oxidants, possibly 
via TLR2, prime monocytes from smokers for challenge via bacteria and TLRs, 
causing enhanced inflammatory responses (242). Macrophage phenotype and 
activation are regulated by cytokines that use the Jak-STAT signalling pathway, 
TLRs and Immunoreceptor Tyrosine-based Activation Motifs (ITAMS). There is 
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cross talk between the signalling pathways, and dysregulation of this cross talk 
may contribute to the pathogenesis of chronic inflammatory diseases (416). 
6.2.4 Effects of menadione and xanthine/xanthine oxidase on biological 
systems 
Menadione (Vitamin K3) has the molecular formula 2-methyl-1,4- 
naphtoquinone. It generates superoxide through auto oxidation of one electron- 
reduced menadione or inhibition of the mitochondrial respiratory chain, which 
also generates H202. Menadione also causes superoxide generation through 
non-enzymatic interaction with thiols such as reduced glutathione; it also inhibits 
glutathione reductase and causes depletion of reduced glutathione (417). It is 
important to note that these processed occur intracellularly, the menadione 
must cross the cell membrane before it exerts it oxidant effects. The effects of 
vitamin K analogues on human neutrophil function have been evaluated (418). 
Menadione inhibits neutrophil spreading, locomotion, phagocytosis, 
degranulation of lysosomal constituents, bactericidal activity, superoxide 
generation, hydrogen peroxide production and microtubule assembly. A 
concentration of 10"5 M produced 50% inhibition of these functions. Xanthine is 
a precursor of uric acid, and is converted to uric acid by xanthine oxidase. This 
reaction leads to the formation of superoxide ions, and the addition of xanthine 
and xanthine oxidase to blood will lead to superoxide generation in the 
extracellular space and hence could be utilised as a model of oxidative stress. 
This model has previously been used to determine effect of oxygen radicals on 
receptor-dependent nitric oxide production by coronary endothelium (419). 
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6.2.5 Use of flow cytometry in the study of leukocytes 
Flow cytometry allows the physical characteristics of a single cell to be 
determined as it passes through a chamber where lasers are shone on it. The 
use of labelled anti-bodies also allows the immunological characteristics of the 
cell to be determined. In the case of whole blood it is possible to identify the 
leukocyte population using the nuclear dye LDS-751. Within the leukocyte 
population it is possible to discriminate the granulocytes 
(neutrophils/eosinophils) from other cells based on their physical (forward 
scatter and side scatter) properties. Figure 6.1 shows a dot-plot of whole blood, 
the threshold of the cytometer can then be adjusted so that the RBCs and 
platelets are removed from the analysis. 
Figure 6-1 Dot-plot of whole blood stained with LDS-751 which is brightest in the FL-3 
channel plotted against the side scatter characteristics. R1= RBCs and platelets, R2= 
granulocytes, R3= lymphocytes, R4= monocytes. 
A gate can then be placed around R2 or R4 depending if neutrophils or 
monocytes are to be studied. The use of anti-CD14 for monocytes and anti- 
CD16 for neutrophils allows these cells to be distinguished. A plot can be made 
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of CD11 b against CD16 to determine CD11 b levels on neutrophils, since low 
levels of CD16 are present on eosinophils, and these can be gated off as shown 
in fig7.2 below. The mean fluorescence intensity of the FL-1 channel where 
FITC bound to CD11 b is detected indicates the level of CD11 b expressed on 
cells. The size of cells can also be determined by analysing their forward scatter 
characteristics, while the granularity of cells influences their side scatter. 
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Figure 6-2 Dot-plot of CD16-PE in the FL-2 channel against CD11b-FITC in FL-1 channel. 
There are 2 distinct populations, the population on the right with higher levels of CD16 
are the neutrophils and those on the left are the eosinophils. A gate can be placed 
around the neutrophils and the geometric mean of the CD11b level determined. 
When performing short term stimulation assays to cause shape change, a 
measure of chemokinesis and chemotaxis, the change in shape is transient and 
very sensitive. Hence, Shannon Bryan and colleagues developed a system 
where a gentle fixation was performed immediately after stimulation, and prior 
to cell lysis and flow cytometry (420). 
An analogous situation is found for CD11b, where levels on leukocytes can 
rapidly fluctuate with venepuncture, cooling, incubation and storage. A normal 
flow cytometry cell surface marker labelling protocol has the fixation step 
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following the antibody labelling step because it is performed on unstimulated 
cells with stable levels of cell surface markers. Grant Nicholson and colleagues 
introduced a light fixation step immediately after short term stimulation, prior to 
antibody binding (see figure). Grant Nicholson and colleagues developed this 
method to permit detection of CD1 1b on the surface of leukocytes in response 
to stimulation with chemokines (421), and in this chapter this method is adapted 
to oxidant stimulation of CD11 b upregulation. 
METHOD: WHOLE BLOOD STIMULATION AND LABELLING PROTOCOL 
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Figure 6-3 Protocol for whole blood stimulation for CD11b labelling 
6.2.6 CD11 b upregulation 
CD11 b (Mac-1, aMß2) is found both in preformed cytoplasmic granules and on 
the cell surface of leukocytes, and is combined with CD18 to form one of the ß2- 
integrins. In combination with CD18, CD11 b acts as a leukocyte adhesion 
molecule by binding to intercellular adhesion molecule- (ICAM-) 1 and a 
complement receptor (CR3). The exact mechanism of rapid CD11b 
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upregulation on the cell surface remains to be clarified, but involves recruitment 
of preformed CD11 b from granules as well as membrane externalisation. It has 
been shown that G-protein activation is necessary for CD1 Ib upregulation but 
the process is not simply a by-product of granule exocytosis (422). It seems that 
avidity changes due to re-configuration at the cell surface are also important in 
activation of CD11 b (423). 
It has also been shown that intracellular calcium, tyrosine kinase and MAP 
kinase are all involved in ß2-integrin expression. Celecoxib (specific COX2 
inhibitor) leads to superoxide anion generation within neutrophils and this in turn 
causes ß2-integrin upregulation which can be inhibited by superoxide dismutase 
(424). Exogenously applied H202 and TNFa triggers CD11b activation and can 
be inhibited by tyrosine kinase inhibitors, and the activation of the tyrosine 
kinase receptors involves oxido-reduction reactions as the activation can be 
inhibited by the free radical scavengers N-acetylcysteine, glutathione, and iron 
(425). It has also been shown that TNF-induced ß2 integrin activation involves 
redox-regulated activation of p38 MAPK (426). 
CD11 b is upregulated in inflammatory states and disease. Patients with 
tuberculosis have higher expression of CD11 b than healthy controls, and 
following LPS administration to healthy volunteers there is increased leukocyte 
CD11 b upregulation (427). It has been shown that smokers with COPD have 
lower maximal shape change for neutrophils in response to IL-8 stimulation in 
comparison to healthy smokers and a CXCR2 antagonist was found to inhibit 
neutrophil CD11 b upregulation and shape change in COPD patients (421). 
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6.2.7 Aims 
Our aim was to develop a system of short term stimulation of human whole 
blood with CSCM, menadione and xanthine/xanthine oxidase. We hoped to 
identify effects of these known oxidant stimuli in terms of CD11 b upregulation 
on neutrophils and monocytes. We wondered whether CD11 b levels and 
responses may differ in COPD patients and smokers, and whether antioxidants 
and other drugs (such as corticosteroids) could inhibit CD11 b upregulation. 
Finally, it is possible that oxidants could cause effects via TLR2, and prime for 
responses through other TLRs. Oxidants could thus act on particular cell 
signalling pathways, and might cause production of cytokines such as IL-8. 
6.3 Subjects, Materials and Methods 
All subjects gave full informed consent for a blood sample and ethical approval 
was obtained from the independent Ethics Committee of the Royal Brompton, 
Harefield and NHLI Ethics Committee. 
Healthy volunteers were non-smoking adults, who had not smoked in the past, 
and without any significant infective/inflammatory/autoimmune/metabolic/ 
neoplastic disease in their past or current medical history. 
Subjects with COPD were all former heavy cigarette smokers and defined 
according to GOLD guidelines (2005) and classified for severity according to 
post-bronchodilator FEV1, 
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Table 6-1 : Demographics of subjects used to study CSCM upregulation of neutrophil 
CD11 b 
COPD 
n=8 
Healthy smokers 
n=8 
Age (mean, range) 64 (48-75) 55 (42-71) 
Gender (% Female) 50 37.5 
Ethnicity All Caucasian All Caucasian 
Smoking history: pack years (mean, 
range) 
43.5 (17.5-67) 35.91 (16.8- 
82.5) 
Current smoking: number of 
cigarettes/day (mean, range) 
17.75 (12-20) 19.94 (7.5-35) 
FER pre bronchodilator (mean, range) 49.13 (27-63) 77.50 (73-84) 
FEV1: % (mean, range) 58.5 (26-78) 99 (94-105) 
6.3.1 Preparation of CSCM and oxidant stimuli 
CSCM was made by bubbling the smoke of 6 cigarettes through PBS using the 
apparatus shown in figure 6-4, which was installed in an operating fume 
cupboard. After the CSCM was made and filtered through a 0.2pM filter it was 
diluted with PBS on the basis of optical density measured on a 
spectrophotometer at a fixed wavelength of 320nM (428; 429). An optical density 
of 0.15 was taken to represent a CSCM concentration of 1 Arbitrary Unit (AU) 
based on previously published work (398). Due to corrosive effects of cigarette 
smoke constituents on the equipment, I used fresh equipment to prepare each 
batch of CSCM. Fresh CSCM was prepared on the day of each experiment, 
stored on ice, and employed within 30 minutes. 
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Figure 6-4 Apparatus used to prepare cigarette smoke conditioned medium 
The following reagents were used. Menadione (Sigma-Aldrich, MO cat 67900), 
xanthine (Sigma, St Louis, MO cat X0626) and xanthine oxidase (Sigma, St 
Louis, MI cat X-2252). 
Menadione was initially solubilised in DMSO to make a 0.1 M solution and then 
serially diluted in RPMI or PBS. Xanthine was initially solubilised in NaOH to 
make a 0.25M solution and then serially diluted in PBS. Microbial xanthine 
oxidase was diluted in PBS. These solutions were stored at -20°C for a 
maximum of 6 weeks and serially diluted immediately prior to use. 
6.3.2 Preparation of anti-oxidants 
Reduced glutathione (Sigma-Aldrich, St Louis, MO, Cat G4251) was dissolved 
in PBS to give the required concentrations. N-acetylcysteine (-Aldrich, St Louis, 
MO, Cat A7250) was dissolved in modified RPMI with HEPES buffer to maintain 
a neutral pH. Fresh solutions were made immediately prior to use. 
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6.3.3 Venepuncture technique to obtain blood samples 
Blood was gently taken by hand using a syringe and a 21G "butterfly" needle 
into sterile EDTA. Vacutainers were not used since the rapid withdrawal of 
blood causes CD11b upregulation. Blood was incubated at 37 C for up to 10 
min before use. Cooling and agitation were observed to cause CD11 b 
upregulation. 
6.3.4 Washing of blood 
In the experiments using washed cells 3mls whole blood anti-coagulated with 
EDTA was made up to 12 mis using phosphate buffered saline (PBS) at 37°C 
and spun at 400g for 10 minutes. The supernatant was removed taking care not 
to disrupt the buffy coat; the cell suspension was then restored to 3mls using 
PBS. The washed blood was then left to rest for 60 minutes in a water bath at 
37°C. A paired sample of whole blood was also placed in the water bath for 60 
minutes to act as a control. 
6.3.5 Stimulation of blood 
Stimulation was carried out in sterile polypropylene tubes in a water bath at 
37°C, for incubations longer than 30 minutes capped tubes were used to 
prevent excess evaporation. 100pL of blood was added to 100pL of stimulus. 
The tubes were gently rotated every 10 minutes throughout the stimulation. 
6.3.6 Fixation of cells and antibody binding 
At the end of the stimulation phase the tubes were placed on ice and 
immediately fixed with a 0.25% formaldehyde solution. (CeIIFIXTM, Becton 
Dickinson). A fresh dilute formaldehyde solution was made weekly by adding 
l ml CeDIFIXTM to 9mis water and 30mIs FACSflow (Becton Dickinson). 250pL of 
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dilute CeIIFIXTM was added to each stimulation tube and left in ice for one 
minute. 50pL of fixed cells were added to an Eppendorf tube containing 10pL of 
mouse anti-human CD11 b labelled with FITC (Beckman Coulter, High 
Wycombe, Cat IM0530) and 5pL of mouse anti-human CD16 labelled with PE 
for neutrophil discrimination from eosinophils (Dako, Ely, Cat R7012) or mouse 
anti-human CD14 labelled with PE for monocyte analysis (Dako, Ely, Cat 
R0864). Both antibodies were added at the same time to prevent the binding of 
one antibody affecting the binding of a subsequent antibody. An isotypic mouse 
IgGI labelled with FITC was used to determine non specific binding. After 20 
minutes on ice the samples were placed into 500pL of ice cold PBS in a 
polystyrene tube. 10NL of a 0.02% LDS-751 a far red fluorescent DNA dye 
(Cambridge Bioscience Cat No. L-7595) was added to each tube and gently 
agitated and placed on ice for a further 20 minutes. All samples were read on 
the flow cytometer within 1 hour. 
6.3.7 Lysis for GAFS analysis 
After 50pl of blood had been removed for assessment of CD11 b levels by 
incubation with antibody, the remaining fixed sample was added to 1.75ml of 
155mM ammonium chloride lysis buffer and agitated gently by hand and left on 
ice for 20 minutes. The lysed blood sample becomes visibly darker due to 
released haemoglobin, and was then used for flow cytometry. Samples must be 
analysed within 1 hour. 
6.3.8 Flow cytometry 
Flow cytometry was performed on a FACS Calibur machine (BD Biosciences, 
Cowley, Oxford). Samples were run on medium flow rate until 1000 neutrophils 
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were counted. Data was collected and analysed using Cell Quest v. 1.2.2. (BD 
Biosciences, Cowley, Oxford). 
For CD11 b measurement gating off the red cells and platelets using the LDS- 
751 reading in the FL-3 channel identified the leukocyte population. Neutrophils 
were identified within the granulocyte cloud based on their forward and side 
scatter characteristics and CD16 binding, while eosinophils have are CD16 
negative. Monocytes are CD14 positive. The required cell population was gated 
using the Cell Quest software and the geometric mean of fluorescence intensity 
of FITC bound to CD11 b recorded. 
For shape change analysis the neutrophils and eosinophils were distinguished 
on the basis of autofluorescence characteristics, since eosinophils have 
autofluorescent granule proteins. The geometric mean of forward scatter was 
calculated for the required cell population. 
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6.4 Results 
6.4.1 Effect of cigarette smoke conditioned medium on levels of 
neutrophil CD11 b 
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Figure 6-5 Whole blood was incubated with varying concentrations of cigarette smoke 
conditioned medium standardised by optical density for a period of 5-30 minutes. CD11 b 
was measured on neutrophils. n=4 Mean ± SEM 
When whole blood is incubated with CSCM there is a dose dependent increase 
in CD1 1b upregulation on neutrophils. The levels of CD1 1b are highest at a 
CSCM concentration of 2 AU, and stimulation for between 10 and 30 min gave 
equivalent effects. It was therefore decided to measure CD11 b upregulation 
(neutrophils, monocytes, eosinophils) and shape change (neutrophils and 
eosinophils) at 10 and 20 minutes employing CSCM at a concentration of 2 AU. 
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6.4.2 Effect of cigarette conditioned smoke medium (CSCM) stimulation 
on neutrophils, eosinophils and monocytes 
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Figure 6-6 Whole blood was incubated with CSCM at a concentration of 2AU for 10 or 20 
minutes and CD11b measured on neutrophils, eosinophils and monocytes. Shape 
change of neutrophils and eosinophils was measured. n=6 Mean ± SEM Baseline and 
2AU were compared using a paired t-test. 
When whole blood was incubated with CSCM at a concentration of 2 AU for 10 
minutes there was an increase in CD11 b expression in all leukocyte subtypes, 
with an approximate doubling of levels on neutrophils. This represented an 
increase from d mean of 20.22 to 39.16; however this did not reach statistical 
significance. (p=0.08). There was an increase in CD11 b on eosinophils from a 
mean of 36.23 to 42.91 (p=0.07), and on monocytes there was a statistically 
significant increase from 24.47 to 33.98 (p=0.04). As a comparator 100pM 
GROa was used a positive control. This caused an increase in CD11b on 
neutrophils from a mean of 21.81 to 77.04, n=6. Therefore at 10 minutes CSCM 
is not as potent a stimulus as a chemokine. 
2 
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CSCM at a concentration of 2 AU caused a significant increase in CD11b 
upregulation on neutrophils, eosinophils and monocytes after incubation with 
whole blood for 20 minutes. This represented a mean increase from 17.49 to 
40.25 on neutrophils (56%, p=0.026), a mean increase from 34.23 to 41.09 on 
eosinophils (17%, p=0.007), and an increase from 27.70 to 38.99 on 
monocytes. (29%, p=0.02). Therefore a stimulation time of 20 minutes was 
used in future experiments. The greatest increase occurs in neutrophils, and 
also neutrophils are more abundant in blood and hence are easier to measure 
using flow cytometry. For these reasons the model was developed further only 
studying neutrophils. 
Shape change (Gated autofluorescence, GAFS): When whole blood was 
incubated with CSCM at a concentration of 2 AU for 10 minutes there was a 
non-statistically significant change in shape of neutrophils and eosinophils, 
representing an increase from 257.8 to 298.6 (p=0.14) in neutrophils and from 
232.6 to 251.7 (p=0.10) in eosinophils. After 10 minutes incubation with a 
CSCM concentration of 5 AU and 10 AU it was noted that the cloud positions 
had shifted in a disorganised manner reflective of toxic swelling and damage, 
and neutrophils were showing increased autofluorescence. When whole blood 
was incubated with CSCM at a concentration of 2 AU for 20 minutes there was 
a non-statistically significant change in shape of neutrophils and eosinophils, 
representing an increase from 247.5 to 266.1 (p=0.09) in neutrophils and from 
224.4 to 226.3 (p=0.85) in eosinophils. It was noted that the shape change was 
not in terms of a discrete increase in forward scatter as would be seen with a 
chemokine such as CXCL8, and this was taken to infer that CSCM has little 
chemotactic activity. 
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Figure 6-7 Effect of bench decay on effect of CSCM on neutrophil CD11b upregulation 
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Figure 6-8 CSCM was made and standardised to give a concentration of 2AU. Blood was 
taken from 2 subjects and incubated with CSCM for 20 minutes and neutrophil CD11b 
upregulation was measured to give a baseline measure of activity. The CSCM was then 
left at room temperature for 24 hours and the experiment repeated. 
It was found that there is reduced activity of CSCM on neutrophil CD11b upregulation 
after CSCM has been left at room temperature for 24 hours. In subject 1 this was a 
change from 155% increase to 82% increase at 24 hours, while in subject 2 this was a 
change from 63% at baseline to -2% at 24 hours. 
Page 196 of 293 
02020202 
CSCM (AU) 
6.4.3 Effect of glutathione and N-acetyl cysteine (NAC) on neutrophil 
CD11 b response to stimulation with cigarette smoke conditioned medium 
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Figure 6-9 Neutrophil CD11 b expression was measured in whole blood after incubation 
with varying concentrations of CSCM for 20 minutes in the presence of 10mM 
Glutathione. The glutathione was added at the same time as the CSCM. n=6 Mean ± SEM. 
The effect of glutathione at 2AU was compared using a paired t-test. 
At 2AU there was no significant difference between the 2 groups, p=0.56. Glutathione is 
an anti-oxidant, and addition to whole blood does not reduce the stimulation of 
neutrophils by CSCM. It was not possible to use higher concentrations of glutathione as 
more concentrated solutions of glutathione caused upregulation of CD11b at baseline. 
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Figure 6-1o Neutrophil CD11b expression was measured in whole blood after incubation 
with varying concentrations of CSCM in the presence of 5mM n-acetylcysteine. The n- 
acetylcysteine was incubated with the CSCM for 60 minutes prior to the addition of whole 
blood. The blood was stimulated for 20 minutes. n=4 Mean ± SEM 
N-acetylcysteine is an anti-oxidant, and after incubation for 1 hour with CSCM 
the stimulating effect of CSCM is not reduced. Higher concentrations of n- 
acetylcysteine could not be used as more concentrated solutions caused 
CD11 b upregulation at baseline. 
To demonstrate that the effect of CSCM is in some part due to an oxidant effect, 
incubation of CSCM was performed with superoxide dismutase and catalase to 
attempt to degrade active oxidants. However when this was attempted it was 
found that the preparations of superoxide dismutase and catalase caused 
CD11b upregulation on their own, possible due to preservatives in the 
commercially available preparations. 
This is one potential limitation of this CD1 1b upregulation assay for the 
development of new drugs. It is extremely sensitive and it is possible that the 
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drugs under test may cause CD11 b upregulation by themselves unless they ý3re 
available in a pure form and are soluble in a physiological solution such as PBS. 
6.4.4 Effect of removal of plasma on neutrophil CD11b response to 
stimulation with cigarette smoke conditioned medium. 
- Whole blood 
""r" Washed blood 
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Figure 6-6-11 Whole blood was mixed with PBS and spun at 400g to remove the plasma. 
The cells were re-suspended in PBS and left to rest for 60 minutes. This was then 
stimulated with CSCM for 20 minutes. A matched whole blood sample was stimulated 
simultaneously. CD11b expression on neutrophils was measured. n=6 Mean ± SEM. The 
groups were compared at 2AU using a paired t-test. 
At a CSCM concentration of 2AU there was no significant difference between the 2 
groups, p=0.53. Removal of plasma from whole blood does not affect the response to 
stimulation with CSCM. 
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6.4.5 Comparison of CD11 b upregulation in response to stimulation with 
CSCM in healthy smokers and smokers with COPD 
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Figure 6-12 Whole blood from healthy smokers and smokers with COPD was stimulated 
with CSCM for 20 minutes and neutrophil CD11b expression measured. n=8 MEAN ± SEM 
Baseline and 2AU were compared using a paired t-test. 
Both healthy smokers and smokers with COPD show a dose-related increase in response 
to stimulation with CSCM. Both groups have comparable baselines and do not differ in 
their neutrophil CD11b responses to stimulation with CSCM at 2AU (p=0.64). 
6.4.6 Effect of menadione on CD11 b upregulation on neutrophils 
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Figure 6-13 was stimulated with mpnadinno fnr times ranninn frnm 3 0 to 240 
minutes and CD11b measured on neutrophils. 90 minutes stimulation resulted in an 
increase from baseline of 9.41 to 22.68. 
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Figure 6-14 Whole blood was stimulated with menadione for 90 minutes and CD11b 
measured on neutrophils. n=6 Mean ± SEM. The maximum response was seen at a 
concentration of 15NM showing an increase from baseline MFI of 12.66 to 33.05. 
6.4.7 Effect of removal of plasma on neutrophil CD11 b response to 
stimulation with menadione 
Figure 6-15 Whole blood was mixed with PBS and spun at 400g to remove the plasma. 
The cells were re-suspended in PBS. This was then stimulated with 100NM menadione for 
90 minutes. A matched whole blood sample was stimulated simultaneously. CD11b 
expression on neutrophils was measured. n=6 Mean ± SEM. The groups were compared 
using a paired t-test. 
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There was no significant difference between whole and washed blood In the response to 
neutrophil CD1Ib upregulation in response to 100pM menadione, p=0.053. 
6.4.8 Effect of glutathione on neutrophil CD11 b response to stimulation 
with menadione. 
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Figure 6-16 Whole blood was stimulated with 100pM menadione for 90 minutes In the 
presence and absence of 10mM glutathione. n=6 Mean ±SEM. The groups were compared 
using a paired t-test. 
There was a significant reduction in neutrophil CD11b upregulation In response to 
stimulation with menadione in the presence of glutathione, p=0.0015. 
6.4.9 Effect of xanthine/ xanthine oxidase (X/XO) on neutrophil CD11 b 
upregulation 
Xanthine/xanthine oxidase causes the extracellular generation of free radicals 
such as superoxide. When employing whole blood with xanthine/xanthine 
oxidase (X/XO) I could not cause CD11 b upregulation 
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6.4.10 Effect of removal of plasma on neutrophil CD11b response to 
stimulation with xanthine/ xanthine oxidase 
35 
30 
25 
- 20 U- 
15 
10 
5 
0 
II Baseline 
0500pM xanthine 
Figure 6-17 Whole blood was mixed with PBS and spun at 400g to remove the plasma. 
The cells were re-suspended in PBS. This was then stimulated with 500NM xanthinel 
xanthine oxidase for 90 minutes. A matched whole blood sample was stimulated 
simultaneously. CD11 b expression on neutrophils was measured. n=6 Mean ± SEM. The 
groups were compared using a paired t-test. 
There was a significant difference between whole and washed blood, p=0.006. There was 
no response to stimulation of whole blood with xanthine/ xanthine oxidase. 
Preliminary experiments were done on a limited number of individuals to establish 
stimulation time (data not shown) There was only a very small increase at 30 and 60 
minutes, however at 90 minutes the increase was much greater. 
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Figure 6-18 Washed blood was stimulated with xanthine/ xanthine oxidase for 90 minutes 
and CD11b measured on neutrophils. n=5 Mean ± SEM. 
The maximum increase was seen at 500pM xanthine/ xanthine oxidase showing an 
increase from a baseline MFI of 18.22 to 36.22. 
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6.4.11 Effect of glutathione on neutrophil CD11 b response to stimulation 
with xanthine/ xanthine oxidase. 
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Figure 6-19 Whole blood was stimulated with 500pM xanthinel xanthine oxidase for 90 
minutes in the presence and absence of 10mM glutathione. n=6 Mean ±SEM. The 2 
groups were compared using a paired t-test. 
There was a significant reduction in neutrophil CD11b upregulation in response to 
stimulation with xanthine/ xanthine oxidase in the presence of glutathione, p=0.02. 
6.5 Discussion 
CSCM causes a dose dependent increase in CD11 b upregulation on human 
neutrophils which is maximal at 20 minutes stimulation. CSCM has its greatest 
effects on neutrophils, with much lesser effects on monocytes and eosinophils. 
The fact that CSCM does not have effects on neutrophil shape change at 
concentrations that cause large increases in CD11 b upregulation may be 
because CSCM does not contain any chemotactic components, and this is itself 
interesting. The shape change that was seen with higher concentrations of 
CSCM may have been due to toxic apoptotic effects on the neutrophils as it was 
also associated with an increased auto-fluorescence of the cells. Indeed, 
apoptosis is a well known effect of oxidants at high doses (430). 
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The fact that glutathione and n-acetyl-cysteine do not have an effect on the 
whole blood model suggests that oxidant effect may not be the prominent effect 
of CSCM, or that the oxidant effect of CSCM is so great that it cannot be 
overcome by the concentrations of glutathione and n-acetyl cysteine used. 
Since CSCM had less activity in stimulating CD11 b upregulation after bench 
decay, this suggests that the CSCM contains labile stimuli. The whole blood 
model required CSCM to be present at 10 times the concentration used in cell 
culture work (428). This may be due to the complex nature of whole blood with 
its proteins and oxidant buffering capacity. 
CSCM caused CD11 b upregulation, but I could not inhibit this activity with anti- 
oxidants, so I could not be sure that the CSCM is acting by specific oxidant 
mechanisms. Hence I turned to stimulation with menadione, which causes 
intracellular generation of ROS. Menadione caused a dose dependent increase 
in neutrophil CD11b upregulation, this was a greater increase in CD11 b 
upregulation in comparison to stimulation with CSCM (3 fold versus 2 fold); and 
a longer time (90 min) was required to achieve CD11 b upregulation. There are 
two possible explanations for this; menadione acts intracellularly and has to 
diffuse across the cell membrane before oxygen radical generation begins 
whereas CSCM may contain pre-formed mediators of oxidative stress. The 
removal of plasma does not greatly increase the effects of menadione on 
CD11 b upregulation, this is most likely to be explained by the fact that oxygen 
radical generation is intracellular, and hence the plasma is not able to remove 
any of these stimulants before they have an effect on the cells. These results 
are not consistent with the results obtained by Gatlin et al. (418), who found 
inhibition of neutrophil functions with similar concentration ranges of 
menadione. However, they were working with purified neutrophils in longer term 
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stimulation systems and this may have affected the way in which the cells 
responded to the menadione. 
The xanthine/ xanthine oxidase system generates extracellular ROS and 
causes a dose dependent increase in CD11 b expression on human neutrophils. 
For this effect to be seen plasma must be removed from the whole blood, this 
may be due to the presence of anti-oxidants in plasma that buffer the oxidants 
as soon as they are generated. Whilst having to remove plasma reduces the 
simplicity of a whole blood model it is still less inconvenient than having to 
isolate neutrophils by methods such as Percoll gradients. 
I have developed menadione and xanthine/xanthine oxidase systems for 
stimulation of human blood. These methods could be used to screen new anti- 
oxidant therapies by adding therapies to the stimulation system. The 
observation that 10mM glutathione is able to inhibit the effect of menadione and 
xanthine/ xanthine oxidase suggests that these stimuli are acting via a 
mechanism of oxidant stress. The reason that glutathione at the same 
concentration does not inhibit the effects of CSCM in generating CD11 b 
upregulation may be because the CSCM is a mixture of toxic substances 
including oxidants, and that oxidants may not be causing the CD11 b 
upregulation. However, the demonstration that CSCM loses activity on bench 
storage suggests that oxidants may still be involved. 
Another system that has been used in cell culture work to generate oxidant 
stress is hydrogen peroxide. When hydrogen peroxide is added to blood the 
presence of large amounts of serum catalase leads to the rapid generation of 
oxygen and water and this in turn leads to effervescence of the blood. This 
means that this is not a suitable stimulus for our assay of whole blood CD11 b 
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upregulation as the physical stimulation of the cells by the effervescence leads 
to CD1 Ib upregulation. Even when washed blood is used the effervescence 
persists due to the presence of intracellular catalase. 
6.6 Conclusions 
CSCM stimulation of whole blood causes a dose dependent increase in 
neutrophil CD11b upregulation. CSCM has little chemotactic effect on neutrophil 
shape change at concentrations that cause CD11 b upregulation, and seems to 
cause toxic damage. 
CSCM causes its greatest effect on neutrophils, with lesser effects on 
monocytes and eosinophils. The effects of CSCM could not be reversed by anti- 
oxidants (N-acetyl cysteine and glutathione). However, CSCM is less effective 
as a stimulant after overnight storage at room temperature, suggesting that the 
stimulating agent is labile and subject to decay. This would be consistent with 
an oxidant causing some of the effects on CD11 b upregulation. 
Menadione stimulation of whole blood causes a dose dependent increase in 
neutrophil CD11b upregulation that can be reversed by the addition of 10mM 
glutathione. 
Xanthine/ xanthine oxidase stimulation of washed blood causes a dose 
dependent increase in neutrophil CD11 b upregulation that can be reversed by 
the addition of 10mM glutathione. 
Further work could demonstrate whether oxidants generated by xanthine / 
xanthine oxidase act on TLR2, and might prime cells for CD11 b upregulation 
and IL-8 production when stimulating with PAMPs for TLR4 (LPS), TLR2/1, 
TLR2/6 (242). In addition intracellular signalling events could be studied after 
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menadione and X/XO, as well as the anti-inflammatory Nrf2 pathway. To 
establish the whole blood stimulation methods in the context of assessing 
drugs, we could study the effects of corticosteroids and new potent anti-oxidant 
agents (such as thiol anti-oxidants and Nrf2 agonists) on menadione and X/XO 
stimulation of CD11 b upregulation. The system could also be used to define 
human whole blood reactions to oxidants. 
6.7 Future study 
The following diagram shows the signalling pathways that are activated during 
stimulation of extracellular receptors and that lead to the production of 
inflammatory mediators. It can be seen that there is a complex interaction with 
cross-talk of the signalling pathways. The TLR2 receptor is stimulated by 
oxidants and hence forms the basis of further study of the inflammation 
generated as a result of oxidant stress. 
Immune Oxidants 
complexes INFaIBIy 
LIPS 
Mill 
PTK AP-1 
Ca NF-K(3 
STAT 
PRO-INFLAMMATORY GENES 
Figure 6-20 Signal transduction pathways during cellular activation. Based on (416) (242) 
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6.7.1 TLR2 involvement 
We speculate that extracellular oxidants (CSCM and X/XO) may cause 
neutrophil activation via TLR2 (Toll-like receptor, TLR-2), as has been recently 
claimed by other workers when studying a CSCM stimulation system with 
human blood (242). TLR2 is a cell surface "pattern recognition receptor" (PRR) 
for "pathogen-associated molecular patterns" (PAMPs), that may recognise 
oxidants. One could use specific MoAbs against TLR2 to see if one can block 
the effects of extracellular oxidants on CD11 b upregulation. These effects could 
be compared in neutrophils and monocytes, and we need to compare 
menadione and X/XO stimulation in neutrophils and monocytes. Flow cytometry 
can also be used to detect levels TLRs on the cell surface in response to 
stimulation. (431) 
6.7.2 Priming by extracellular oxidants: TLR4 agonists 
We speculate whether X/XO may cause priming for immune surveillance to 
Gram negative and Gram positive bacteria, as has been recently demonstrated 
with CSCM and human blood cells (242). Further work could assess if oxidants 
generated by X/XO might prime cells for CD11 b upregulation and IL-8 
production when stimulating with PAMPs (agonists) for TLR4 (LPS), TLR2/1 
(Pam3CSK4), and TLR2/6 (FSL-1) (242). This would involve studying CD11 b 
upregulation in the presence of these separate agonists, and then looking for 
priming effects of extracellular oxidants. Oxidant stress activates p38 MAP 
kinase in an Src-dependent manner and oxidants alter the response to LPS 
induced activation p38 MAP kinase in macrophages (234). Cigarette smoke 
induced IL-8 production by monocytes can be blocked by a TLR-4 inhibitor and 
an inhibitor of NF-KB (241). 
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6.7.3 Cell signalling 
It would be interesting to study rapidly activated intracellular signalling after 
stimulation with CSCM, menadione and X/XO. There is generally considerable 
cross-talk involved in activation by oxidants via TLR2. TLR2 activation may 
initially involve IRAK, and then MAPk/AP-1, NF-KB and IRF (IFN regulatory 
factors) Reactive oxygen species (ROS) may also deplete intracellular 
glutathione, and initiate the anti-inflammatory Nrf2 pathway. Nrf2 activation acts 
on ARE (antioxidant response element), and Nrf2 agonists have the potential to 
counteract the effects of oxidants (Kensler TW et al. 2006). 
6.7.4 Development of a preclinical screening system for new drugs 
To establish the whole blood stimulation methods in the context of assessing 
drugs, we could study the effects of corticosteroids and new potent anti-oxidant 
agents (such as thiol anti-oxidants and Nrf2 agonists) on menadione and X/XO 
stimulation of CD11 b upregulation. It would also be interesting to see the effects 
of inhibitors of intracellular signalling on CD11 b upregulation, eg. MAP kinase 
inhibitors and IKK2 inhibitors. Finally we could develop automated additional 
readouts: mRNA for induction of proteins (e. g. IL-8), measurement of 
generation of IL-8 into supernatant after some hours of stimulation. These in 
vitro systems could also be employed ex vivo in subjects after taking novel anti- 
oxidant drugs. 
6.7.5 Assessment of primed status in patients 
We could develop human whole blood systems for monitoring 
inflammation/oxidant status in patients. These could measure CD11 b basal 
levels, and then perform dose responses for stimulation with X/XO and 
menadione in terms of CD11 b, additionally looking at maximal CD11 b levels. It 
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would be interesting to study this system in subjects after smoking, and in 
situations such as COPD smokers compared with healthy smokers. 
7 Discussion and Conclusions 
7.1 Discussion 
The nasal allergen challenge model has great potential as an in vivo model of 
allergic inflammation; since it involves mast cell degranulation, and recruitment 
of Th2 cells and eosinophils. Studies presented in this thesis show it to be safe 
and well tolerated by subjects. By defining those mRNA species and proteins, 
as well as inflammatory mediators and transcription factors, it allows us to 
define targets for asthma and allergy therapy. It also allows the collection of 
multiple samples following a single challenge to demonstrate the 
pharmacodynamics of a drug. The model is also well suited to cross-over 
design trials allowing the effects of a novel therapeutic agent to be studied as a 
dose response and compared to placebo. 
A variety of samples can be collected from the nose. Nasal lavage samples can 
be collected to determine eosinophil levels, and nasal secretions can be 
collected by a SAM to allow for cytokine and chemokine analysis. A small 
scrape of the nasal epithelial mucosa can also be collected to allow for mRNA 
and genomic studies, 
Studies presented in this thesis show very disappointing results for filter paper 
eluates using the Whatman's 42 filter paper, despite this being the paper used 
in the original description of the method (258), and also on the CSU by Erin and 
colleagues (50; 100; 101) Analysis of data for the single allergen challenge 
repeatability and dose response failed to show increased levels of IL-4, IL-5 and 
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11-13, and the expected late response was not found. Because of a delay in 
availability of the correctly processed data for this study, we had already 
embarked on 2 further studies with the same deficient method: the repeat dose 
NAC and the nasal cigarette smoke challenge which were conducted in parallel. 
The lack of response in the subsequent two trials lead to a review of the data for 
all 3 studies: this showed that single dose NAC did not cause a consistent late 
phase response for IL-4, IL-5 and IL-13. 
Faced with these negative results, I was involved in a detailed review of the 
NAC methodology, and helped make a series of recommendations on how the 
NAC could be modified to be able to detect levels of IL-4, IL-5 and IL-13 in the 
late phase. I contributed to the design of a NAC study that was carried out in the 
first quarter of 2007, but did not carry out the clinical or laboratory work. This 
study employed novel synthetic absorptive media (SAM) instead of Whatman's 
filter paper No. 42. SAM is a synthetic fibrous hydroxylated polyester which has 
been specifically developed to have low protein binding, whereas Whatman's 
filter paper is derived from cotton plant and is subject to an acid wash during its 
manufacture and is not subject to quality control with regards to its protein 
binding activity. In addition, a higher dose of Phleum pratense allergen was 
employed. This study was very successful and IL-4, IL-5 and IL-13 levels were 
consistently over 100pg/ml in the majority of individuals in the late phase: these 
high levels have never previously been reported, nor found in our laboratory. 
Hence, we think that we have potentially solved the technical problems I 
encountered in my thesis. 
However, on a positive note, data presented in this thesis suggests that a 
repeat dose model of NAC causes increased levels of cytokines in nasal lavage 
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samples with repeated allergen, and hence repeat NAC may be useful for 
testing certain new drugs, and higher initial levels of cytokines increases the 
power to detect changes from a novel therapeutic agent. Repeat NAC is 
especially useful when looking at a potentially immuno modulatory agent, that 
may operate on altering T cell differentiation in the presence of allergenic 
stimulation. 
New anti-inflammatory therapies are also needed in the treatment of COPD, 
and a non-invasive model would be useful to assess new drugs early in clinical 
development, although this might need to relate to oxidants, neutrophils and 
macrophages, as opposed to mast cells, Th2 cells and eosinophils. Patients 
with COPD are generally over 40 years of age and have other co-morbidities as 
a result of their smoking and hence a model that removes the need for them to 
have invasive procedures such as bronchoscopy is desirable. The nasal 
cigarette smoke challenge shows potential as a model although a number of 
modifications to enhance its usefulness are required. In particular we need to 
assess this method with the new SAM, rather than Whatman's No 42 filter 
paper. 
It has previously been shown that correcting for the weight of secretions 
obtained using the filter paper method does not effect the results in terms of 
levels of cytokines measured (95). On review of the filter paper weights 
obtained during the studies presented in this thesis it has been shown that there 
is an increase in weight of secretions during the early phase (5 min to 30min) 
following allergen challenge, compared to prechallenge nasal secretion weights. 
However the weights obtained during the late phase following allergen 
challenge (2 to 8h post challenge) are not significantly different from those 
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obtained prior to challenge, and remain remarkably constant with a weight of 
34.36 (19.82-48.91) pg (mean, 95% confidence interval) . Hence correcting for 
weight does not change the overall level of cytokine when studying the late 
phase response. The aim of the studies presented here was to develop a model 
of allergen challenge to measure the Th2 cytokines IL-4, -5 and -13 during the 
late phase, and such a model does not require correction for weight of 
secretions. In the cigarette smoke nasal study the weight of secretions obtained 
did not vary significantly across the whole study period with a weight of 39.89 
(27.05-52.73) pg (mean, 95% confidence interval) and hence correcting for 
weight of secretions does not affect the overall comparison of cytokine levels. 
Whole blood stimulation in vitro is an ideal technique for initial screening of 
some anti-inflammatory compounds. It does not require subjects to be exposed 
to new drugs, yet human cells are stimulated which has distinct advantages 
over the use of animal models especially when studying the immune system 
which may have important differences between the species. In addition subjects 
could take a novel therapeutic agent and then their blood taken at intervals and 
stimulated ex vivo. Blood sampling allows for the pharmacokinetics of a drug to 
be determined but importantly this stimulation of whole blood model could allow 
for the associated pharmacodynamics of the drug to be determined. 
Development of this model to use allergen, LPS or other stimulators of TLRs will 
increase the scope of usefulness of this model. The model presented in this 
thesis would allow for the screening of new anti-oxidant compounds for the 
treatment of COPD. A drawback with this methodology is that many drugs do 
not act on blood cells, and effects on blood may differ compared to tissue 
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6 
effects. Nevertheless, for drugs such as chemokine receptor antagonists, this 
methodology holds great promise. 
Non-invasive biomarkers that are currently in use for the assessment of 
respiratory disease have a series of technical drawbacks. Exhaled breath 
condensate has the problem of contamination, there is a high chance that 
samples become contaminated by saliva and the presence of cells from the 
buccal mucosa and even airborne keratin flakes makes genomic analysis 
difficult to interpret (432). Sputum is often studied as it is relatively easy to 
obtain and can reflect inflammatory changes in the lower airways. However the 
only real proven clinical usefulness of sputum is the determination of eosinophil 
counts in asthma. The difficulties with determining the significance of finding 
increased levels of inflammatory mediators in sputum is that it is not possible to 
determine how long the sample has been sitting in the bronchial tree and hence 
its relationship to the timing of a challenge. It is also often contaminated by 
bacteria which may effects levels of proteins, and also it is possible that 
inflammatory cells may have undergone lysis and released their intracellular 
stores of chemokines and cytokines. In addition the release of a fluid phase for 
determination of cytokine and chemokine levels has numerous technical 
difficulties. The use of ultrasonication may cause cell lysis and cause falsely 
elevated protein levels, and treatment with the reducing agent dithiothreitol 
(DTT) may lead to a reduction in the levels of proteins measured (433). The 
SAM described in this thesis to obtain nasal secretions could be utilised down 
the sampling channel of a bronchoscope to obtain epithelial lining fluid, this 
would remove all the problems associated with sputum analysis and would 
allow for correlations between changes in the upper and lower airways. 
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Any new biomarkers that are developed must be extensively validated and their 
repeatability and usefulness in clinical practice determined. A relationship 
between the biomarker and the disease state must be established and levels of 
the biomarker must correlate with disease severity and/or progression. A 
reduction of biomarker levels due to a novel therapeutic agent must be shown 
to translate to reduction in disease severity. Examples where biomarkers have 
been useful include glucose levels in diabetes, cholesterol levels in 
cardiovascular disease, and viral load in HIV infection. The use of a challenge 
situation to increase the level of a biomarker must reproduce the changes that 
occur in the disease state. The advantage of a challenge model is that it allows 
for the collection of serial samples for biomarker analysis following challenge 
which permits assessment of pharmacodynamic properties. 
Biomarkers can be used during early phase studies as a guide to dose selection 
and escalation, and can also be used to rapidly screen new drugs to eliminate 
drugs before they progress to costly and complex large clinical trials. This 
model of drug development does have limitations in that biomarkers do not 
identify potential side-effects and may cause misleading results. An example of 
this is that the drug milrinone appeared to cause haemodynamic changes that 
would be beneficial in heart failure; however in a longer term clinical trial it 
increased mortality patients with heart failure (434). 
Once a biomarker has been validated for a particular disease it could be used in 
the diagnosis and monitoring of the disease. It could also be used to guide the 
choice of therapeutic agent and also to monitor the response to any new 
therapies. 
Page 216 of 293 
The future of determining pathogenesis of disease and hence drug 
development lies in the exploration of the genetics of disease in relation top 
environmental and infectious influences. Rapid analysis of gene expression 
(mRNA) is now possible with such techniques as Affymetrix. These mRNA 
microarrays allow screening of thousands of genes for differences in expression 
or differences in how genes are connected in molecular networks (435). It is 
possible to study genes (SNPs) and gene expression in normal and disease- 
associated tissue, and it has been proposed that it would have clinical value in 
the characterisation of interstitial lung disease (436). The use of gene 
expression profiling in asthma has also been studied. It has been shown that 
airway epithelial cells in asthma have a distinct activation profile and changes 
within the gene expression can identify differences in clinical responsiveness to 
treatment with corticosteroids (437). This an extremely important advance as it 
show the value of pharmacogenetics whereby therapies are chosen based on a 
individual patients genetic profile to ensure that only the most effective 
treatments are given. An example of this that is already in widespread clinical 
use in the use of trastuzumab in patients whose tumour cells show evidence of 
HER2 protein expression(438). 
Knowledge of the mechanisms of disease can also help to identify gene target. 
A study of normal and asthmatic bronchial biopsies has shown that IL-4 and IL- 
13 regulate the squamous cell carcinoma antigens (SCCA) and that serum 
levels of SCCA were raised in the serum of asthmatic suggesting that SCCA 
may be an important biomarker in asthma (439). DNA microarray can also 
examine the expression of genes that occur over time following a challenge. 
Bronchial epithelial cells show three distinct phases of gene expression 
following challenge with oxidants (440) showing the complex nature of disease 
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pathogenesis and the importance of the need to understand the changes that 
occur at various time point following a challenge. The interaction of genes has 
lead to the suggestion that this should be viewed as a systems genetics model 
of disease that takes into account this complexity (441). 
This thesis has shown that biomarkers can have usefulness in the study of 
allergic inflammation. The use of a SAM can considerably improve the 
detectable levels of cytokines form nasal secretions. Whole blood has the 
potential to be used to screen new anti-oxidants for the treatment of COPD and 
possibly other diseases where oxidant stress is a significant factor in the 
aetiology. However biomarkers do have their limitations and they must be 
carefully validated and their relevance to the clinical situation established. 
7.2 Conclusions 
NAC is a safe effective model for screening new drugs; however nasal 
secretions must be collected using a SAM that has been validated for use with 
human proteins. 
A model of repeated doses of nasal allergen may lead to an increase in levels 
of IL-4, IL-5 and IL-13 in nasal secretion. 
Cigarette smoke nasal challenge has the potential to be used to characterise 
the inflammatory changes that occur in smoking related lung disease and also 
to be used for the evaluation of new anti-inflammatory therapies for the 
treatment of COPD 
CSCM stimulation of whole blood causes a dose dependent increase in 
neutrophil CD1 lb upregulation. CSCM causes its greatest effect on neutrophils, 
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with lesser effects on monocytes and eosinophils. The effects of CSCM could 
not be reversed by anti-oxidants (N-acetyl cysteine and glutathione). 
Menadione and xanthine/ xanthine oxidase stimulation of whole blood causes a 
dose dependent increase in neutrophil CD11 b upregulation that can be 
reversed by the addition of 1 0mM glutathione. 
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8 Future work 
8.1 Nasal allergen challenge 
1. One should only employ Whatman's filter paper if it has appropriate elution 
characteristics for a particular batch demonstrated by spiking with commercial 
standards and nasal samples. Given the complexities of such an approach, 
there is a need to identify and validate novel absorptive matrices with 
reproducible and efficient elution characteristics. 
2. Determination of maximum dose of NAC and further determination of dose 
response effects of NAC. 
3. It would be beneficial to determine subjects' responsiveness to allergen 
challenge at screening prior to inclusion in the study, with documentation of 
serial nasal cytokine and chemokine responses 
4. Use of nasal scrape samples to assess events at a tissue level including 
proteomic analysis. In addition nasal cells could be cultured to determine in vitro 
responses to cytokine challenge. 
8.2 Nasal cigarette smoke challenge 
1. Characterise subjects further at screening with CT scans and full lung 
function, to ensure that "healthy" group are free of any respiratory disease. 
2. Collect samples at time points beyond 8 hours. 
3. Refine laboratory techniques of nasal lavage cytology and also determine the 
elution characteristics of an alternative matrix for the collection of nasal filter 
paper samples. 
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8.3 Blood oxidant challenge model 
1. Determine extent of TLR2 involvement in oxidant signalling 
2. Study effects of priming by extracellular oxidants using TLR4 agonists 
3. Study cell signalling pathways involved in CD11 b upregulation in relation to 
oxidant stimulation 
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11 Appendices 
11.1 Appendix I Nasal Symptom Score Card for Nasal Challenge 
Please complete the following table on hay fever symptoms, entering numbers 
between 0 to 3 
0- Absent symptoms (no sign/symptoms evident) 
I- Mild symptoms (sign/symptoms clearly present, but minimal awareness; 
easily tolerated) 
2- Moderate symptoms (definite awareness of sign/symptom that is 
bothersome) 
3- Severe symptoms (sign/symptom that is like severe hay fever). 
Subject initials: Subject randomisation Date: 
code: 
0 15 30 1 hr 2hr 3h 4h 5h 6h 7h 8h 
min mi 
n 
Nasal Obstruction: 
Have you had difficulty 
in breathing through a 
blocked nose today1 or 
since your last 
assessment today? 
Rhinorrhoea: 
Has your nose been 
running today or since 
the last assessment 
today? 
Nasal Itch: 
Has your nose been 
itching today or since 
the last assessment 
today? 
Sneezing: 
Have you been 
sneezing today or 
since the last 
assessment today? 
Total Nasal Symptom 
Score (TNSS) 
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11.2 Appendix 2 Whatman's filter paper (Number 42) versus Synthetic 
Absorptive Matrix (SAM) (Accuwik Ultra, Pall Gellman) for sampling nasal 
secretions 
Failure to detect significant levels of IL-4, IL-5 and 11-13 in nasal filter paper 
eluates prompted a comparative analysis of potential reasons (see discussion in 
Chapter 3). A potential reason was considered to be batch variability in 
Whatman's filter paper, and for this reason a series of experiments were carried 
out to compare the Whatman's filter paper with SAM (Accuwik Ultra). I 
contributed to the design of these experiments that were carried out by Mr 
Grant Nicholson. 
11.2.1 In vitro spiking experiment: Comparison of Accuwik and Whatman 
paper with Beadlyte standard 
Whatman's filter paper no. 42 is designed for filtration, and limits to protein- 
binding are not included in the specification. Cellulose is a natural product from 
the cotton plant, and there may therefore be variation in protein-binding 
potential between batches, especially since there is a final step involving 
washing the paper in acid. (Conversations with Mr. Giles Barton, Head of 
Technical Department, Whatman International Ltd. Tel: 01622 676670). 
Conversely, Accuwik Ultra SAM (manufactured by Pall Corporation) is fibrous 
hydroxylated polyester, with low protein binding, and free of binders and 
surfactants. Each batch has quality assurance for protein-binding, and this 
medium is used during biological immuno-assays (holding monoclonal antibody 
reagents) and for sampling of urine in pregnancy-testing kits 
Beadlyte pooled standard contains known levels of 26 cytokines and 
chemokines and was applied to Accuwik and Whatman's paper. 100 microlitres 
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of Beadlyte pooled standard was added to two of the paper strips (3Ox7mm). 
The strips were placed in an Eppendorf containing Beadlyte assay buffer 
(500ul). The Eppendorf were briefly vortexed and placed on a rolling mixer for 
10 minutes. The tubes were then centrifuged at 400g for 10 minutes, following 
which the supernatant was removed, vortexed and analysed by Luminex. 
Table 11-1. Recovery of pooled standard containing cytokines and chemokines from 
Accuwik Ultra (A) in comparison to Whatman's 42 (WI Filter Paner 
Beadlyte Actual Conc. 
Accuwik 26-plex conc. corrected % % recovery Ratio of Cytokine (A) pooled detected for dil. (corrected 
(pg/ml) Whatman standard on factor recovery for dil. recovery 
W conc Luminex (x6) 
(actual) factor) AM 
(pg/ml) 1) (pg/ml) 
11-1a A 117 42.24 253.44 36% 217% 183% w 117 23.09 138.54 20% 118% 
ILAP A 175 28.26 169.56 16% 97% 160% w 175 17.7 106.2 10% 61% 
IL-4 A 70 3.86 23.16 6% 33% 278% w 70 1.39 8.34 2% 12% 
A 140 13.34 80.04 10% 57% 536% IL-5 w 140 2.49 14.94 2% 11% 
IL-6 A 187 30.87 185.22 17% 99% 110% w 187 28.13 168.78 15% 90% 
IL-10 A 70 7.55 45.3 11% 65% 452% 
w 70 1.67 10.02 2% 14% 
IL-13 A 93 14.78 88.68 16% 95% 201% 
w 93 7.34 44.04 8% 47% 
IFNg A 117 13.72 82.32 12% 70% 122% w 117 11.23 67.38 10% 58% 
TNFa A 117 7.29 43.74 6% 37% 170% w 117 4.3 25.8 4% 22% 
Eotaxin A 175 51.7 310.2 30% 177% 119% w 175 43.52 261.12 25% 149% 
RANTES A 37 13.96 83.76 38% 226% 133% 
1 w1 37 1 10.51 1 63.06 1 28% 170% 1 
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11.2.2 Ex vivo NAC on a single hay fever sufferer out of season: 
Comparison of detectable levels of IL-4, IL-5 and 11-13 using Whatman's 
versus Accuwik SAM 
IL-4 
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35 
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The results clearly show enhanced chemokine/cytokine recovery using the 
Accuwik paper for IL-4, IL-5 and IL-13. 
On 1St September 2006, one subject (TTH) with confirmed allergic rhinitis to 
Timothy grass pollen, was given NAC with timothy grass pollen (500BU each 
nostril) from the Dolphin delivery device. The NAC was preceded by nasal 
lavage with PBS in each nostril (20 times over 1 minute). Sampling was 
undertaken by placing Accuwik in the left nostril and Whatman's in the right 
nostril (2 papers/nostril), and leaving in situ for one minute at the time points up 
to 6 hours. 
The results indicate clearly that Accuwik paper is superior to Whatman 42 in 
absorbing nasal fluid and releasing higher detectable levels of IL-4, IL-5 and IL- 
13. 
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To ensure reliable results in future, the NAC technique will be simplified and 
enhanced by using Accuwik paper, and diluting straight into commercially 
available Luminex assay buffer. Accuwik ultra paper is synthetic and has quality 
control for protein elution and individual batches should be tested for elution of a 
standard source of IL-4, IL-5, IL-13 (commercial standard and biological positive 
control). 
11.3 Use of SAM in a clinical trial of a novel therapeutic agent using the 
nasal allergen challenge model 
Results are shown for a clinical trial carried out on the NHLI CSU that employed 
a single oral dose of a novel therapeutic given 30 min before a NAC. There 
were major changes employed in this study, compared with a previous 
published study with nasal filter paper (100): 
Dose of timothy grass pollen increased from 500 BU (0.3µg of Phleum pratense 
allergen per nostril) to 1.0 pg of Phleum pratense allergen per nostril 
Accuwik Ultra SAM was employed instead of Whatman's filter paper number 42. 
Data is shown for levels of IL-4, IL-5 and IL-13 in individual subjects, and it 
should be noted that in 8 of 12 subjects there are demonstrable significant late 
phase increases in IL-4, IL-5 and IL-13 to levels >100pg/ml. 
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Figure 11-1 Levels of IL-4 detectable in Accuwik Ultra eluate in relation to nasal allergen 
challenge 
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Figure 11-2 Levels of IL-5 detectable in Accuwik Ultra eluate in relation to nasal allergen 
challenge 
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Figure 11-3 Levels of IL-13 detectable in Accuwik Ultra eluate in relation to nasal allergen 
challenge 
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Figure 11-4 Effect of a novel therapeutic agent on cytokine levels in nasal SAM eluate 
following NAC. Subjects receiving active drug are shown in red. There is a statistically 
significant effect of the drug on IL-13 levels at 8 hours post challenge 
In this thesis Whatman's filter paper was employed in: 
NAC repeatability and dose response (Chapter 3) 
Repeated NAC on 4 consecutive days (Chapter 4) 
Cigarette smoke nasal challenge (Chapter 5) 
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